Top

William Fraser Symmans, MB.ChB.

Department of Anatomical Pathology, Division of Pathology-Lab Medicine Div

About Dr. William Fraser Symmans

Dr. Symmans’ defining contributions to the field of breast cancer include an improved method to measure pathologic response, and the development of genomic assays to predict both response and survival following neoadjuvant chemotherapy. Within 5 years of initial publication, the residual cancer burden (RCB) method of pathologic evaluation has become a standard secondary or primary response endpoint in clinical trials (e.g. the online RCB calculator website had 17,000 visits in 2011). RCB has also formed a basis for training more effective chemopredictive genomic assays that consider primary resistance separately from excellent response, and for understanding the sequential synergy that can be achieved with chemo-endocrine therapy for Stage II-III breast cancer. These findings are re-shaping the approach to development of “omics-based” predictive tests. In parallel, he has advanced the practical application of minimally invasive breast biopsy techniques for translational research through evidence-based studies of biospecimen yield and quality.

He has mentored translational researchers from several breast cancer disciplines, including Sandra Demaria (pathologist, New York, immunological response to chemotherapy); Radikha Rajan (pathologist, New Zealand, RCB); Yun Gong (pathologist, MDACC, genomic measurement of receptors); Florentia Peintinger (surgeon, Austria, surgical implications of RCB); Shivani Shinde (public health, India, odds of TNBC phenotype with increased parity and short breastfeeding and race); and Abigail Caudle (surgeon, MDACC, prediction of nodal status after chemotherapy). In collaboration with Lajos Pusztai, genomic and response data from his laboratory has been broadly used by clinical and statistical fellows’ projects within MDACC, statisticians from the FDA, and also constitutes a sizeable proportion of the annotated breast cancer genomic data that are available in the public domain. He has actively advised or taught clinical trial groups in the assessment of pathologic response and/or biobanking for genomic studies (I-SPY 1&2 trials, NCI Latin American Trials Group, ABCSG, and TBCRC).

Primary Appointment

Winterhof Family Chair, Division of Pathology-Lab Medicine Div, Univ Texas MD Anderson Cancer Center, Houston, Texas

Professor, Department of Translational Molecular Pathology - Joint Appointment, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Anatomic Pathology/Division of Pathology and Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1987	University of Auckland School of Medicine, Auckland, NZ, Bachelor of Medicine and Surgery, MB.ChB
1984	University of Auckland School of Medicine, Auckland, US, Human Biology, BHB

Postgraduate Training

1992-1993	Fellow, Cytopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
1991-1992	Chief Resident, Pathology, Columbia Presbyterian Medical Center, New York, New York
1988-1992	Resident, Anatomic Pathology, Columbia Presbyterian Medical Center, New York, New York
1986-1988	Intern, Rotating - Med/Surgery, Waikato Public Hospital, Hamilton

Licenses & Certifications

2000	Texas Medical Board License
1997	American Board of Pathology, Cytopathology
1992	American Board of Pathology, Anatomic Pathology
null	New York Medical License

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001 - 2007

Assistant Professor, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2000 - 2001

Assistant Attending, Bellevue Hospital, New York, NY, 1997 - 2000

Assistant Professor, New York University, New York, NY, 1996 - 2000

Attending Pathologist, Tisch Hospital, New York University Medical Center, New York, NY, 1996 - 2000

Consultant Pathologist, Veterans Administration Medical Center, New York, NY, 1994 - 2000

Instructor, Department of Pathology, New York University, New York, NY, 1993 - 1995

Administrative Appointments/Responsibilities

Director/Principal Investigator, Department of Translational Research Program, The Alliance for Clinical Trials, Chicago, IL, 2014 - Present

Director of Research Operations, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2021

Co-Director, Department of Breast Cancer Pharmacogenomics Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - Present

Resident Advisory Committee, Department of Pathology, New York University Medical Center, New York, NY, 1998 - 2000

Co-chair, Curriculum Review, Department of Pathology, New York University Medical Center, New York, NY, 1998 - 2000

Director of Needle Biopsies, Department of Pathology, New York University Medical Center, New York, NY, 1997 - 2000

Resident Selection Subcommittee, Department of Pathology, New York University Medical Center, New York, NY, 1996 - 2000

Other Professional Positions

Pathology Consultant - DESTINY Trial, Astra Zeneca, Wilmington, DE, 2021 - Present

Commissioner, Lancet Breast Cancer Commission, London, 2021 - Present

Chair, U01 Biospecimen Sciences Steering Committee, National Cancer Institute, Bethesda, MD, 2020 - Present

Member, Memorial Sloan Kettering Cancer Center, New York, NY, 2019 - Present

Member, Board of Directors, The Alliance Foundation for Clinical Trials, Boston, MA, 2017 - Present

Member, Cancer Research Committee, American Society for Clinical Oncology, Alexandria, VA, 2016 - Present

Member, Steering Committee, Translational Breast Cancer Research Consortium, Baltimore, MD, 2016 - Present

Voting Member, Correlative Sciences Review Committee, Clinical Trials Evaluation Program, National Cancer Institute, Bethesda, MD, 2015 - 2021

Chair, TransPALLAS Translational Research Committee - PALLAS Trial, Pfizer, New York, NY, 2014 - Present

Global Advisor, Pathology Protocol - BRIGHTNESS Trial, Abbvie, Chicago, IL, 2014 - Present

Voting Member, National Cancer Institute, Bethesda, MD, 2014 - 2019

Chair, Translational Research Committee (trans-PALLAS), PALLAS trial, Pfizer, New York, NY, 2014 - Present

Member, Executive Committee, The Alliance for Clinical Trials, Chicago, IL, 2014 - Present

Member, Steering Committee, BRIGHTNESS Trial, AbbVie, Chicago, IL, 2014 - Present

Advisor, Roche/Genentech, Global, 2012 - Present

Member, Executive Committee, I-SPY2 Clinical trial, UCSF, San Francisco, CA, 2012 - Present

Member, Steering Committee, KRISTINE Trial, Roche/Genentech, San Francisco, CA, 2012 - Present

Member, External Advisory Committee, Breast Cancer Translational Research Program, University of Toronto, Toronto, 2012 - Present

Co-chair, North American Breast Groups (BIG-NABG) Residual Disease Working Group, National Cancer Institute, Breast International Group, Houston, TX, 2012 - Present

Consultant Pathologist, National Cancer Institute Latin American Breast Cancer Clinical Trials, Bethesda, MD, 2011 - Present

Member, External Advisory Committee, Breast Cancer Spore Grant, UCSF San Francisco, CA, 2011 - Present

Ixabeilone Advisory Board, Bristol Myers Squibb, New York, NY, 2010 - Present

Komen Scholar, Scientific Advisory Council Member, Susan G. Komen For the Cure, Dallas, TX, 2010 - 2016

Chair, iSPY 2 Clinical Trial Investigators, San Francisco, CA, 2009 - Present

Member, National Cancer Institute, Bethesda, MD, 2009 - 2014

Member ad hoc, Scientific Advisory Board, Agendia, US, 2008 - Present

Member, U.S. Food and Drug Administration, Little Rock, AR, 2008 - 2014

Co-Chair, ASCO Breast Cancer Symposium, Alexandria, VA, 2008 - 2009

Member ad hoc, Pertuzumab Advisory Board, Genentech, US, 2007 - Present

Co-Chair, Correlative Science Working Group, Translational Breast Cancer Research Consortium, Baltimore, MD, 2007 - 2016

Co-Chair Elect, ASCO Breast Cancer Symposium, Alexandria, VA, 2007 - 2008

Member ad hoc, Herceptin Diagnostics Advisory Board, Genentech, US, 2006 - Present

Member ad hoc, Lapatinib Think Tank, GlaxoSmithKline, US, 2006 - Present

Member, Translational Breast Cancer Research Consortium, Baltimore, MD, 2006 - Present

Member, Diagnostics Scientific Advisory Board, Invitrogen, US, 2006 - 2008

Member, Program Committee, ASCO Breast Cancer Symposium, Alexandria, VA, 2006 - 2007

Member, Scientific Advisory Board, Nuvera Biosciences, Inc, US, 2005 - Present

Extramural Institutional Committee Activities

Chair, Conflict of Interest Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present

Chair, Institutional Conflict of Interest Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2023

Member, Institutional Biospecimen Utilization Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2019

Member, Conflict of Interest Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present

Member, Search Committee, Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 2012 - 2013

Member, Search Committee, Division Head, Quantitative Sciences, The University of Texas MD Anderson Cancer Center, 2011 - Present

Member, Clinical Research Advisory Committee, The University of Texas MD Anderson Cancer Center, 2011 - Present

Chair, Serum Bank Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2011

Member, Department of Pathology Executive Committee, The University of Texas MD Anderson Cancer Center, 2010 - Present

Recruitment of Vice President for Global Oncology Research, Advisory Committee to The Provost, The University of Texas MD Anderson Cancer Center, 2010 - 2011

Member, Institutional Multidisciplinary Research Advisory Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2010

Member, Organizing Committee, UT M.D. Anderson Cancer Center 58th Annual Symposium on Fundamental Cancer Research, The University of Texas MD Anderson Cancer Center, 2005 - 2005

Elected Member, UT M.D. Anderson Cancer Center Faculty Senate, The University of Texas MD Anderson Cancer Center, 2003 - 2006

Appointed Member, Blue Ribbon Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2003

Appointed Member, Executive Committee, University Physicians Network, New York University Medical Center, 1999 - 2000

Editorial Activities

Associate Editor, Breast Cancer Research, 2013 - 2014

Author, Genomic Testing for Sensitivity of Breast Cancer to Hormonal Therapy, 2006

Editor, Core Biopsy of the Breast with Atypical Ductal Hyperplasia

Contributing Editor, E-cadherin as a Prognostic Indicator in Primary Breast Cancer

Contributing Editor, VEGF-B Expression in Human Primary Breast Cancer

Editor, Using Fine Needle Aspiration Samples to Predict Breast Cancer Response to Expert Perspectives

Editor, Percutaneous Core Needle Biopsy of Radial Scars of the Breast

Author, Fingerprinting Lymph Node Metastases

Author, Interpreting the Complex Landscape of Immune-Tumor Interface

Honors & Awards

2019	Robert M. Chamberlain Distinguished Mentor Nominee, MD Anderson Cancer Center
2018	Neera Patel Lectureship, 1st United Kingdom Interdisciplinary Breast Cancer Symposium
2015 - 2021	Director's Certificate of Appreciation for Service to the Cancer Biomarkers Correlative Science Committee, National Cancer Institute
2014 - 2019	Director's Certificate of Appreciation for Service as a Special Expert to the Breast Cancer Steering Committee, National Cancer Institute
2014	Outstanding Research Faculty Award, University of Texas MD Anderson Cancer Center
2014	Robert Sutherland Award for Excellence in Translational Research, Australia & New Zealand Breast Cancer Trials Group
2012	Director's Innovation Award: Co-chair Clinical Trials Planning Meeting for ER+ Breast Cancer, National Cancer Institute
2011	Director's Innovation Award: Training of Pathologists for the Latin American Clinical Trials Network, National Cancer Institute
2011	Provost's Hall of Science Recognition for Leading a High Impact Publication (JAMA), UT M.D. Anderson Cancer Center
2010 - 2023	Komen Scholar, Susan G. Komen for the Cure
2008 - 2025	Researcher, Breast Cancer Research Foundation
2007	Yolanda Oertel Interventional Cytology Award, The Papanicolaou Society Of Cytopathology
1993	Travel Award, Fifth International Congress on Malignant Lymphoma

Professional Memberships

I-SPY2 Clinical Trial

2012 - Present

I-SPY2 Clinical Trial Investigators (CALGB, ACRIN)

2009 - Present

ASCO Breast Cancer Symposium

2008 - 2009

American College of Surgeons Oncology Group (ACOSOG)

2007 - 2012

Translational Breast Cancer Research Consortium

2007 - Present

Southwest Oncology Group

2006 - 2013

American Society of Clinical Oncology

2005 - Present

American Society of Cytopathology

1998 - Present

American Society of Breast Disease

1998 - Present

Kaplan Comprehensive Cancer Center, NYU

1995 - 2000

New York Pathological Society

1994 - 2000

American Association for Cancer Research

1993 - Present

United States and Canadian Academy of Pathology

1993 - Present

Selected Presentations & Talks

Local Presentations

2017. Using Multigene Assays for Prognostic and Predictive Considerations in Breast Cancer Treatment. Conference. Using Multigene Assays for Prognostic and Predictive Considerations in Breast Cancer Treatment. Houston, TX, US.
2016. Pathological Evaluation of Breast Specimens After Neoadjuvant Chemotherapy. Conference. Pathological Evaluation of Breast Specimens After Neoadjuvant Chemotherapy. Houston, TX, US.
2014. Treatment Insights Based on Molecular Subtypes and Novel Diagnostics: Endopredict vs Oncotype. Conference. Treatment Insights Based on Molecular Subtypes and Novel Diagnostics: Endopredict vs Oncotype. Houston, TX, US.
2008. Molecular Classification of Breast Cancer, Pathology of the Breast: Current Issues and Future Directions,. Conference. Houston Society of Clinical Pathologists 48th Annual Spring Symposium. Houston, TX, US.

Regional Presentations

2023. Interpretation of Residual Cancer After Neoadjuvant Treatment for Breast Cancer. Conference. Interpretation of Residual Cancer After Neoadjuvant Treatment for Breast Cancer. New York, NY, US.
2021. Residual Cancer Burden and Prognosis. Conference. Residual Cancer Burden and Prognosis. Virtual presentation, US.
2021. Development of genomics assays to predict response and survival following neoadjuvant chemotherapy and endocrine therapy. Conference. Development of genomics assays to predict response and survival following neoadjuvant chemotherapy and endocrine therapy. Virtual Meeting, US.
2021. Interpretation of Residual Cancer After Neoadjuvant Treatment for Breast Cancer. Conference. Interpretation of Residual Cancer After Neoadjuvant Treatment for Breast Cancer. Virtual presentation, US.
2021. Residual Cancer Burden. Conference. Residual Cancer Burden. Virtual presentation, US.
2020. Pathology Updates on Tumor Biology, Residual Disease in the Breast and Circulating Cells/DNA. Conference. Pathology Updates on Tumor Biology, Residual Disease in the Breast and Circulating Cells/DNA. Chicago, IL, US.
2019. I-SPY 2.2 Design Meeting. Conference. I-SPY 2.2 Design Meeting. San Francisco, CA, US.
2019. Hormonal Therapy: Upfront response testing, duration and prevention. Conference. Hormonal Therapy: Upfront response testing, duration and prevention. San Francisco, CA, US.
2017. Innovations in Cancer Prevention and Research. Conference. Innovations in Cancer Prevention and Research. Austin, TX, US.
2017. The Pathologist's Role in Guiding Breast Cancer Treatment in the Era of Neoadjuvant Therapy. Invited. 106th USCAP. San Antonio, TX, US.
2015. Tips and tricks to identify and develop clinical assay from actionable biomarkers. Conference. Tips and tricks to identify and develop clinical assay from actionable biomarkers. Austin, TX, US.
2015. New Concepts in Neoadjuvant Treatment. Conference. New Concepts in Neoadjuvant Treatment. New York, NY, US.
2014. Breast Cancer Research, on behalf of BCRF. Conference. Breast Cancer Research, on behalf of BCRF. Chicago, IL, US.
2014. Perspectives with Prognostic and Predictive Factors. Conference. Perspectives with Prognostic and Predictive Factors. Chicago, IL, US.
2014. Prognostic and Predictive Tests. Conference. Prognostic and Predictive Tests. Orlando, FL, US.
2012. Molecular Markers in Breast Cancer. Conference. Molecular Markers in Breast Cancer. San Antonio, TX, US.
2012. . Conference. Sydney Catalyst Translational Cancer Research Meeting. Camperdown, AU.
2011. NCI Cooperative Group Trial Planning Meeting. Conference. NCI Cooperative Group Trial Planning Meeting. Chicago, IL, US.
2009. A Pathologist's Perspective on Genomic Tests for Breast Cancer. Invited. Miami Breast Cancer Conference. Miami, FL, US.
2009. Molecular Aspects of Breast Cytology and Pathology in the Neoadjuvant Setting. Conference. New York Pathological Society. New York, NY, US.
Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis. 2019 San Antonio Breast Cancer Symposium. San Antonio, TX, US.

National Presentations

2022. Translational Research Program Updates. Plenary Session, Group Meeting. Conference. Translational Research Program Updates. Plenary Session, Group Meeting. Chicago, IL, US.
2022. Development of clinical assay for Breast Cancer using Invitrogen QuantiGene Plex Technology. Conference. Development of clinical assay for Breast Cancer using Invitrogen QuantiGene Plex Technology. Houston, TX, US.
2021. Pathologic Reporting of Breast Cancer Following Neoadjuvant Chemotherapy: Residual Cancer Burden. Conference. Pathologic Reporting of Breast Cancer Following Neoadjuvant Chemotherapy: Residual Cancer Burden. Virtual presentation, US.
2021. Measurable Residual Disease (MRD) and pathologic Complete Response (pCR): What are they? How do we measure them? How do we use them?. Conference. Measurable Residual Disease (MRD) and pathologic Complete Response (pCR): What are they? How do we measure them? How do we use them?. Virtual presentation, US.
2021. RCB Assessment and pooled analysis to predict breast cancer outcome. Conference. RCB Assessment and pooled analysis to predict breast cancer outcome. Virtual presentation, US.
2021. Molecular Subtypes and Histologic Types of Triple-negative Breast Cancer (TNBC). Conference. Molecular Subtypes and Histologic Types of Triple-negative Breast Cancer (TNBC). Virtual Webinar, US.
2021. Complex Lesions and Atypia. Conference. Complex Lesions and Atypia. Virtual conference, US.
2021. Clinical Implications of Measuring Response to Neoadjuvant Treatments. Conference. Clinical Implications of Measuring Response to Neoadjuvant Treatments. Virtual conference, US.
2021. Predicting sensitivity to endocrine-based therapies. Conference. Predicting sensitivity to endocrine-based therapies. Virtual presentation, US.
2020. HER-2 Low, A New Breast Cancer Subtype?. Conference. 19th Annual International Congress on the Future of Breast Cancer - WEST. Virtual presentation, US.
2019. Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: a multi-center pooled analysis. Conference. Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: a multi-center pooled analysis. San Antonio, TX, US.
2019. 2019 San Antonio Breast Cancer Symposium. Conference. 2019 San Antonio Breast Cancer Symposium. San Antonio, TX, US.
2019. Sent to Symmans. Invited. ASCO Cancer Research Committee Meeting. Alexandria, VA, US.
2019. Contemporary Strategies to Optimize HER2 Assessment for Patients with Breast Cancer. Conference. 3rd International Congress on Oncology Pathology. Manhattan, NY, US.
2019. Reproducibility of the Sensitivity to Endocrine Therapy (SET) Assay for Stage II/III Breast Cancer Within and Between Pathology Laboratories. Conference. USCAP. National Harbor, MD, US.
2018. Molecular Biomarker Development in Alliance Breast Cancer Trials. Conference. Molecular Biomarker Development in Alliance Breast Cancer Trials. Washington, DC, US.
2018. Refined Pathological Endpoints for Assessment of Response to Neoadjuvant Therapy. Conference. FDA Early Breast Cancer Workshop. Hyattsville, MD, US.
2018. The Surgeon-Pathologist Relationship in This New Era: Refining and Redefining. Conference. The Surgeon-Pathologist Relationship in This New Era: Refining and Redefining. Miami, FL, US.
2018. Residual Cancer Burden After Neoadjuvant Therapy. Conference. Residual Cancer Burden After Neoadjuvant Therapy. Miami, FL, US.
2018. Pathology Update on Marker Assessment and Grade. Conference. Pathology Update on Marker Assessment and Grade. Miami, FL, US.
2018. Molecular signatures in breast cancer: Present and future applications. Conference. Molecular signatures in breast cancer: Present and future applications. Kansas City, MO, US.
2017. Scientific Advisory Board, Panelist. Conference. ALMAC. San Antonio, TX, US.
2017. Customized Multigene Expression Assay for Formalin-Fixed Breast Cancer Tissues Using MAGPIX. Conference. Luminex xMap Connect. Boston, MA, US.
2017. Assessment and Prognostic Significance of Residual Tumor Burden after Neoadjuvant Chemotherapy. Conference. Lynn Sage Breast Cancer Symposium. Chicago, IL, US.
2017. The Pathologist’s Role in Guiding Breast Cancer Treatment in the Era of Neoadjuvant Therapy. Conference. USCAP. San Antonio, TX, US.
2017. RCB 2/3 as a predictor of progression. Conference. I-SPY 2 Retreat/Investigators Meeting. San Francisco, AR, US.
2017. Circulating Cell Free DNA. Conference. Molecular Med Tri-Conference. San Francisco, CA, US.
2016. Quality Biobanking for Precision Research and Medicine: Overcoming Scientific, Information Technology and Policy Challenges. Conference. ISBER Regional Meeting. Bethesda, MD, US.
2016. Development of Clinical Assays: The Breast Cancer Experience. Conference. American Society of Clinical Oncology, the European Organization for Research and Treatment of Cancer, and the National Cancer Institute. Bethesda, MD, US.
2016. Standardizing of pathology in cases treated with neoadjuvant therapy. Conference. Standardizing of pathology in cases treated with neoadjuvant therapy. Dallas, TX, US.
2016. The Pathologist's Role In Guiding Breast Cancer Treatment In The Era Of Neoadjuvant Therapy. Conference. US and Canadian Academy of Pathology Short Course. Seattle, WA, US.
2016. HER 2 Status Determination: Best Practices FISH, SISH, RT-PCR. Conference. 33rd Annual Miami Breast Cancer Conference. Miami, FL, US.
2016. Update on the Moonshot Trial for TNBC. Conference. 33rd Annual Miami Breast Cancer Conference. Miami, FL, US.
2016. Is it time to stop removing borderline epithelial lesions identified on core biopsy?. Conference. 33rd Annual Miami Breast Cancer Conference. Miami, FL, US.
2016. International guidelines for pathological response assessment after neoadjuvant tratment. Conference. International guidelines for pathological response assessment after neoadjuvant tratment. Miami, FL, US.
2015. Overcoming challenges of working with FFPE samples. Conference. Overcoming challenges of working with FFPE samples, US.
2014. Evolving Clinical Utility of Molecular Genomic Testing for Breast Cancer. Conference. World Congress on Breast Healthcare. Orlando, FL, US.
2014. RNA Sequencing and It's Clinical Impact. Conference. World Congress on Breast Healthcare. Orlando, FL, US.
2014. Understanding Pre-Analytic Effects on RNA Gene Expression from Fresh Samples and Applying it to Formalin Fixed Paraffin-embedded (FFPE) Samples. Conference. Next Generation Diagnostics Summit. Washington, DC, US.
2014. Clinical Validation Studies of Chemopredictive Gene Expression Profiles in Breast Cancer. Conference. Next Generation Diagnostics Summit. Washington, DC, US.
2014. Clinical Validation Studies of Chemopredictive Gene Expression Profiles in Breast Cancer. Conference. Clinical Validation Studies of Chemopredictive Gene Expression Profiles in Breast Cancer. Washington, DC, US.
2014. Biomarker Development and Accelerated Drug Approval: Neoadjuvant Treatment As The Poster Child. Conference. ASCO. Chicago, IL, US.
2014. Pre-analytic variables and analytical considerations. Conference. Pre-analytic variables and analytical considerations. San Diego, CA, US.
2014. Assessing The Risk of Relapse After Adjuvant Therapy. Conference. Assessing The Risk of Relapse After Adjuvant Therapy. Glasgow.
2014. New Messages for Pathology and Molecular Diagnostics. Conference. EBCC. Glasgow.
2014. The Emerging Role of the Surgical Oncologist in the Management of Breast Cancer. Conference. The Emerging Role of the Surgical Oncologist in the Management of Breast Cancer. Phoenix, AZ, US.
2013. Long-term prognostic value of residual cancer burden (RCB) classification following neoadjuvant chemotherapy. Conference. 2013 San Antonio Breast Cancer Symposium. San Antonio, TX, US.
2013. Lessons from Neoadjuvant Therapy. Conference. Breast Cancer: New Horizons, Current Controversies. Boston, MA, US.
2013. Putting Genomics into Clinical Practice. Conference. 2013 ASCO Annual Meeting. Chicago, IL, US.
2013. Discussion: SOPs for collection of metastatic biopsies. Conference. 9th Annual BIG-NABCG. Washington, DC, US.
2013. The Role of Stem Cells in Tumorgenesis - Can We Identify and Inhibit Them?. Conference. 30th Annual Miami Breast Cancer Conference. Miami, FL, US.
2012. Development of Genomic Predictors of Treatment Response from the Neoadjuvant Model. Conference. 36th Annual Symposium. Dallas, TX, US.
2012. Effects of Biospecimen Integrity, Intratumoral Heterogeneity, and Analytical Variance on Micoarray-Based Pharmacogenomics Tests of Breast Cancer. Conference. NIH Biospecimen Research Network. Bethesda, MD, US.
2011. Molecular tumor characteristics influence adjuvant endocrine treatment outcome. Conference. Molecular tumor characteristics influence adjuvant endocrine treatment outcome. San Antonio, TX, US.
2011. Molecular Testing in Breast and Lung Cancer: A Diagnostic Immunology and Molecular Pathology Update. Conference. 2011 ASCP Annual Meeting/WASPaLM XXVI World Congress. Las Vegas, NV, US.
2011. Ensuring Consistent Results: Exploring Key Variables Affecting the Results of Molecular Analysis of Tissues. Conference. Hanson Wade. Boston, MA, US.
2011. Pathology Response to Neoadjuvant Treatment. Conference. Breast Cancer Imaging and Treatment: State of the Art. Bethesda, MD, US.
2011. Targeting DNA Repair and Mitosis in Breast and Ovarian Cancers. Conference. 102nd Annual Meeting. Orlando, FL, US.
2011. Effects of Biospecimen Integrity, Intratumoral Heterogeneity, and Analytical Variance on Micoarray-Based Pharmacogenomics Tests of Breast Cancer. Conference. National Cancer Institute. Bethesda, MD, US.
2011. Biomarkers For Resistance In Residual Tumor. Conference. 28th Annual Miami Breast Cancer Conference. Miami, FL, US.
2011. Predicting Survival From Adjuvant Therapy. Conference. 28th Annual Miami Breast Cancer Conference. Miami, FL, US.
2011. Can We Personalize Adjuvant Chemotherapy?. Conference. 28th Annual Miami Breast Cancer Conference. Miami, FL, US.
2011. Translational Advances from a Pathologist's Perspective. Conference. 8th Annual The Best of San Antonio: Breast Cancer-Bench to Bedside. Chicago, IL, US.
2010. Markers in Neoadjuvant Therapy. Conference. San Antonio Breast Cancer Symposium. San Antonio, TX, US.
2010. The Biology of ER-Positive (Luminal) Breast Cancer. Conference. The Biology of ER-Positive (Luminal) Breast Cancer. New York, NY, US.
2010. Integrating Emerging Science into Clinical Practice. Conference. ASCO. Washington, DC, US.
2010. The Pathology of Triple-Negative Breast Cancer. Conference. The Pathology of Triple-Negative Breast Cancer. Atlanta, GA, US.
2010. Effects of Ex Vivo Duration and Host Organ Contamination on RNA Expression Profiles of Breast Cancer. Conference. National Cancer Institute. Bethesda, MD, US.
2010. Pathologic Response Following Neoadjuvant Chemotherapy as an Outcome for Clinical and Translational Research. Conference. USCAP. Washington, DC, US.
2010. Delivering on a Promise: Prospective Evaluation of Molecular Triaging With Pharmacogenomic Tests to Select Neoadjuvant Treatment, Impact of Investment. Conference. Komen Leadership Conference. Dallas, TX, US.
2009. Personalizing Treatment: Molecular Diagnostics for Risk Assessment and Treatment Individualization. Conference. Personalizing Treatment: Molecular Diagnostics for Risk Assessment and Treatment Individualization. Dallas, TX, US.
2009. Adjuvant Chemotherapy of Breast Cancer. Conference. Personalized Medicine in Oncology Meeting. Baltimore, MD, US.
2009. The Pathology of Triple Negative Breast Cancer. Conference. The Pathology of Triple Negative Breast Cancer. Atlanta, GA, US.
2009. Neoadjuvant Therapy: Who, Why, How? Pathology Issues. Conference. Neoadjuvant Therapy: Who, Why, How? Pathology Issues. San Diego, CA, US.
2009. In Situ Carcinoma Management, Lobular Neoplasia. Conference. In Situ Carcinoma Management, Lobular Neoplasia. San Diego, CA, US.
2009. Molecular Classification of Breast Cancer, Pathology Features and Prognosis. Conference. Molecular Classification of Breast Cancer, Pathology Features and Prognosis. San Diego, CA, US.
2009. How Do You Measure Residual Breast Cancer and Its Relationship to Survival: Is Residual Tumor Enhanced for Stem Cells?. Conference. How Do You Measure Residual Breast Cancer and Its Relationship to Survival: Is Residual Tumor Enhanced for Stem Cells?. Miami, FL, US.
2009. A Pathologist’s Perspective on Genomic Tests for Breast Cancer. Conference. A Pathologist’s Perspective on Genomic Tests for Breast Cancer. Miami, FL, US.
2009. Long-Term Outcome of Patients With Mucinous, Medullary, Tubular, and Invasive Breast Cancer After Lumpectomy. Conference. Long-Term Outcome of Patients With Mucinous, Medullary, Tubular, and Invasive Breast Cancer After Lumpectomy. Miami, FL, US.
2009. Are genomic predictive signatures developed from human genomic data ready for clinical testing?. Conference. National Cancer Institute. Bethesda, MD, US.
2009. Progress in Molecular Pathology. Conference. Progress in Molecular Pathology. Chicago, IL, US.
2009. What are the molecular predictors of response to adjuvant endocrine therapy?. Conference. What are the molecular predictors of response to adjuvant endocrine therapy?. Miami, FL, US.
2009. Case Study in Personalized Medicine in Breast Cancer, Molecular Oncology. Conference. Case Study in Personalized Medicine in Breast Cancer, Molecular Oncology. Phoenix, AZ, US.
2008. Molecular Profiling To Predict For Response To Adjuvant Systemic Therapy. Conference. Molecular Profiling To Predict For Response To Adjuvant Systemic Therapy. San Antonio, TX, US.
2008. Prognostic and Predictive Markers. Conference. Prognostic and Predictive Markers. Chicago, IL, US.
2008. Development and Clinical Implementation of Pharmacogenomic Predictors For Breast Cancer Treatments. Conference. American Society of Clinical Pathology. Baltimore, MD, US.
2008. Biologic and Natural History Insights Into Triple-Negative Breast Cancer. Conference. 6th Annual Controversies in Breast Cancer: Adjuvant & Neoadjuvant Therapy. New York, NY, US.
2008. Does Receptor Status Matter For Picking Adjuvant Therapy? Controversies in Breast Cancer. Conference. 6th Annual Controversies in Breast Cancer: Adjuvant & Neoadjuvant Therapy. Brooklyn, NY, US.
2008. Does Pathologic Complete Response (pCR) Matter For ER-Positive Breast Cancer? Controversies in Breast Cancer. Conference. 6th Annual Controversies in Breast Cancer: Adjuvant & Neoadjuvant Therapy. Brooklyn, NY, US.
2008. Molecular Diagnostics for Risk Assessment and Treatment Individualization. Conference. New Developments in Breast Cancer. Dallas, TX, US.
2008. A Pathologist's Perspective on Emerging Molecular Tests. Invited. Second Annual Biological Basis of Breast Cancer Conference. San Diego, CA, US.
2008. Residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy is independently prognostic in every phenotypic subset of breast cancer. Conference. Era of Hope Conference. Baltimore, MD, US.
2008. The Pathology of Triple-Negative Breast Cancer. Conference. The Pathology of Triple-Negative Breast Cancer. Atlanta, GA, US.
2008. Assessment of Residual Cancer Burden After Neoadjuvant Chemotherapy. Conference. Assessment of Residual Cancer Burden After Neoadjuvant Chemotherapy. San Diego, CA, US.
2008. Assessment After Neoadjuvant Therapy: Pathologic Techniques and Prognostic Implications. Conference. The Society of Surgical Oncology. Chicago, IL, US.
2008. New Findings For The Breast Clinical Pathologist, Best of San Antonio-From Bench to Bedside. Conference. New Findings For The Breast Clinical Pathologist, Best of San Antonio-From Bench to Bedside. Chicago, IL, US.
2007. Microarray-Based Gene Expression Profiling Of Breast Cancer. Conference. Microarray-Based Gene Expression Profiling Of Breast Cancer. Los Angeles, CA, US.
2007. Residual Cancer Burden After Neoadjuvant Chemotherapy. Conference. Residual Cancer Burden After Neoadjuvant Chemotherapy. Chicago, IL, US.
2007. NCI BCSC Clinical Trial Planning Meeting. Conference. NCI Breast Cancer Steering Committee. Rockville, MD, US.
2007. A 200-gene endocrine sensitivity index (SET) predicts survival for patients who receive adjuvant endocrine therapy, but not for untreated patients. Conference. A 200-gene endocrine sensitivity index (SET) predicts survival for patients who receive adjuvant endocrine therapy, but not for untreated patients. San Francisco, CA, US.
2007. Residual Cancer Burden After Neoadjuvant Chemotherapy. Conference. Breast Cancer Committee Meeting. St. Louis, MO, US.
2007. A Pathologist's Perspective on Emerging Molecular Tests. Invited. Second Annual Biological Basis of Breast Cancer Conference. Los Angeles, CA, US.
2007. Design of MAQC Study to Assess Reliability of Gene Expression Based Predictors. Conference. The 7th Project Meeting MicroArray Quality Control (MAQC-II). Carey, NC, US.
2007. Pathologic Evaluation of the Breast and Axilla After Preoperative Therapy, NCI State of the Science Meeting. Conference. Preoperative Therapy in Invasive Breast Cancer. Bethesda, MD, US.
2006. Gene Expression Profiling And Breast Cancer – State Of The Art. Conference. The 6th Project Meeting MicroArray Quality Control (MAQC-II). Silver Spring, MD, US.
2006. A Pathologist's Perspective on Emerging Molecular Tests. Invited. First Annual Biological Basis of Breast Cancer Conference. San Diego, CA, US.
2006. A New Measurement of Residual Cancer Burden After Neoadjuvant Chemotherapy. Conference. Breast Cancer III. Chicago, IL, US.
2006. A New Measurement of Residual Cancer Burden After Neoadjuvant Chemotherapy. Conference. Breast Cancer Translational Medicine. Seattle, WA, US.
2006. Intraoperative Evaluation of Margins and Sentinel Lymph Nodes. Conference. 23rd Annual Miami Breast Cancer Conference. Miami, FL, US.
2006. Gene Expression Profiles of Breast Cancer Tumor Cells to Select Systemic Therapy. Conference. 23rd Annual Miami Breast Cancer Conference. Miami, FL, US.
2006. Pathologic Evaluation Before and After Pre-operative Adjuvant Therapy. Conference. 23rd Annual Miami Breast Cancer Conference. Miami, FL, US.
2005. Genomics and Cancer. Conference. Genomics and Cancer. Chicago, IL, US.
2005. MD Anderson Cancer Center Proposal for a National Network of Gene Expression Profiling Centers. Conference. Breast Cancer Intergroup of North America. Chicago, IL, US.
2005. A Radiologic-Pathologic Method to Quantify Response to Neoadjuvant Chemotherapy Predicts Time to Distant Recurrence. Conference. A Radiologic-Pathologic Method to Quantify Response to Neoadjuvant Chemotherapy Predicts Time to Distant Recurrence. Philadelphia, PA, US.
2004. Neoadjuvant Chemotherapy and Effect on Pathologic Evaluation of Breast Cancer. Conference. Lynn Sage Breast Cancer Symposium. Chicago, IL, US.

International Presentations

2022. Interpreting the Complex Landscape of Immune-Tumor Interface. Conference. Interpreting the Complex Landscape of Immune-Tumor Interface. Virtual presentation, BE.
2022. Pathological response as predictor of outcome after neoadjuvant chemotherapy for operable breast cancer. Conference. Pathological response as predictor of outcome after neoadjuvant chemotherapy for operable breast cancer. Virtual presentation, ES.
2019. Risk Stratification in patients with ductal carcinoma in situ. Conference. BCC. Vienna, AT.
2018. Evaluation of the Therapeutic Response to RCB 10 Years Later. Conference. Evaluation of the Therapeutic Response to RCB 10 Years Later. Lima, PE.
2018. Breast Cancer Staging System: Perspective of the Pathologist. Conference. XII International Congress of Mastology. Lima, PE.
2018. Breast Cancer Prevention. Conference. XII International Congress of Mastology. Lima, PE.
2018. The Pathologist's Role in Guiding Breast Cancer Treatment in the Era of Neoadjuvant Therapy. Conference. US and Canadian Academy of Pathology. Vancouver, CA.
2018. The Pathologist’s Role in Guiding Breast Cancer Treatment in the Era of Neoadjuvant Therapy. Conference. The Pathologist’s Role in Guiding Breast Cancer Treatment in the Era of Neoadjuvant Therapy. Vancouver, CA.
2018. Breast Cancer Heterogeneity and Evolution: Relevance to the Histopathologist. Conference. 1st UK Interdisciplinary Breast Cancer Symposium. Manchester, GB.
2018. Relevance to the Histopathologist. Conference. UK Interdisciplinary Breast Cancer Symposium. Manchester, GB.
2018. Neera Patel Lecture: RCB vs pCR as an end-point. Conference. 1st UK Interdisciplinary Breast Cancer Symposium. Manchester, GB.
2017. Global Biomarker Expert Forum. Conference. Barcelona, ES.
2017. Cancer and the Immune System. Conference. Bellairs Research Institute, BB.
2016. Neoadjuvant chemotherapy and its current aspects in breast cancer. Conference. 3rd Annual Joint Meeting. Vienna, AT.
2016. Molecular classifications of breast tumors beyond TCGA & ICGC. Conference. Molecular classifications of breast tumors beyond TCGA & ICGC. Sao Paulo, BR.
2016. Novel Treatment Perspectives for Basal-like tumors. Conference. Novel Treatment Perspectives for Basal-like tumors. Sao Paulo, BR.
2016. Tumor Heterogeneity – implications for diagnosis and treatment. Conference. Tumor Heterogeneity – implications for diagnosis and treatment. Sao Paulo, BR.
2016. Characterization of immune landscape after conventional and targeted therapies. Conference. Characterization of immune landscape after conventional and targeted therapies. Brussels, BE.
2015. Beyond ER/PR/HER2, what is on the horizon?. Conference. Beyond ER/PR/HER2, what is on the horizon?. Brisbane, AU.
2015. All you wanted to know about in situ neoplasia and you were afraid to ask. Conference. All you wanted to know about in situ neoplasia and you were afraid to ask. Milan, IT.
2015. The special case of equivocal pathological biomarkers (ER, PgR and HER2): implications for breast cancer treatment. Conference. St. Gallen Oncology Conferences. Vienna, AT.
2015. Neoadjuvant therapy in breast cancer: Clinical considerations and future discussions. Conference. St. Gallen Oncology Conferences. Vienna, AT.
2014. Quantifying Post-Neoadjuvant Therapy Residual Disease and It's Impact on Relapse Risk. Conference. Quantifying Post-Neoadjuvant Therapy Residual Disease and It's Impact on Relapse Risk. Madrid, ES.
2014. Translational of Biomarker Research to Predictive Diagnostic Oncology. Conference. The Robert Sutherland Award Lecture. Wellington, NZ.
2014. Pathology After Neoadjuvant Chemotherapy. Conference. Annual Scientific Meeting. Wellington, NZ.
2014. Logistics and Feasibility of Biopsies in Clincal Trials. Conference. Logistics and Feasibility of Biopsies in Clincal Trials. Wellington, NZ.
2014. Updates on Manuscripts. Conference. Breast International Group (BIG). Brussels, BE.
2014. Overcoming Operational Challenges of Personalized Cancer Therapy. Conference. IMPAKT Breast Conference. Brussels, BE.
2014. Overcoming operational challenges of personalized cancer therapy. Conference. Overcoming operational challenges of personalized cancer therapy. Brussels, BE.
2013. Biological changes induced by the treatment: influences on clinical approach. Conference. 5th Fifth International Symposium: Primary systemic treatment in the management of operable breast cancer. Cremona, IT.
2013. The role of cytopathology in personalized medicine. Conference. 10th Panhellenic Congress of Cytology Meeting. Athens, GR.
2013. Molecular Markers for treatment response: an overview. Conference. Annual Meeting of the Austrian Society of Senology. Velden, AT.
2013. In situ lesions and microinvasive disease. Conference. 15th Milan Breast Cancer Conference. Milan, IT.
2013. Fine Needle Aspiration For Development and Use of Predictive Genomic Tests of Cancer. Conference. 18th Annual International Congress of Cytology. Paris, FR.
2013. Independent Blinded Validation of the Genomic Index of Sensitivity to Endocrine Therapy. Conference. 5th IMPAKT Breast Cancer Conference. Brussels, BE.
2013. Valoration Criteria of Response in Neoadjuvant therapy and of Survival Prediction. Conference. Valoration Criteria of Response in Neoadjuvant therapy and of Survival Prediction. Malaga, ES.
2012. Personalized Medicine – Are we there Yet?. Conference. Breast Cancer Network of Australia (BCNA). Sydney, AU.
2012. Neoadjuvant Systemic Therapy: Challenges For The Pathologist. Conference. Neoadjuvant Systemic Therapy: Challenges For The Pathologist. Sydney, AU.
2012. Tissue-Based Indicators of Chemotherapy Response. Conference. Tissue-Based Indicators of Chemotherapy Response. Sydney, AU.
2012. Personalized Medicine – Are we there Yet? The Pathologist’s View. Conference. Personalized Medicine – Are we there Yet? The Pathologist’s View. Sydney, AU.
2012. Translational Research at the Breakthrough Research Centre. Visiting. London, GB.
2012. School of Molecular, Genetic and Population Health Sciences. Visiting. Edinburgh, GB.
2012. Genomic Profiling and Personalized Breast Cancer Diagnostics. Conference. The University of Texas MD Anderson Cancer Center. Madrid, ES.
2012. Are whole Genome Arrays Feasible in daily Practice?. Conference. 4th IMPAKT Breast Cancer Conference. Brussels, BE.
2012. Detecting Heterogeneity in Biospecimens. Conference. 3rd Conference on Therapeutic Resistance in Cancer. Montreal, CA.
2012. Breast Cancer. Conference. 8th European Breast Cancer Conference. Vienna, AT.
2011. Breast Cancer Her2/ER. Conference. American Society of Clinical Oncology. Lima, PE.
2011. Update on BIG-NABCG Tissue Handling Recommendations. Conference. Update on BIG-NABCG Tissue Handling Recommendations. Gold Coast, AU.
2011. Challenges for Development and Validation of Predictive Diagnostics. Conference. Challenges for Development and Validation of Predictive Diagnostics. Vancouver, CA.
2010. Assessments of Biologic Pathways as Predictors of Response to Therapy. Conference. Assessments of Biologic Pathways as Predictors of Response to Therapy. Cascais, PT.
2010. Response Assessment. Conference. German Breast Group. Biedenkopf, DE.
2010. Insufficient Response to Neoadjuvant Chemotherapy. Conference. Peruvian Society of Medical Oncology. Cusco, PE.
2010. Role of Molecular Platforms in Breast Cancer. Conference. Role of Molecular Platforms in Breast Cancer. Cusco, PE.
2010. Breast Cancer Tissue Banking For Translational Research. Conference. The Royal Society. London, GB.
2010. Biological Specimen SOPs. Conference. BIG-NABCG Annual Meeting. Brussels, BE.
2010. What Can We Do With This Knowledge? Discussant of Keynote Lecture by Dr. Larry Norton, A decade of translational research in breast cancer: conquests and questions for the future. Conference. What Can We Do With This Knowledge? Discussant of Keynote Lecture by Dr. Larry Norton, A decade of translational research in breast cancer: conquests and questions for the future. Brussels, BE.
2010. Systems Pathology of Breast Cancer. Conference. Systems Pathology of Breast Cancer. Brussels, BE.
2010. Prediction Using Genetic Technologies. Conference. Prediction Using Genetic Technologies. Tokyo, JP.
2009. Molecular Predictors of Response. Conference. 3rd National Congress of Oncology. Manta, EC.
2009. Pathologic Assessment After Neoadjuvant Chemotherapy. Conference. Annual Scientific Meeting. Darwin, AU.
2009. Pathology of Breast Cancer. Conference. European School of Oncology. Tianjin, CN.
2008. Use Of Multigene Signatures In Clinical Samples Of Breast Cancer. Conference. Use Of Multigene Signatures In Clinical Samples Of Breast Cancer. Innsbruck, AT.
2008. Multigene signatures to predict response to taxane-based chemotherapy and endocrine therapy. Conference. Multigene signatures to predict response to taxane-based chemotherapy and endocrine therapy. Hyogo, JP.
2008. Breast Cancer Genomics: an Overview; Standardization of Breast Pathology; Breast Cancer in Saudi Arabia: Road to the Future. Conference. Riyadh, SA.
2008. Measurement of Residual Cancer Burden to Predict Survival After Preoperative Therapy. Conference. Measurement of Residual Cancer Burden to Predict Survival After Preoperative Therapy. Leoben, AT.
2007. A 200-gene endocrine sensitivity index (SET) predicts survival for patients who receive adjuvant endocrine therapy, but not for untreated patients. Conference. A 200-gene endocrine sensitivity index (SET) predicts survival for patients who receive adjuvant endocrine therapy, but not for untreated patients. Crete, GR.
2007. Pathology Evaluation After Preoperative Chemotherapy Lecture. Conference. Pathology Evaluation After Preoperative Chemotherapy Lecture. Lima, PE.
2007. Circulating Tumor Cells. Conference. Circulating Tumor Cells. Cusco, PE.
2007. Genomic Profiling For Prognosis and Response Prediction in Breast Cancer. Conference. Genomic Profiling For Prognosis and Response Prediction in Breast Cancer. Cusco, PE.
2007. Prognostic And Predictive Molecular Markers In Breast Cancer. Conference. Prognostic And Predictive Molecular Markers In Breast Cancer. Sevilla, ES.
2006. Pathology Evaluation After Preoperative Chemotherapy. Conference. Pathology Evaluation After Preoperative Chemotherapy. Lima, PE.
2006. Microarray Profiles to Predict Chemotherapy Response. Conference. Microarray Profiles to Predict Chemotherapy Response. Lima, PE.
2006. Genomic Tests for Response to Hormonal Therapy. Conference. Genomic Tests for Response to Hormonal Therapy. Lima, PE.
2005. Pharmacogenomics at the Bedside. Conference. The Society for Biomolecular Screening 11th Annual Conference. Geneva, CH.
2005. Development of Predictive Genomic Tests for Chemotherapy Response from Neoadjuvant Trials. Conference. Grupo Espanol de Investigacion del Cancer de Mama (GEICAM). Madrid, ES.
2004. Gene Expression Profiling of Breast Cancer. Conference. Australian Society of Cytology. Brisbane, AU.
2004. Use of Fine Needle Aspiration For Gene Expression Profiling of Breast Cancers. Conference. Italian Division of International Academy of Pathology. Naples, IT.
2004. Microarrays and Breast Cancer. Conference. Peruvian Mastology Society. Lima, PE.
2004. The Pathologist’s Role in Sentinel Lymph Node Biopsy. Conference. Peruvian Mastology Society. Lima, PE.
2004. Reliable Measurement of Estrogen Receptor (ER) and Her-2/neu in Needle Biopsies Using Oligonucleotide and cDNA Microarrays. Conference. Reliable Measurement of Estrogen Receptor (ER) and Her-2/neu in Needle Biopsies Using Oligonucleotide and cDNA Microarrays. Vancouver, CA.
2004. Paxillin Overexpression: a Reporter of Her-2/neu Activity That Predicts Response to Docetaxel/Herceptin Chemotherapy. Conference. Paxillin Overexpression: a Reporter of Her-2/neu Activity That Predicts Response to Docetaxel/Herceptin Chemotherapy. Vancouver, CA.
2003. Potential Clinical Utility of Fine Needle Aspiration for Genomic Studies in Breast Cancer, International Symposium to Honor Dr. Torsten Lowhagen. Conference. Potential Clinical Utility of Fine Needle Aspiration for Genomic Studies in Breast Cancer, International Symposium to Honor Dr. Torsten Lowhagen. Stockholm, SE.
2003. Transcriptional Profiling of Breast Cancer: Integration into Clinical Medicine as a Molecular Pathological Assay. Conference. Keynote Lecture, Korean Society of Cytology. Seoul.
2002. Comparison of Fine Needle and Core Needle Biopsies of Breast Cancers for cDNA Microarray Analyses of Gene Expression. Conference. 28th European Congress of Cytology. Antwerp, BE.
2001. Serial fine needle aspirations during neoadjuvant chemotherapy: assessment of Apoptotic responses in breast cancer. Conference. 6th World Congress on Advances in Oncology. Hersonissos, GR.

Formal Peers

2023. Characterization of Chemotherapy Response and a Novel Biomarker of Endocrine Activity in HR+/HER2- Breast Cancer. Oncology Grand Rounds. Invited. New York, NY, US.
2023. Characterization of Chemotherapy Response and a Novel Biomarker of Endocrine Activity in HR+/HER2- Breast Cancer. Pathology Grand Rounds. Invited. New York, NY, US.
2022. Characterization of a Novel Biomarker for HR+/HER2- Breast Cancer. Invited. Houston, TX, US.
2022. Interpretation of Residual Cancer After Neoadjuvant Treatment for Breast Cancer. Pathology Grand Rounds. Invited. Houston, TX, US.
2019. ASCO Neoadjuvant Therapy for Breast Cancer Guideline Expert Panel Meeting. Invited. Alexandria, VA, US.
2019. Fall TBCRC Meeting. Invited. Dallas, TX, US.
2019. BCRF Annul Scientific Retreat. Invited. New York, NY, US.
2019. ASCO Cancer Research Committee Meeting. Invited. Alexandria, VA, US.
2018. Neera Patel Lecture: RCB vs pCR as an end-point,. Visiting. Manchester, England, GB.
2017. MGH Grand Rounds. Invited. Boston, MA, US.
2016. FDA_ PDS Symosium. Invited. Bethesda, MD, US.
2016. NCI/BBRB Workshop. Invited. Rockville, MD, US.
2016. Pathological Evaluation of Breast Specimens After Neoadjuvant Chemotherapy. Invited. Boston, MA, US.
2016. Making Sense of Multi-Gene Expression Panels in Breast Cancer Trials. Invited. Dublin, IE.
2015. RNA Stability in Surgical Resections and Core Biopsies. Invited. Bethesda, MD, US.
2015. Cytology as a Clinical Tool. Invited. Brisbane, AU.
2015. Biomarkers Before and After Neoadjuvant Systemic Therapy. Invited. Medellin, CO.
2015. Genomic Evaluation of Breast Cancer: It's Impact on Classification, Prognosis, and Selection of Local and Systemic Treatments. Invited. Medellin, CO.
2015. Determination of HER2 positivity (IHC, CISH or FISH) - current concepts. Invited. Medellin, CO.
2015. Pathologic Assessment in Neoadjuvant Trials. Invited. Rochester, MN, US.
2015. Translational Approaches to Reduce Residual Risk from Stage II-III Breast Cancer. Invited. Rochester, MN, US.
2014. The Heterogeneity of Triple Negative Breast Cancer in the Molecular Era. Invited. Philadelphia, PA, US.
2013. High dimensional gene expression profiling of breast cancer for prognosis and prediction. Invited. Bronx, NY, US.
2013. Pre-Analytical Effects on Gene Expression in Breast Cancer. Visiting. Rockville, MD, US.
2012. Measurement and prediction of pathological response as a surrogate for survival. Invited. Brussels, BE.
2012. Genomic Profiling of Breast Cancer to Develop Predictors of Treatment Sensitivity; Measurement and prediction of pathological response as a surrogate for survival. Visiting. Minneapolis, MN, US.
2012. Objective Pathological Measurement Of Response To Neoadjuvant Therapy: The Residual Cancer Burden Score. Invited. Dublin, IE.
2012. Predicting Endocrine Sensitivity In Hormone Receptor Positive Breast Cancer: The SET Index. Invited. Dublin, IE.
2012. Development of Predictive Genomic Signatures for Adjuvant Chemotherapy and Endocrine Therapy of Breast Cancer. Invited. Edinburgh, GB.
2012. Training in Method of RCB for Pathologic Response. Invited. London, GB.
2011. Neoadjuvant Chemotherapy For Breast Cancer: A Model To Understand Chemosensitivity, Pathologic Response and Survival. Invited. Vienna, AT.
2011. Genomic Profiling of Breast Cancer to Develop Predictors of Treatment Sensitivity. Invited. Houston, TX, US.
2011. Pharmacogenomic Prediction of Breast Cancer Treatment Efficacy – Lessons Learned. Invited, US.
2011. Expression Biomarkers For Clinical Translational Research. Invited. Houston, TX, US.
2011. Developing, Testing and Implementing Molecular Approaches to Tailor Treatment of Breast Cancer Patients. Invited. Amsterdam, NL.
2011. Cell-Based Breast Cancer Risk Assessment. Visiting. New York, NY, US.
2011. Applications of Breast Cancer Genomics to Clinical Biopsy Samples. Invited. New Haven, CT, US.
2011. Molecular Determinants of Response to Neoadjuvant Treatment. Invited. Paris, FR.
2011. Molecular Determinants of Response to Neoadjuvant Treatment. Invited. San Francisco, CA, US.
2011. Personalized Oncology: Future Translational Research Paradigms, Women's Cancer 2011. Invited. Beirut, LB.
2010. Extent of Disease From the Pathologist’s Perspective. Invited. Chicago, IL, US.
2010. Lobules and Ducts. Invited. Chicago, IL, US.
2010. Pathology and Translational Breast Cancer Research. Invited. Chapel Hill, NC, US.
2010. Development of Gene Expression-Based Predictors of Response To Treatments of Breast Cancer. Invited. Albuquerque, NM, US.
2009. Biopsies of Breast Cancer: Sample and RNA Integrity. Invited. New York, NY, US.
2009. Breast Cancer after Preoperative Chemotherapy, Benign Breast Changes: Moving Towards Breast Cancer. Invited. Chicago, IL, US.
2009. What to Do with High Risk Lesions: The Pathologist’s Perspective, Benign Breast Changes: Moving Towards Breast Cancer. Invited. Chicago, IL, US.
2009. The Role of Molecular Profiling in Guiding Therapeutic Choices for Breast Cancer Treatment, Keynote Lecture. Visiting. New York, NY, US.
2009. Next Generation Predictive Tests in Breast Cancer, Research Seminar. Invited. Raritan, NJ, US.
2008. Staging of Breast in the Context of Neoadjuvant Chemotherapy. Invited. Spartanburg, SC, US.
2008. A Pathologist’s Perspective on Emerging Molecular Tests. Visiting. San Francisco, CA, US.
2008. Development and Clinical Implementation of Pharmacogenomic Predictors For Breast Cancer Treatments. Invited. Nashville, TN, US.
2008. Personalized Healthcare: Breast Cancer. Invited. New Orleans, LA, US.
2008. Pathologic Evaluation of Breast Cancers After Neoadjuvant Chemotherapy. Invited. Boston, MA, US.
2008. Multidisciplinary Breast Cancer Panel. Invited. San Diego, CA, US.
2008. Measurement of Residual Cancer Burden to Predict Survival after Neoadjuvant Chemotherapy, Preoperative Therapy in Breast Cancer. Invited. Leoben, AT.
2008. New Findings For the Breast Clinical Pathologist. Invited. Chicago, IL, US.
2007. Clinical Developments in Gene Expression Profiling of Breast Cancer. Invited. Mexico City, MX.
2007. Is Molecular Profiling Ready for Use in Clinical Practice?. Invited. Los Angeles, CA, US.
2007. A Pathologist’s Perspective on Emerging Molecular Tests. Visiting. Los Angeles, CA, US.
2007. Residual Cancer Burden After Neoadjuvant Chemotherapy. Invited. Boston, MA, US.
2007. Genomic Prediction of Treatment Benefit in Breast Cancer. Invited. New York, NY, US.
2007. Targeted Therapy and Genomics. Invited. Cincinnati, OH, US.
2007. Is Molecular Profiling Ready for Use in Clinical Practice? Challenges and Controversies in Breast Cancer. Invited. Seattle, WA, US.
2006. Biomarkers in Predicting Therapeutic Responses. Invited. Durham, NC, US.
2006. Pharmacogenomic Research and Neoadjuvant Treatment of Breast Cancer” Research Seminar. Invited. Melburne, AU.
2006. A Pathologist’s Perspective on Emerging Molecular Tests. Visiting. San Diego, CA, US.
2006. Gene Expression Profiling of Breast Cancer Samples to Select Systemic Therapy, Plenary Lecture. Visiting. San Francisco, CA, US.
2006. Measurement of Pathologic Response to Neoadjuvant Chemotherapy” Lecture, I Spy 2 Think Tank. Invited. Napa, CA, US.
2005. Integration of Pharmacogenomic Studies Into Clinical Trials. Invited. Beerse, BE.
2005. Breast Cancer Genomics: Proximity To Clinical Diagnostics. Invited. Brunswick, GA, US.
2005. Gene Expression Microarrays Of Breast Cancer: Integration Into Clinical Trials And Proximity To The Diagnostic Laboratory. Invited. Miami, FL, US.
2005. Breast Cancer Genomics. Invited. Albany, NY, US.
2005. Breast Cancer Genomics. Invited. Glenn Falls, NY, US.
2004. Use of Needle Biopsies for Translational Research of Breast Cancer. Invited. Sydney, AU.
2004. Breast Cancer Clinical/Translational Research: Fine Needle Aspiration is a Research Tool. Invited. New York, NY, US.
2004. Breast Cancer Pharmacogenomics: Establishing the Affymetrix Microarray Platform for Clinical Diagnostic/Predictive Testing. Invited. Santa Clara, CA, US.
2003. Use of FNA Samples of Breast Cancer For Genomic Studies. Invited. Chicago, IL, US.
2003. Genomic Profiling of Breast Cancer Samples: Emerging Clinical Utility. Invited. Auckland, NZ.
2003. Transcriptional Profiling of Breast Cancer: Integration into Clinical Medicine as a Molecular Pathological Assay. Invited. Cambridge, MA, US.
2002. Use of Needle Biopsies from Breast Cancer as a Translational Research Tool: Practical Issues and Theoretical Perspective. Visiting. Houston, TX, US.
2001. Early Cellular Responses To Taxane Chemotherapy for Breast Cancer: Implications for Prediction of Therapeutic Response. Invited. Rochester, NY, US.
2001. The Use Of Needle Biopsies To Evaluate Cellular Responses During Neoadjuvant Taxol Therapy. Invited. New York, NY, US.
2001. Initial Apoptotic Response To Paclitaxel May Predict Patients’ Tumor Response To Neoadjuvant Therapy. Invited. New York, NY, US.
2000. Paclitaxel-Induced Apoptosis And Mitotic Arrest Assessed By Serial Fine Needle Aspiration: Implications For Early Prediction Of Breast Cancer Response To Neoadjuvant Treatment. Invited. New York, NY, US.
2000. Use Of Serial Fine-Needle Aspirations To Assess Apoptotic Responses To Neoadjuvant Chemotherapy In Breast Cancer Patients. Invited. Cambridge, MA, US.
2000. Molecular Pathologic Assays For Breast Cancer. Invited. New York, NY, US.
1999. A Prospective Comparison Of Stereotaxic Fine Needle Aspiration Versus Stereotaxic Core Biopsy For The Diagnosis Of Mammographic Abnormalities. Invited. New York, NY, US.
1999. Use Of Fine Needle Aspiration To Measure Mitotic Arrest And Apoptotic Response During Neoadjuvant Paclitaxel Chemotherapy For Breast Cancer. Invited. Auckland, NZ.
1999. A Prospective Comparison Of Stereotaxic Fine Needle Aspiration Versus Stereotaxic Core Biopsy For The Diagnosis Of Mammographic Abnormalities. Invited. Auckland, NZ.
1999. Clinicopathologic Correlation: Histopathological Changes After Neoadjuvant Chemotherapy For Breast Cancer. Invited. New York, NY, US.
1999. Molecular Markers of Breast Cancer. Invited. New York, NY, US.
1999. Needle Biopsies Of Breast Lesions. Invited. New York, NY, US.
1999. Use Of Fine Needle Aspiration To Measure Mitotic Arrest And Apoptotic Response During Neoadjuvant Paclitaxel Chemotherapy For Breast Cancer. Invited. New York, NY, US.
1999. What Is The Meaning Of A Pathology Report Of A Breast Cancer?. Invited. New York, NY, US.
1999. Invasion and Metastasis. New York, NY, US.
1998. Clinicopathologic Correlation: Breast Cancer. Visiting. New York, NY, US.
1998. Needle Breast Biopsy: The Pathologist's Perspective. Invited. New York, NY, US.
1998. A Comparison Of Stereotaxic Breast FNAs And Core Biopsies. Invited. Auckland, NZ.
1997. Stereotaxic FNAs And Core Biopsies In A Community Practice. Invited. New York, NY, US.
1997. A Comparison of Stereotaxic Breast FNAs and Core Biopsies. Invited. New York, NY, US.
1996. Role Of New Breast Cancer Markers. Invited. New York, NY, US.
1996. Biologic Markers Of Breast Cancer. Invited. Auckland, NZ.
1996. The Importance Of Surgical Margins In Breast Cancer. Invited. Auckland, NZ.
1996. Pathology Course. Visiting. New York, NY, US.
1996. Introduction To Neoplasia. Visiting. New York, NY, US.
1996. Invasion And Metastasis. Visiting. New York, NY, US.
1995. Breast Cancer Markers. Invited. New York, NY, US.
1995. Pathology Review. Invited. Chicago, IL, US.
1995. Single Benign Cells That Express CAM 5.2 In The Nipple Epidermis Overlying a Nipple Duct Adenoma: Not Paget’s Disease of the Nipple. Invited. New York, NY, US.
1995. Cytology And Histology. Invited. New York, NY, US.
1994. Radiologic Guided Breast Biopsy. Invited. Auckland, NZ.
1994. Pathology Course. Visiting. New York, NY, US.
1993. The Role Of P53 And Bcl-2 Oncoproteins In The Transformation Of Follicular Lymphoma. Invited. New York, NY, US.
1988. Pathology Course. Visiting. New York, NY, US.

Less

Grant & Contract Support

Date:	2026 - 2032
Title:	Alliance For Clinical Trials in Oncology Operations Grant
Funding Source:	Alliance NCTN Foundation
Role:	PI

Date:	2026 - 2032
Title:	Clinical validation of pre-defined biomarkers to establish new integral tests for prospective trials
Funding Source:	Alliance NCTN Foundation
Role:	Co-PI

Date:	2026 - Present
Title:	Alliance for Clinical Trials in Oncology Operations Center
Funding Source:	NCI via Alliance NCTN Foundation
Role:	PI
ID:	U10CA180821

Date:	2025 - 2030
Title:	Estrogen-dependent Extracellular Vesicle microRNA Regulation in Breast Cancer Microenvironment
Funding Source:	NIH
Role:	Co-I
ID:	PA-25-301

Date:	2025 - 2026
Title:	Translational Research Program for the Alliance for Clinical Trials in Oncology Operations Center - Admin Core
Funding Source:	Brigham And Women's Hospital
Role:	PI

Date:	2024 - 2025
Title:	Clinical Studies Using Genomic Predictors of Breast Cancer Response
Funding Source:	Breast Cancer Research Foundation
Role:	PI
ID:	1327994

Date:	2024 - 2025
Title:	Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
Funding Source:	NCI
Role:	PI

Date:	2024 - 2027
Title:	Elucidating the prediction of benefit from taxane and/or anthracycline chemotherapy treatments for hormone receptor-positive breast cancer
Funding Source:	Department of Defense (DOD)
Role:	PI
ID:	BC230395

Date:	2024 - 2025
Title:	The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes
Funding Source:	Regents of the University of California
Role:	PI

Date:	2024 - 2028
Title:	Alliance Special Project: Validation of the Sensitivity to Endocrine Therapy (SET-ER/PR) index to predict survival benefit from paclitaxel versus anthracycline as dose-dense chemotherapy in CALGB 40101
Funding Source:	The Alliance Foundation
Role:	PI

Date:	2024 - 2027
Title:	Validation of the Sensitivity to Endocrine Therapy (SET-ER/PR) Index To Predict Survival Benefit From Paclitaxel Versus Anthracycline As Dose-Dense Chemotherapy in CALGB 40101
Funding Source:	Alliance for Clinical Trials in Oncology Foundation
Role:	PI

Date:	2024 - 2025
Title:	SWOG S1207 Approved Translational Medicine - testing of the 40-gene Quantigene Plex assay that measures SET2,3 (SET-ER/PR and baseline prognostic indices) and the PIK3 gene expression index
Funding Source:	SWOG Hope Foundation
Role:	PI
ID:	SWOG S1207

Date:	2023 - 2025
Title:	Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
Funding Source:	NIH/NCI
Role:	Principal Investigator-MDACC
ID:	1 UH3 CA276603-01A1

Date:	2023 - 2024
Title:	Clinical Studies Using Genomic Predictors of Breast Cancer Response
Funding Source:	Breast Cancer Research Foundation
Role:	PI
ID:	BCRF-158

Date:	2023 - 2027
Title:	BC221354P1: TAILORx-RxPONDER Clinical Research Extension Award: Advancing Progress, Precision, and Equity in Breast Cancer Care
Funding Source:	Department of Defense (DOD)
Role:	PI
ID:	BC221354P1

Date:	2023 - 2028
Title:	Elucidating the prediction of benefit from taxane and/or anthracycline chemotherapy treatments by measuring endocrine-related transcriptional activity in hormone receptor-positive breast cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	FP17705

Date:	2023 - 2025
Title:	CDK4/6 Inhibitor Resistance Biomarkers in Estrogen
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	FP12390

Date:	2023 - 2025
Title:	Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
Funding Source:	NIH
Role:	PI
ID:	PAR-20-314

Date:	2023 - 2028
Title:	The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes
Funding Source:	Regents of the University of California
Role:	PI

Date:	2023 - 2023
Title:	PALLAS trial translational projects: Testing of the SET2,3 (SET-ER/PR and baseline prognostic indices) in the PALLAS trial tumor samples
Funding Source:	Alliance Foundation
Role:	PI

Date:	2022 - 2023
Title:	Clinical Studies Using Genomic Predictors of Breast Cancer Response
Funding Source:	Breast Cancer Research Foundation
Role:	Principal Investigator-MDACC
ID:	FP00013764

Date:	2022 - 2027
Title:	The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes
Funding Source:	University of California San Francisco
Role:	PI
ID:	PAR-20-077

Date:	2021 - 2022
Title:	Clinical Studies Using Genomic Predictors of Breast Cancer Response
Funding Source:	Breast Cancer Research Foundation
Role:	PI
ID:	FP00013764

Date:	2021 - 2025
Title:	I-SPY 2+: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment in the setting of non-response
Funding Source:	Quantum Leap Healthcare
Role:	Principal Investigator-MDACC
ID:	I-SPY2+

Date:	2021 - 2026
Title:	The University of Texas MD Anderson Cancer Center SPORE in Breast Cancer
Funding Source:	NCI
Role:	Co-I

Date:	2021 - 2023
Title:	CDK4/6 Inhibitor Resistance Biomarkers in Estrogen
Funding Source:	Washington University - St. Louis
Role:	PI
ID:	FP12390

Date:	2021 - 2026
Title:	Modeling patient, healthcare provider-relationship and treatment factors in the dynamic adaptation to challenges in the initial period of daily oral pill in ER+ breast cancer patients
Funding Source:	NIH
Role:	Key

Date:	2020 - 2025
Title:	The University of Texas MD Anderson Cancer Center SPORE in Breast Cancer
Funding Source:	NCI
Role:	Co-I

Date:	2019 - 2025
Title:	Translational Research Program for the Alliance for Clinical Trials in Oncology Operations Center - Admin Core
Funding Source:	NIH/NCI
Role:	PI
ID:	5U10CA180821-09

Date:	2018 - 2023
Title:	Project 3: Rational Combination Treatment Options to Reverse Resistance in Hormone Receptor Positive Breast Cancer Refractory to Standard Therapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Project Leader
ID:	RP180712

Date:	2018 - 2024
Title:	Title: Project 3: Rational Combination Treatment Options to Reverse Resistance in Hormone Receptor Positive Breast Cancer Refractory to Standard Therapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP180712

Date:	2017 - 2022
Title:	I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
Funding Source:	NIH/NCI
Role:	PI
ID:	5P01CA210961-02

Date:	2017 - 2023
Title:	Integrating Biospecimen Science into the Development of RNA-Based Clinical Assays for Patients with Metastatic Breast Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	5U01CA215547-04

Date:	2016 - 2019
Title:	Predicting Sensitivity to Endocrine Therapy and Targeting Resistance for Patients with Advanced Breast Cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP170389

Date:	2016 - 2019
Title:	Predicting Sensitivity to Endocrine Therapy and Targeting Resistance for Patients with Advanced Breast Cancer
Funding Source:	Department of Defense (DOD)
Role:	PI
ID:	BC160920

Date:	2016 - 2021
Title:	Multi-Investigator Research Awards
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP160710-C3

Date:	2016 - 2022
Title:	A Randomized Clinical Trial Platform with Translational Studies to Overcome Resistance in Triple Negative Breast Cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP160710-C3

Date:	2016 - 2021
Title:	Multi-Investigator Research Awards
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP160710-AC

Date:	2016 - 2020
Title:	Measurement of Sensitivity to Endocrine Therapy to Guide Treatment Selection for Patients with Metastatic Breast Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	1UH2CA207069-01

Date:	2015 - 2020
Title:	Genomic Algorithms for Chemoprediction: Stage II-III HER2-Negative Breast Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	1R01CA185175-01A1

Date:	2015 - 2022
Title:	Affymetrix Gene Expression Profiling for I-SPY2 Clinical Trial
Funding Source:	Randall's Foundation
Role:	PI
ID:	I-SPY

Date:	2013 - 2017
Title:	Risk Prediction for ER Negative Breast Cancer Recurrence
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1-RO1-CA172511

Date:	2011 - 2014
Title:	Towards Personalized Cancer Therapy: Stratification of Oral and Pharyngeal Cancer Based on p53 Mutational Status
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I

Date:	2011 - 2014
Title:	Bioinformatics and RNA Test Development
Funding Source:	Khalifa Family Foundation
Role:	PI

Date:	2010 - 2016
Title:	Validation and Implementation of Genomic Testing for Chemotherapy and Endocrine Sensitivity
Funding Source:	Susan G. Komen Breast Cancer Foundation
Role:	PI
ID:	SAC110034

Date:	2010 - 2021
Title:	Clinical Studies Using Genomic Predictors of Breast Cancer Response
Funding Source:	Breast Cancer Research Fund (BCRF)
Role:	PI
ID:	BCRF-20-158

Date:	2010 - 2013
Title:	Genomic Characterization of Metastatic ER-positive Breast Cancer
Funding Source:	Astra Zeneca Research Funds
Role:	PI

Date:	2009 - 2013
Title:	Research and Development on Biospecimen Integrity
Funding Source:	National Cancer Institute/SAIC Frederick
Role:	PI
ID:	HHSN261200800001E

Date:	2008 - 2013
Title:	Prospective evaluation of molecular triaging with pharmacogenomic tests to select neoadjuvant treatment
Funding Source:	Susan G. Komen Breast Cancer Foundation
Role:	PI
ID:	KG081680

Date:	2008 - 2010
Title:	Evidence-Based Quality Control Standards For Microarray-Based Gene Expression Tests
Funding Source:	Breast Cancer Research (BCRF)
Role:	PI

Date:	2007 - 2008
Title:	Reproducibility Of Microarray-Based Predictors for Breast Cancer-Microarray Quality Control (MAQC-II) Clinical Working Group Study
Funding Source:	Breast Cancer Research Foundation (BCRF)
Role:	PI

Date:	2007 - 2009
Title:	Estrogen reporter genes to predict response to endocrine therapy
Funding Source:	Commonwealth Foundation for Cancer Research Funds
Role:	PI

Date:	2006 - 2007
Title:	Molecular triaging of breast cancer patients based on gene expression signatures and further characterization of new molecular targets for drug development
Funding Source:	Breast Cancer Research Foundation (BCRF)
Role:	Co-PI

Date:	2006 - 2008
Title:	Estrogen Reporter Genes To Predict Response To Endocrine Therapy
Funding Source:	NIH/NCI
Role:	PI
ID:	1-R21 CA118156-01A1

Date:	2006 - 2008
Title:	Breastfeeding and undifferentiated breast cancer
Funding Source:	Susan G. Komen Breast Cancer Foundation
Role:	PI
ID:	BCTR0600984

Date:	2005 - 2007
Title:	Validation of Microtubule Associated Protein-Tau as a marker of benefit from adjuvant paclitaxel therapy in the NSABP-B 28 study and identification of further molecular predictors of response to chemotherapy through analysis of transcriptional profile data
Funding Source:	Breast Cancer Research Fund
Role:	Co-PI
ID:	1 R01 CA106290 01 A1

Date:	2005 - 2008
Title:	Development and Validation of Gene-Expression Profile Based Tests that Predict Pathologic Complete Response to Preoperative Chemotherapy for Newly Diagnosed Breast Cancer
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	1 R01 CA106290 01 A1

Date:	2005 - 2009
Title:	Targeting mTOR for Cancer Therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R01 CA 112199-01

Date:	2004 - 2006
Title:	Validation of Tissue Lysate Arrays
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R03 CA110066-01

Date:	2002 - 2006
Title:	Integration of Pathologic Findings with Clinical-Radiologic Tumor Measurements to Quantify Response to Neoadjuvant Chemotherapy
Funding Source:	Department of Defense (DOD)
Role:	PI
ID:	DAMD17-02-1-0458

Date:	2001 - 2004
Title:	Breast Cancer Tissue Arrays for Neoadjuavant Chemotherapy Trials
Funding Source:	Susan G. Komen Breast Cancer Foundation
Role:	PI

Date:	2001 - 2003
Title:	Study of Molecular Profiles Associated with Preoperative FEC (Fluorouracil, Epirubicin And Cyclophosphamide) with and without Trastuzumab for HER-2 Overexpressing Breast Cancer
Funding Source:	Ellence Research Fund
Role:	Co-I

Date:	2001 - 2002
Title:	Phase II study to evaluate XR9576 in chemotherapy resistant advanced breast cancer
Funding Source:	Xenova Ltd
Role:	Co-I
ID:	CS01-266

Date:	1999 - 2003
Title:	Collection of prechemotherapy core biopsies from invasive breast cancer to identify molecular predictors of response to therapy with paclitaxel
Funding Source:	Millennium Predictive Medicine, Inc
Role:	Co-PI

Date:	1999 - 2002
Title:	Paclitaxel in Breast Cancer: Cellular Response and Mechanisms of Resistance
Funding Source:	American Cancer Society
Role:	Co-I

Date:	1999 - 2000
Title:	Cellular Responses During Neoadjuvant Paclitaxel Therapy
Funding Source:	Breast Cancer Research and Education - EMPIRE Program
Role:	PI

Date:	1998 - 2001
Title:	Biological Determinants of Response to and Radiation
Funding Source:	California Breast Cancer research Program
Role:	Co-I

Date:	1997 - 1999
Title:	A Response Biomarker for Paclitaxel Chemotherapy in Patients with Breast Cancer
Funding Source:	NCI Breast Cancer Program Grant
Role:	PI
ID:	R21 CA66229

Selected Publications

Peer-Reviewed Articles

Penault-Llorca, F, Lusque, A, Filleron, T, Tran, K, Du, L, Baehner, R, Dalenc, F, Lacroix-Triki, M, Bachelot, T, Andre, F, Boucher, P, Lemonnier, J, Symmans, WF. Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer. European Journal of Cancer 233, 2026. e-Pub 2026. PMID: 41411882.
Den Hollander, P, Castaneda, M, Vasaikar, S, Maddela, JJ, Gould, C, Demestichas, BR, Joseph, R, Agarwal, S, Deshmukh, A, Zia, A, Shah, S, Zhou, T, Raja, G, Allegakoen, P, Kuburich, NA, Pietilae, MP, Fu, C, Chang, J, Creighton, CJ, Symmans, WF, Soundararajan, R, Mani, S. EMT-induced stem cell and mesenchymal programs can be decoupled via cell division and ESRP1-dependent mechanisms. iScience 29(1), 2026. e-Pub 2026.
Yazdani, A, Lenz, HJ, Pillonetto, G, Méndez-Giráldez, R, Yazdani, A, Sanoff, HK, Hadi, R, Samiei, E, Venook, AP, Ratain, MJ, Rashid, N, Vincent, BG, Qu, X, Wen, Y, Kosorok, M, Symmans, WF, Shen, JY, Lee, MS, Kopetz, S, Nixon, AB, Bertagnolli, MM, Perou, CM, Innocenti, F. Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy. Communications Medicine 5(1), 2025. e-Pub 2025. PMID: 39779996.
Leon-Ferre, R, Dimitroff, K, Yau, C, Giridhar, KV, Mukhtar, RA, Hirst, GL, Hylton, NM, Perlmutter, J, DeMichele, A, Yee, D, van ’t Veer, LJ, Rugo, H, Symmans, WF, Goetz, MP, Esserman, L, Boughey, JC. Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer. Breast Cancer Research 27(1):115, 2025. e-Pub 2025. PMID: 40551254.
Mukhtar, RA, Gottipati, S, Yau, C, Lopez-Tarruella, S, Earl, H, Hayward, L, Hiller, L, Osdoit, M, van der Noordaa, M, de Croze, D, Hamy, AS, Laé, M, Reyal, F, Sonke, GS, Steenbruggen, TG, van Seijen, M, Wesseling, J, Martin, M, del Monte-Millán, M, Boughey, JC, Goetz, MP, Hoskin, TL, Valero, V, Edge, SB, Abraham, JE, Bartlett, JM, Caldas, C, Dunn, J, Provenzano, E, Sammut, SJ, Thomas, J, Graham, A, Hall, P, Mackintosh, L, Fan, F, Godwin, A, Schwensen, K, Sharma, P, Demichele, A, Cole, KS, Pusztai, L, Kim, MO, J van ’t Veer, L, Cameron, D, Esserman, L, Symmans, WF. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer. NPJ Breast Cancer 11(1):14, 2025. e-Pub 2025. PMID: 39948079.
Rinkenbaugh, A, Qi, Y, Cai, S, Shao, J, Baameur Hancock, F, Jeter-Jones, S, Zhang, X, Powell, E, Huo, L, Lau, R, Fu, C, Gould, R, Den Hollander, P, Ravenberg, EE, White, JB, Rauch, GM, Arun, BK, Yam, C, Thompson, A, Echeverria, GV, Moulder, S, Symmans, WF, Chang, J, Piwnica-Worms, H. An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy. Cancer Research 85(21):4062-4080, 2025. e-Pub 2025. PMID: 40801311.
Kaur, M, Dimitroff, K, Boughey, JC, Esserman, L, Yau, C, Tchou, J, Quirarte, A, Lee, MC, Howard-McNatt, M, Switalla, K, Kuerer, HM, Sauder, C, Postlewait, LM, Arciero, CA, Rao, R, Wallace, A, Reyna, C, Ahmed, KA, Gutnik, L, Taunk, NK, Perlmutter, J, DeMichele, A, Yee, D, Hylton, NM, Symmans, WF, Rugo, H, Shatsky, R, Isaacs, C, Rudra, S, Pohlmann, PR, Ewing, CA, Wong, JM, Alvarado, M, Jaskowiak, NT, Prionas, ND, Golshan, M, Piltin, MA, Olopade, OI, Mukhtar, RA. Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial. Annals of surgical oncology 32(11):8211-8219, 2025. e-Pub 2025. PMID: 40699532.
Mukhtar, RA, Dimitroff, K, Yau, C, Chien, AJ, Connolly, E, Howard-McNatt, M, Rao, R, Ladores, V, Golshan, M, Sauder, C, Ahmed, KA, Lancaster, RB, Fox, J, Gutnik, L, Lee, MC, Tchou, J, Prionas, ND, Arciero, CA, Reyna, C, Kuerer, HM, Switalla, K, Taunk, NK, Tuttle, TM, Moran, MS, Postlewait, LM, Perlmutter, J, DeMichele, A, Yee, D, Hylton, NM, Symmans, WF, Rugo, H, Shatsky, R, Isaacs, C, Esserman, L, van‘t Veer, LJ, Boughey, JC. Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer. Annals of surgical oncology 32(11):8243-8253, 2025. e-Pub 2025. PMID: 40705266.
Van Hassel, J, Dimitroff, K, Yau, C, Mukhtar, RA, Boughey, JC, Ladores, V, Howard-McNatt, M, Jaskowiak, NT, Perlmutter, J, DeMichele, A, Yee, D, Hylton, NM, Symmans, WF, Veer, Lt, Rugo, H, Esserman, L, Shatsky, R, Isaacs, C, Kuerer, HM, Wallace, A, Prionas, ND, Tseng, JF, Reyna, C, Taunk, NK, Kesmodel, SB, Lee, MC, Fox, J, Piltin, MA, Tchou, J, Arciero, CA, Postlewait, LM, Sauder, C, Rao, R. Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes. Annals of surgical oncology 32(11):8113-8126, 2025. e-Pub 2025. PMID: 40849380.
Liu, S, Chen, H, Gagea Iurascu, M, Federico, L, Zhang, F, Gomez, J, Do, K, Symmans, WF, Hortobagyi, GN, Mills, GB, González-Angulo, AM, Tripathy, D. ADAMs contribute to triple negative breast cancer via mTORC1 pathway. Cancer Letters 626, 2025. e-Pub 2025. PMID: 40339955.
Winchester, DJ, Singh, L, Edge, SB, Allison, KH, Barlow, WE, Bossuyt, V, Chavez Mac Gregor, M, Conant, EF, Connolly, JL, De los Santos, JF, Hayes, DF, Hylton, NM, Mittendorf, EA, Plichta, JK, Provenzano, E, May, KS, Sharma, P, Symmans, WF, Weaver, DL, Hortobagyi, GN. Novel Postneoadjuvant Prognostic Breast Cancer Staging System. Journal of Clinical Oncology 43(17):1948-1960, 2025. e-Pub 2025. PMID: 40215445.
Shinn, EH, Zahrieh, D, DeMichele, A, Zdenkowski, N, Lemieux, J, Mao, J, Bjelic-Radisic, V, Naughton, MM, Pfeiler, G, Gelmon, K, Balko, JM, Egle, D, Zoppoli, G, Traina, T, Jimenez, MM, Novoa, SA, Haddad, T, Chan, A, Ring, A, Wolff, AC, Symmans, WF, Ponce Lorenzo, J, Sabanathan, D, Burstein, HJ, Nowecki, Z, Pristauz-Telsnigg, G, Brufsky, AM, Bellet, M, Foukakis, T, Novik, Y, Rubovszky, G, Singer, CF, Muehlbacher, K, Filho, OM, Goulioti, T, Law, E, Partridge, AH, Carey, LA, Zoroufy, A, Hlauschek, D, Fesl, C, Mayer, E, Gnant, M. Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer. Breast Cancer Research and Treatment 211(2):385-397, 2025. e-Pub 2025. PMID: 40140172.
Wolf, D, Yau, C, Campbell, M, Glas, AM, Barcaru, A, Mittempergher, L, Kuilman, M, Brown-Swigart, L, Hirst, GL, Basu, A, Magbanua, MM, Sayaman, RW, Huppert, LA, Delson, AL, Symmans, WF, Borowsky, AD, Pohlmann, PR, Rugo, H, Clark, A, Yee, D, DeMichele, A, Perlmutter, J, Petricoin, EF, Chien, J, Stringer-Reasor, E, Shatsky, R, Liu, MC, Han, H, Soliman, H, Isaacs, C, Nanda, R, Hylton, NM, Pusztai, L, Esserman, L, van ’t Veer, LJ, Mukhtar, RA, Melisko, ME, Wallace, A, Yeung, K, Albain, KS, Robinson, P, Lo, S, Olopade, F, Potter, DA, Beckwith, H, Blaes, A, Boughey, JC, Haddad, T, Elias, A, Murthy, RK. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO). JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 40526879.
Metzger-Filho, O, Ballman, KV, Campbell, JD, Liu, MC, Ligibel, JA, Watson, M, Chen, E, Du, L, Stover, DG, Carey, LA, Partridge, AH, Kirshner, J, Muss, H, Hudis, C, Winer, EP, Norton, L, Symmans, WF. Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer. Journal of Clinical Oncology 43(10):1229-1239, 2025. e-Pub 2025. PMID: 39746162.
Ye, Q, Law, T, Klippel, D, Albarracin, C, Chen, H, Contreras, A, Ding, Q, Huo, L, Khazai, L, Middleton, LP, Resetkova, E, Sahin, AA, Sun, H, Sweeney, K, Symmans, WF, Wu, Y, Yoon, EC, Krishnamurthy, S. Prospective and Retrospective Analysis of Whole-Slide Images of Sentinel and Targeted Lymph Node Frozen Sections in Breast Cancer. Mod Pathol 38(4), 2025. e-Pub 2025. PMID: 39788205.
Sura, GH, Tran, K, Trevarton, AJ, Marczyk, M, Fu, C, Du, L, Qu, J, Lau, R, Tasto, AM, Gould, R, Tinnirello, AA, Sinn, BV, Pusztai, L, Hatzis, C, Symmans, WF. Comparative analysis of Ficoll-Hypaque and CytoLyt techniques for blood removal in breast cancer malignant effusions. Journal of the American Society of Cytopathology 14(2):91-101, 2025. e-Pub 2025. PMID: 39668068.
Huppert, LA, Wolf, D, Yau, C, Brown-Swigart, L, Hirst, GL, Isaacs, C, Pusztai, L, Pohlmann, PR, Demichele, A, Shatsky, R, Yee, D, Thomas, A, Nanda, R, Perlmutter, J, Heditsian, D, Hylton, NM, Symmans, WF, van't Veer, LJ, Esserman, L, Rugo, H. Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial. Annals of Oncology 36(2):172-184, 2025. e-Pub 2025. PMID: 39477071.
Rugo, H, Campbell, MJ, Yau, C, Jo Chien, A, Wallace, A, Isaacs, C, Boughey, JC, Han, HS, Buxton, M, Clennell, J, Asare, S, Steeg, K, Wilson, A, Singhrao, R, Matthews, JB, Perlmutter, J, Symmans, WF, Hylton, NM, DeMichele, A, Yee, D, van‘t Veer, LJ, Berry, D, Esserman, L. Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. Breast Cancer Research and Treatment 209(3):487-492, 2025. e-Pub 2025. PMID: 39625569.
Stover, DG, Salgado, R, Savenkov, O, Ballman, KV, Mayer, E, Magbanua, MM, Loi, S, Vater, M, Glover, K, Watson, M, Wen, Y, Symmans, WF, Perou, CM, Carey, LA, Partridge, AH, Rugo, H. Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy. NPJ Breast Cancer 10(1):75, 2024. e-Pub 2024. PMID: 39169033.
Khoury, K, Meisel, JL, Yau, C, Rugo, H, Nanda, R, Davidian, M, Tsiatis, B, Chien, AJ, Wallace, A, Arora, M, Rozenblit, M, Hershman, D, Zimmer, AS, Clark, A, Beckwith, H, Elias, A, Stringer-Reasor, E, Boughey, JC, Nangia, C, Vaklavas, C, Omene, C, Albain, KS, Kalinsky, K, Isaacs, C, Tseng, J, Roussos Torres, ET, Thomas, B, Thomas, A, Sanford, A, Balassanian, R, Ewing, CA, Yeung, K, Sauder, C, Sanft, T, Pusztai, L, Trivedi, M, Outhaythip, A, Li, W, Onishi, N, Asare, A, Beineke, P, Norwood, P, Brown-Swigart, L, Hirst, GL, Matthews, JB, Moore, B, Symmans, WF, Price, ER, Beedle, C, Perlmutter, J, Pohlmann, PR, Shatsky, R, Demichele, A, Yee, D, van ’t Veer, LJ, Hylton, NM, Esserman, L. Datopotamab–deruxtecan in early-stage breast cancer. Nature medicine 30(12):3728-3736, 2024. e-Pub 2024. PMID: 39277671.
Telli, M, Litton, J, Beck, JT, Jones, JM, Andersen, J, Mina, L, Brig, R, Danso, MA, Yuan, Y, Symmans, WF, Hopkins, JF, Albacker, LA, Abbattista, A, Noonan, K, Mata, M, Laird, AD, Blum, JL. Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer. Breast Cancer 31(5):886-897, 2024. e-Pub 2024. PMID: 38869771.
Kim, T, Li, Y, Calhoun, BC, Thennavan, A, Carey, LA, Symmans, WF, Troester, MA, Perou, CM, Marron, JS. Stain SAN. Journal of Medical Imaging 11(4):44006, 2024. e-Pub 2024. PMID: 39185474.
Lim, B, Seth, S, Yam, C, Huo, L, Fujii, T, Lee, J, Bassett Jr, R, Nasser, S, Ravenberg, L, White, JB, Clayborn, A, Guerra, G, Litton, J, Damodaran, S, Layman, RM, Valero, V, Tripathy, D, Lewis, MT, Dobrolecki, LE, Lei, JT, Candelaria, RP, Arun, BK, Rauch, GM, Zhao, L, Zhang, J, Ding, Q, Symmans, WF, Chang, J, Thompson, A, Moulder, S, Ueno, NT. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC. Cell Reports Medicine 5(6), 2024. e-Pub 2024. PMID: 38838676.
Bossuyt V, Provenzano E, Symmans WF, Webster F, Allison KH, Dang C, Gobbi H, Kulka J, Lakhani SR, Moriya T, Quinn CM, Sapino A, Schnitt S, Sibbering DM, Slodkowska E, Yang W, Tan PH, Ellis I. A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology 84(7):1111-1129, 2024. e-Pub 2024. PMID: 38443320.
Powell, RT, Rinkenbaugh, A, Guo, L, Cai, S, Shao, J, Zhou, X, Zhang, X, Jeter-Jones, S, Fu, C, Qi, Y, Baameur Hancock, F, White, JB, Stephan, C, Davies, P, Moulder, S, Symmans, WF, Chang, JT, Piwnica-Worms, H. Targeting neddylation and sumoylation in chemoresistant triple negative breast cancer. npj Breast Cancer 10(1):37, 2024. e-Pub 2024. PMID: 38802426.
Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, Symmans WF, Park BH, Burnette BL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Brown-Glaberman U, Flaum LE, Mayer EL, Sikov WM, Rodler ET, DeMichele AM, Sparano JA, Wolff AC, Miller KD, Wagner LI. Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131. Cancer 130(10):1747-1757, 2024. e-Pub 2024. PMID: 38236702.
Coles CE, Earl H, Anderson BO, Barrios CH, Bienz M, Bliss JM, Cameron DA, Cardoso F, Cui W, Francis PA, Jagsi R, Knaul FM, McIntosh SA, Phillips K, Radbruch L, Thompson MK, André F, Abraham JE, Bhattacharya IS, Franzoi MA, Drewett L, Fulton A, Kazmi F, Rajah DI, Mutebi M, Ng D, Ng S, Olopade OI, Rosa WE, Rubasingham J, Spence D, Stobart H, Enciso VV, Vaz-Luis I, Villarreal-Garza C, Cancer Commission LB. The Lancet Breast Cancer Commission. Lancet 403(10439):1895-1950, 2024. e-Pub 2024. PMID: 38636533.
Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy. Clin Cancer Res 30(11):2444-2451, 2024. e-Pub 2024. PMID: 38470545.
Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown-Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJ. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res 30(4):729-740, 2024. e-Pub 2024. PMID: 38109213.
Jahangir CA, Page DB, Broeckx G, Gonzalez CA, Burke C, Murphy C, Reis-Filho JS, Ly A, Harms PW, Gupta RR, Vieth M, Hida AI, Kahila M, Kos Z, van Diest PJ, Verbandt S, Thagaard J, Khiroya R, Abduljabbar K, Haab GA, Acs B, Adams S, Almeida JS, Alvarado-Cabrero I, Azmoudeh-Ardalan F, Badve S, Baharun NB, Bellolio ER, Bheemaraju V, Blenman KR, Mendonça Fujimoto LB, Burgues O, Chardas A, U Cheang MC, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dantas Portela FL, Deman F, Demaria S, Dudgeon SN, Elghazawy M, Fernandez-Martín C, Fineberg S, Fox SB, Giltnane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hart SN, Hartman J, Hewitt S, Horlings HM, Husain Z, Irshad S, Janssen EA, Kataoka TR, Kawaguchi K, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Akturk G, Scott E, Kovács A, Laenkholm A, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Li X, Madabhushi A, Maley SK, Narasimhamurthy VM, Marks DK, McDonald ES, Mehrotra R, Michiels S, Kharidehal D, Afsar Minhas FUA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papathomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Pusztai L, Rajpoot NM, Rapoport BL, Rau TT, Ribeiro JM, Rimm D, Vincent-Salomon A, Saltz J, Sayed S, Hytopoulos E, Mahon S, Siziopikou KP, Sotiriou C, Stenzinger A, Sughayer MA, Sur D, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson E, Tramm T, Tran WT, der Laak JV, Verghese GE, Viale G, Wahab N, Walter T, Waumans Y, Wen HY, Yang W, Yuan Y, Bartlett J, Loibl S, Denkert C, Savas P, Loi S, Stovgaard ES, Salgado R, Gallagher WM, Rahman A. Image-based multiplex immune profiling of cancer tissues. J Pathol 262(3):271-288, 2024. e-Pub 2024. PMID: 38230434.
Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé J, Investigators I2, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, W Fraser Symmans W, Rugo HS, Isaacs C, DeMichele AM, Yee D, Pohlmann PR, Hirst GL, Esserman LJ, 't Veer LJV, Petricoin EF. Protein signaling and drug target activation signatures to guide therapy prioritization. Cell Rep Med 4(12), 2023. e-Pub 2023. PMID: 38086377.
Yazdani A, Lenz H, Pillonetto G, Mendez-Giraldez R, Yazdani A, Sanof H, Hadi R, Samiei E, Venook AP, Ratain MJ, Rashid N, Vincent BG, Qu X, Wen Y, Kosorok M, Symmans WF, C Shen JPY, Lee MS, Kopetz S, Nixon AB, Bertagnolli MM, Perou CM, Innocenti F. Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy. Res Sq. e-Pub 2023. PMID: 38168324.
Echeverria, GV, Cai, S, Tu, Y, Shao, J, Powell, E, Redwood, AB, Jiang, Y, McCoy, A, Rinkenbaugh, A, Lau, R, Trevarton, AJ, Fu, C, Gould, R, Ravenberg, EE, Huo, L, Candelaria, RP, Santiago, L, Adrada, BE, Lane, DL, Rauch, GM, Yang, WT, White, JB, Chang, JT, Moulder, S, Symmans, WF, Hilsenbeck, SG, Piwnica-Worms, H. Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. npj Breast Cancer 9(1), 2023. e-Pub 2023. PMID: 36627285.
Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, A Jo Chien A, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, Isaacs CJ, Nanda R, Han HS, Yung RL, Tripathy D, Edmiston KK, Viscusi RK, Northfelt DW, Khan QJ, Asare SM, Wilson A, Hirst GL, Lu R, Symmans WF, Yee D, DeMichele AM, 't Veer LJV, Esserman LJ, Olopade OI. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer. JAMA Netw Open 6(12):e2349646, 2023. e-Pub 2023. PMID: 38153734.
Rediti, M, Fernandez-Martinez, A, Venet, D, Rothé, F, Hoadley, KA, Parker, JS, Singh, B, Campbell, JD, Ballman, KV, Hillman, DW, Winer, EP, El-Abed, S, Piccart, MJ, Di Cosimo, S, Symmans, WF, Krop, IE, Salgado, R, Loi, S, Pusztai, L, Perou, CM, Carey, LA, Sotiriou, C. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature communications 14(1), 2023. e-Pub 2023. PMID: 37923752.
Trevarton, AJ, Chang, JT, Symmans, WF. Simple combination of multiple somatic variant callers to increase accuracy. Scientific reports 13(1), 2023. e-Pub 2023. PMID: 37231022.
Clelland, E, Rothschild, HT, Patterson, A, Molina-Vega, J, Kaur, M, Symmans, WF, Schwartz, CJ, Chien, AJ, Benz, C, Mukhtar, RA. Quantifying hormone receptor status in lobular breast cancer in an institutional series. Breast Cancer Research and Treatment 202(2):367-375, 2023. e-Pub 2023. PMID: 37500962.
Sura GH, Tran K, Fu C, Du L, Marczyk M, Gould RE, Chen E, Tasto AM, Tinnirello AA, W Fraser Symmans W. Pre-analytical effects on whole transcriptome and targeted RNA sequencing analysis in cytology. Cytopathology 34(6):551-561, 2023. e-Pub 2023. PMID: 37712171.
Litton JK, J Thaddeus Beck J, Jones JM, Andersen J, Blum JL, Mina LA, Brig R, Danso M, Yuan Y, Abbattista A, Noonan K, Niyazov A, Chakrabarti J, Czibere A, Symmans WF, Telli ML. Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer. Oncologist 28(10):845-855, 2023. e-Pub 2023. PMID: 37318349.
Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, García-Pedrero J, Cañadas I, Agudo J, Huang Y, Sella T, Jin Q, Tayob N, Mittendorf EA, Symmans WF, Tolaney SM, Qiu X, Long H, Lin J-R, Santagata S, Bedrosian I, Yardley DA, Mayer IA, Richardson ET, Oliveira G, Wu CJ, Schuster EF, Dowsett M, Welm AL, Barbie D, Metzger O. Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer. Cancer Res 83(19):3284-3304, 2023. e-Pub 2023. PMID: 37450351.
Mukhtar RA, Chau H, Woriax H, Piltin M, Ahrendt G, Tchou J, Yu H, Ding Q, Dugan CL, Sheade J, Crown A, Carr M, Wong J, Son J, Yang R, Chan T, Terando A, Alvarado M, Ewing C, Tonneson J, Tamirisa N, Gould R, Singh P, Godellas C, Larson K, Chiba A, Rao R, Sauder C, Postlewait L, Lee MC, Symmans WF, Esserman LJ, Boughey JC, Working Group IL. Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective. Ann Surg 278(3):320-327, 2023. e-Pub 2023. PMID: 37325931.
Abuhadra, NK, Sun, R, Yam, C, Rauch, GM, Ding, Q, Lim, B, Thompson, A, Mittendorf, EA, Adrada, BE, Damodaran, S, Virani, K, White, JB, Ravenberg, EE, Sun, J, Choi, J, Candelaria, RP, Arun, BK, Ueno, NT, Santiago, L, Saleem, S, Abouharb, S, Murthy, RK, Ibrahim, NK, Sahin, AA, Valero, V, Symmans, WF, Litton, J, Tripathy, D, Moulder, S, Huo, L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers 15(13), 2023. e-Pub 2023. PMID: 37444385.
Magbanua, MM, Brown-Swigart, L, Ahmed, Z, Sayaman, RW, Renner, D, Kalashnikova, E, Hirst, GL, Yau, C, Wolf, D, Li, W, Delson, AL, Asare, S, Liu, MC, Albain, KS, Chien, AJ, Forero-Torres, A, Isaacs, C, Nanda, R, Tripathy, D, Rodriguez, AA, Sethi, H, Aleshin, A, Rabinowitz, M, Perlmutter, J, Symmans, WF, Yee, D, Hylton, NM, Esserman, L, Demichele, A, Rugo, H, van ’t Veer, LJ. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer cell 41(6):1091-1102.e4, 2023. e-Pub 2023. PMID: 37146605.
Rothschild, HT, Clelland, E, Patterson, A, Molina-Vega, J, Kaur, M, Symmans, WF, Schwartz, CJ, Chien, AJ, Mukhtar, RA. HER-2 low status in early-stage invasive lobular carcinoma of the breast. Breast Cancer Research and Treatment 199(2):349-354, 2023. e-Pub 2023. PMID: 37017812.
Yam, C, Mittendorf, EA, Garber, HR, Sun, R, Damodaran, S, Murthy, RK, Ramirez, DL, Karuturi, MS, Layman, RM, Ibrahim, NK, Rauch, GM, Adrada, BE, Candelaria, RP, White, JB, Ravenberg, EE, Clayborn, A, Ding, Q, Symmans, WF, Prabhakaran, S, Thompson, A, Valero, V, Tripathy, D, Huo, L, Moulder, S, Litton, J. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Research and Treatment 199(3):457-469, 2023. e-Pub 2023. PMID: 37061619.
Abuhadra, NK, Sun, R, Bassett Jr, R, Huo, L, Chang, JT, Teshome, M, Clayborn, A, White, JB, Ravenberg, EE, Adrada, BE, Candelaria, RP, Yang, WT, Ding, Q, Symmans, WF, Arun, BK, Damodaran, S, Koenig, KB, Layman, RM, Lim, B, Litton, J, Thompson, A, Ueno, NT, Piwnica-Worms, H, Hortobagyi, GN, Valero, V, Tripathy, D, Rauch, GM, Moulder, S, Yam, C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer. Investigational New Drugs 41(3):391-401, 2023. e-Pub 2023. PMID: 37043123.
Sahoo, S, Krings, G, Chen, YY, Carter, J, Chen, B, Guo, H, Hibshoosh, H, Reisenbichler, E, Fan, F, Wei, S, Khazai, L, Balassanian, R, Klein, M, Shad, S, Venters, S, Borowsky, AD, Symmans, WF, Tolgay Ocal, I. Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy. Archives of Pathology and Laboratory Medicine 147(5):591-603, 2023. e-Pub 2023. PMID: 35976643.
Marczyk, M, Fu, C, Lau, R, Du, L, Trevarton, AJ, Sinn, BV, Gould, R, Pusztai, L, Hatzis, C, Symmans, WF. Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted messenger RNA sequencing. Cancer Cytopathology 131(5):289-299, 2023. e-Pub 2023. PMID: 36650408.
Osman, AA, Arslan, E, Bartels, MD, Michikawa, C, Lindemann, A, Tomczak, K, Yu, W, Sandulache, VC, Ma, W, Shen, L, Wang, J, Singh, A, Frederick, MJ, Spencer, ND, Kovacs, J, Heffernan, TP, Symmans, WF, Rai, K, Myers, JN. Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 29(7):1344-1359, 2023. e-Pub 2023. PMID: 36689560.
Speers, C, Symmans, WF, Barlow, W, Trevarton, AJ, The, S, Du, L, Rae, JM, Shak, S, Baehner, R, Sharma, P, Pusztai, L, Hortobagyi, GN, Hayes, DF, Albain, KS, Godwin, A, Thompson, A. Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. Journal of Clinical Oncology 41(10):1841-1848, 2023. e-Pub 2023. PMID: 36649570.
Liedtke, C, Mazouni, C, Hess, KR, Andre, F, Tordai, A, Mejia, JA, Symmans, WF, González-Angulo, AM, Hennessy, BT, Green, MC, Cristofanilli, M, Hortobagyi, GN, Pusztai, L. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. J Clin Oncol 41(10):1809-1815, 2023. e-Pub 2023. PMID: 36989609.
Sura, GH, Tran, K, Fu, C, Du, L, Marczyk, M, Martinez, Y, Tinnirello, AA, Gould, R, Lau, R, Symmans, WF. Molecular testing opportunities on cytology effusion specimens. Journal of the American Society of Cytopathology 12(1):10-19, 2023. e-Pub 2023. PMID: 36270909.
Garcia-Recio, S, Hinoue, T, Wheeler, GL, Kelly, BJ, Garrido-Castro, AC, Pascual, T, de Cubas, AA, Xia, Y, Felsheim, BM, McClure, MB, Rajkovic, A, Karaesmen, E, Smith, MA, Fan, C, Ericsson, PG, Sanders, ME, Creighton, CJ, Bowen, J, Leraas, KM, Burns, R, Coppens, SE, Wheless, A, Rezk, S, Garrett, AL, Parker, JS, Foy, KK, Shen, H, Park, BH, Krop, IE, Anders, CK, Gastier-Foster, JM, Rimawi, MF, Nanda, R, Lin, NU, Isaacs, C, Marcom, PK, Storniolo, AM, Couch, FJ, Chandran, U, Davis, M, Silverstein, J, Ropelewski, A, Liu, MC, Hilsenbeck, SG, Norton, L, Richardson, AL, Symmans, WF, Wolff, AC, Davidson, NE, Carey, LA. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nature Cancer 4(1):128-147, 2023. e-Pub 2023. PMID: 36585450.
Chen, H, Ding, Q, Khazai, L, Zhao, L, Damodaran, S, Litton, J, Rauch, GM, Yam, C, Chang, JT, Seth, S, Lim, B, Thompson, A, Mittendorf, EA, Adrada, BE, Virani, K, White, JB, Ravenberg, EE, Song, X, Candelaria, RP, Arun, BK, Ueno, NT, Santiago, L, Saleem, S, Abouharb, S, Murthy, RK, Ibrahim, NK, Routbort, MJ, Sahin, AA, Valero, V, Symmans, WF, Tripathy, D, Wang, WL, Moulder, S, Huo, L. PTEN in triple-negative breast carcinoma. Therapeutic Advances in Medical Oncology 15, 2023. e-Pub 2023. PMID: 37547448.
Lang, J, Forero-Torres, A, Yee, D, Yau, C, Wolf, D, Park, JW, Parker, BA, Chien, AJ, Wallace, A, Murthy, RK, Albain, KS, Ellis, ED, Beckwith, H, Haley, B, Elias, A, Boughey, JC, Yung, RL, Isaacs, C, Clark, A, Han, HS, Nanda, R, Khan, Q, Edmiston, K, Stringer-Reasor, E, Price, ER, Joe, BN, Liu, MC, Brown-Swigart, L, Petricoin, E, Wulfkuhle, JD, Buxton, M, Clennell, J, Sanil, A, Berry, S, Asare, S, Wilson, A, Hirst, GL, Singhrao, R, Asare, A, Matthews, JB, Melisko, ME, Perlmutter, J, Rugo, H, Symmans, WF, Van't Veer, L, Hylton, NM, DeMichele, A, Berry, D, Esserman, L. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. npj Breast Cancer 8(1), 2022. e-Pub 2022. PMID: 36456573.
Osdoit, M, Yau, C, Symmans, WF, Boughey, JC, Ewing, CA, Balassanian, R, Chen, YY, Krings, G, Wallace, A, Zare, S, Fadare, O, Lancaster, RB, Wei, S, Godellas, CV, Tang, P, Tuttle, TM, Klein, M, Sahoo, S, Hieken, TJ, Carter, J, Chen, B, Ahrendt, GM, Tchou, J, Feldman, MM, Tousimis, EA, Zeck, JC, Jaskowiak, NT, Sattar, H, Naik, AM, Lee, MC, Rosa, M, Khazai, L, Rendi, M, Lang, J, Lu, J, Tawfik, OW, Asare, S, Esserman, L, Mukhtar, RA. Association of Residual Ductal Carcinoma in Situ with Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. JAMA Surgery 157(11):1034-1041, 2022. e-Pub 2022. PMID: 36069821.
Suman, VJ, Du, L, Hoskin, TL, Anurag, M, Ma, C, Bedrosian, I, Hunt, KK, Ellis, MJ, Symmans, WF. Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). Clinical Cancer Research 28(15):3287-3295, 2022. e-Pub 2022. PMID: 35653124.
Marczyk, M, Mrukwa, A, Yau, C, Wolf, D, Chen, YY, Balassanian, R, Nanda, R, Parker, BA, Krings, G, Sattar, H, Zeck, JC, Albain, KS, Boughey, JC, Liu, MC, Elias, A, Clark, A, Venters, S, Shad, S, Basu, A, Asare, S, Buxton, M, Asare, A, Rugo, H, Perlmutter, J, DeMichele, A, Yee, D, Berry, D, Veer, Lt, Symmans, WF, Esserman, L, Pusztai, L. Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. Annals of Oncology 33(8):814-823, 2022. e-Pub 2022. PMID: 35513244.
Shinn, EH, Busch, BE, Jasemi, N, Lyman, CA, Toole, JT, Richman, SC, Symmans, WF, Chavez Mac Gregor, M, Peterson, SK, Broderick, G. Network Modeling of Complex Time-Dependent Changes in Patient Adherence to Adjuvant Endocrine Treatment in ER+ Breast Cancer. Frontiers in Psychology 13, 2022. e-Pub 2022. PMID: 35903747.
Wolf, D, Yau, C, Wulfkuhle, JD, Brown-Swigart, L, Gallagher, IR, Lee, PE, Zhu, Z, Magbanua, MM, Sayaman, RW, O'Grady, N, Basu, A, Delson, AL, Coppé, JP, Lu, R, Braun, J, Asare, S, Sit, L, Matthews, JB, Perlmutter, J, Hylton, NM, Liu, MC, Pohlmann, PR, Symmans, WF, Rugo, H, Isaacs, C, DeMichele, A, Yee, D, Berry, D, Pusztai, L, Petricoin, E, Hirst, GL, Esserman, L, Van't Veer, L. Redefining breast cancer subtypes to guide treatment prioritization and maximize response. Cancer cell 40(6):609-623.e6, 2022. e-Pub 2022. PMID: 35623341.
Geyer, C, Sikov, W, Huober, J, Rugo, H, Wolmark, N, O'Shaughnessy, J, Maag, D, Untch, M, Golshan, M, Lorenzo, JP, Metzger-Filho, O, Dunbar, M, Symmans, WF, Rastogi, P, Sohn, JH, Young, RR, Wright, GS, Harkness, C, McIntyre, K, Yardley, D, Loibl, S. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer. Annals of Oncology 33(4):384-394, 2022. e-Pub 2022. PMID: 35093516.
Abuhadra, NK, Sun, R, Litton, J, Rauch, GM, Yam, C, Chang, JT, Seth, S, Bassett Jr, R, Lim, B, Thompson, A, Mittendorf, EA, Adrada, BE, Damodaran, S, White, JB, Ravenberg, EE, Candelaria, RP, Arun, BK, Ueno, NT, Santiago, L, Saleem, S, Abouharb, S, Murthy, RK, Ibrahim, NK, Sahin, AA, Valero, V, Symmans, WF, Tripathy, D, Moulder, S, Huo, L. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers 14(5), 2022. e-Pub 2022. PMID: 35267631.
Yau, C, Osdoit, M, van der Noordaa, M, Shad, S, Wei, J, de Croze, D, Hamy, AS, Laé, M, Reyal, F, Sonke, GS, Steenbruggen, TG, van Seijen, M, Wesseling, J, Martin, M, del Monte-Millán, M, Lopez-Tarruella, S, Adamson, K, Albain, KS, Asare, A, Asare, S, Balassanian, R, Beckwith, H, Berry, S, Berry, D, Boughey, JC, Buxton, M, Chen, YY, Chen, B, Chien, AJ, Chui, SY, Clark, A, Clennell, J, Datnow, B, DeMichele, A, Duan, X, Edmiston, K, Elias, A, Ellis, ED, Esserman, LL, Euhus, D, Fadare, O, Fan, F, Feldman, MM, Forero-Torres, A, Khazai, L, Moulder, S, Murthy, RK, Symmans, WF, Tripathy, D, Valero, V. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer. The lancet oncology 23(1):149-160, 2022. e-Pub 2022. PMID: 34902335.
Yee, D, Isaacs, C, Wolf, D, Yau, C, Haluska, P, Giridhar, KV, Forero-Torres, A, Jo Chien, A, Wallace, A, Pusztai, L, Albain, KS, Ellis, ED, Beckwith, H, Haley, B, Elias, A, Boughey, JC, Kemmer, KA, Yung, RL, Pohlmann, PR, Tripathy, D, Clark, A, Han, HS, Nanda, R, Khan, Q, Edmiston, K, Petricoin, E, Stringer-Reasor, E, Falkson, C, Majure, M, Mukhtar, RA, Helsten, T, Moulder, S, Robinson, P, Wulfkuhle, JD, Brown-Swigart, L, Buxton, M, Clennell, J, Paoloni, M, Sanil, A, Berry, S, Asare, S, Wilson, A, Hirst, GL, Singhrao, R, Asare, A, Matthews, JB, Hylton, NM, DeMichele, A, Melisko, ME, Perlmutter, J, Rugo, H, Symmans, WF, van‘t Veer, LJ, Berry, D, Esserman, L. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. npj Breast Cancer 7(1), 2021. e-Pub 2021. PMID: 34611148.
Metzger-Filho, O, Collier, KA, Asad, S, Ansell, P, Watson, M, Bae, J, Cherian, M, O'Shaughnessy, J, Untch, M, Rugo, H, Huober, J, Golshan, M, Sikov, W, von Minckwitz, G, Rastogi, P, Li, L, Cheng, L, Maag, D, Wolmark, N, Denkert, C, Symmans, WF, Geyer, C, Loibl, S, Stover, DG. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. npj Breast Cancer 7(1), 2021. e-Pub 2021. PMID: 34764307.
Clark, A, Yau, C, Wolf, D, Petricoin, E, Van't Veer, L, Yee, D, Moulder, S, Wallace, A, Chien, AJ, Isaacs, C, Boughey, JC, Albain, KS, Kemmer, KA, Haley, B, Han, HS, Forero-Torres, A, Elias, A, Lang, J, Ellis, ED, Yung, RL, Tripathy, D, Nanda, R, Wulfkuhle, JD, Brown-Swigart, L, Gallagher, RI, Helsten, T, Roesch, E, Ewing, CA, Alvarado, M, Crane, EP, Buxton, M, Clennell, J, Paoloni, M, Asare, S, Wilson, A, Hirst, GL, Singhrao, R, Steeg, K, Asare, A, Matthews, JB, Berry, S, Sanil, A, Melisko, ME, Perlmutter, J, Rugo, H, Schwab, R, Symmans, WF, Hylton, NM, Berry, D, Esserman, L, DeMichele, A. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nature communications 12(1), 2021. e-Pub 2021. PMID: 34741023.
O'Sullivan, C, Ballman, KV, McCall, LM, Kommalapati, A, Zemla, TJ, Weiss, A, Mitchell, MP, Blinder, VS, Tung, N, Irvin, WJ, Lee, M, Goetz, MP, Symmans, WF, Borges, VF, Krop, IE, Carey, LA, Partridge, AH. Alliance A011801 (compassHER2 RD). Future Oncology 17(34):4665-4676, 2021. e-Pub 2021. PMID: 34636255.
Fu, C, Marczyk, M, Samuels, M, Trevarton, AJ, Qu, J, Lau, R, Du, L, Pappas, T, Sinn, BV, Gould, R, Pusztai, L, Hatzis, C, Symmans, WF. Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples. BMC cancer 21(1), 2021. e-Pub 2021. PMID: 33541297.
Symmans, WF, Yau, C, Chen, YY, Balassanian, R, Klein, M, Pusztai, L, Nanda, R, Parker, BA, Datnow, B, Krings, G, Wei, S, Feldman, MM, Duan, X, Chen, B, Sattar, H, Khazai, L, Zeck, JC, Sams, S, Mhawech-Fauceglia, P, Rendi, M, Sahoo, S, Ocal, IT, Fan, F, Lebeau, LG, Vinh, T, Troxell, ML, Chien, AJ, Wallace, A, Forero-Torres, A, Ellis, ED, Albain, KS, Murthy, RK, Boughey, JC, Liu, MC, Haley, B, Elias, A, Clark, A, Kemmer, KA, Isaacs, C, Lang, J, Han, HS, Edmiston, K, Viscusi, RK, Northfelt, D, Khan, Q, Leyland-Jones, B, Venters, S, Shad, S, Matthews, JB, Asare, S, Buxton, M, Asare, A, Rugo, H, Schwab, R, Helsten, T, Hylton, NM, Van't Veer, L, Perlmutter, J, DeMichele, A, Yee, D, Berry, D, Esserman, L. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer. JAMA Oncology 7(11):1654-1663, 2021. e-Pub 2021. PMID: 34529000.
Symmans, WF. Interpreting the Complex Landscape of Immune–Tumor Interface. Clinical Cancer Research 27(20):OF1-OF3, 2021. e-Pub 2021. PMID: 34389608.
Yam, C, Yen, EY, Chang, JT, Bassett Jr, R, Al-Atrash, G, Garber, HR, Huo, L, Yang, F, Philips, A, Ding, Q, Lim, B, Ueno, NT, Kannan, KS, Sun, X, Sun, B, Parra Cuentas, ER, Symmans, WF, White, JB, Ravenberg, EE, Seth, S, Guerriero, JL, Rauch, GM, Damodaran, S, Litton, J, Wargo, J, Hortobagyi, GN, Futreal, A, Wistuba, II, Sun, R, Moulder, S, Mittendorf, EA. Immune phenotype and response to neoadjuvant therapy in triple-negative breast cancer. Clinical Cancer Research 27(19):5365-5375, 2021. e-Pub 2021. PMID: 34253579.
Bossuyt, V, Lau, R, Young, B, Howe, JG, Zhao, F, Leyland-Jones, B, Du, L, Foli, T, Hatzis, C, Symmans, WF. Intra- A nd Interlaboratory Reproducibility of the Sensitivity to Endocrine Therapy Assay for Stage II/III Breast Cancer. Clinical chemistry 67(9):1240-1248, 2021. e-Pub 2021. PMID: 34374711.
Mayer, IA, Zhao, F, Arteaga, CL, Symmans, WF, Park, BH, Burnette, BL, Tevaarwerk, AJ, Garcia, S, Smith, KL, Makower, D, Block, M, Morley, KA, Jani, CR, Mescher, C, Dewani, SJ, Tawfik, B, Flaum, LE, Mayer, E, Sikov, W, Rodler, E, Wagner, LI, DeMichele, A, Sparano, JA, Wolff, AC, Miller, KD. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy. Journal of Clinical Oncology 39(23):2539-2551, 2021. e-Pub 2021. PMID: 34092112.
Pusztai, L, Yau, C, Wolf, D, Han, HS, Du, L, Wallace, A, String-Reasor, E, Boughey, JC, Chien, AJ, Elias, A, Beckwith, H, Nanda, R, Albain, KS, Clark, A, Kemmer, KA, Kalinsky, K, Isaacs, C, Thomas, A, Shatsky, R, Helsten, T, Forero-Torres, A, Liu, MC, Brown-Swigart, L, Petricoin, E, Wulfkuhle, JD, Asare, S, Wilson, A, Singhrao, R, Sit, L, Hirst, GL, Berry, S, Sanil, A, Asare, A, Matthews, JB, Perlmutter, J, Melisko, ME, Rugo, H, Schwab, R, Symmans, WF, Yee, D, Van't Veer, L, Hylton, NM, DeMichele, A, Berry, D, Esserman, L. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer. Cancer cell 39(7):989-998.e5, 2021. e-Pub 2021. PMID: 34143979.
Korde, L, Somerfield, MR, Carey, LA, Crews, JR, Denduluri, N, Hwang, ES, Khan, SA, Loibl, S, Morris, E, Perez, AT, Regan, MM, Spears, PA, Sudheendra, PK, Symmans, WF, Yung, RL, Harvey, BE, Hershman, D. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer. Journal of Clinical Oncology 39(13):1485-1505, 2021. e-Pub 2021. PMID: 33507815.
Du, L, Yau, C, Brown-Swigart, L, Gould, R, Krings, G, Hirst, GL, Bedrosian, I, Layman, RM, Carter, J, Klein, M, Venters, S, Shad, S, van der Noordaa, M, Chien, AJ, Haddad, T, Isaacs, C, Pusztai, L, Albain, KS, Nanda, R, Tripathy, D, Liu, MC, Boughey, JC, Schwab, R, Hylton, NM, DeMichele, A, Perlmutter, J, Yee, D, Berry, D, Van't Veer, L, Valero, V, Esserman, L, Symmans, WF. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy. Annals of Oncology 32(5):642-651, 2021. e-Pub 2021. PMID: 33617937.
Yam, C, Rauch, GM, Rahman, T, Karuturi, MS, Ravenberg, EE, White, JB, Clayborn, A, McCarthy, P, Abouharb, S, Lim, B, Litton, J, Ramirez, DL, Saleem, S, Stec, J, Symmans, WF, Huo, L, Damodaran, S, Sun, R, Moulder, S. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Investigational New Drugs 39(2):509-515, 2021. e-Pub 2021. PMID: 32984932.
Filho, OM, Stover, DG, Asad, S, Ansell, P, Watson, M, Loibl, S, Geyer, C, Bae, J, Collier, KA, Cherian, M, O'Shaughnessy, J, Untch, M, Rugo, H, Huober, J, Golshan, M, Sikov, W, von Minckwitz, G, Rastogi, P, Maag, D, Wolmark, N, Denkert, C, Symmans, WF. Association of Immunophenotype with Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. JAMA Oncology 7(4):603-608, 2021. e-Pub 2021. PMID: 33599688.
Gu, G, Tian, L, Herzog, SK, Rechoum, Y, Gelsomino, L, Gao, M, Du, L, Kim, JA, Dustin, D, Lo, HC, Beyer, AR, Edwards, DE, Gonzalez, T, Tsimelzon, A, Huang, H, Fernandez, NM, Grimm, SL, Hilsenbeck, SG, Liu, D, Xu, J, Alaniz, A, Li, S, Mills, GB, Janku, F, Kittler, R, Zhang, XH, Coarfa, C, Foulds, CE, Symmans, WF, Andò, S, Fuqua, SW. Hormonal modulation of ESR1 mutant metastasis. Oncogene 40(5):997-1011, 2021. e-Pub 2021. PMID: 33323970.
Powell, RT, Redwood, AB, Liu, X, Guo, L, Cai, S, Zhou, X, Tu, Y, Zhang, X, Qi, Y, Jiang, Y, Echeverria, GV, Feng, N, Ma, X, Giuliani, V, Marszalek, JR, Heffernan, TP, Vellano, CP, White, JB, Stephan, C, Davies, P, Moulder, S, Symmans, WF, Chang, JT, Piwnica-Worms, H. Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer. Scientific reports 10(1), 2020. e-Pub 2020. PMID: 33087803.
Kos, Z, Roblin, E, Kim, RS, Michiels, S, Gallas, BD, Chen, W, Van De Vijver, K, Goel, S, Adams, S, Demaria, S, Viale, G, Nielsen, TO, Badve, S, Symmans, WF, Sotiriou, C, Rimm, DL, Hewitt, SM, Denkert, C, Loibl, S, Luen, SJ, Bartlett, JM, Savas, P, Pruneri, G, Dillon, D, Cheang, M, Tutt, A, Hall, JA, Kok, M, Horlings, HM, Madabhushi, A, van der Laak, J, Ciompi, F, Lænkholm, AV, Bellolio, E, Gruosso, T, Fox, SB, Araya O, JC, Floris, G, Hudeček, J, Voorwerk, L, Beck, AH, Kerner, J, Larsimont, D, Declercq, S, Van Den Eynden, GG, Pusztai, L, Yang, W, Yuan, Y, Lazar, A, Sebastian, MM. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. npj Breast Cancer 6(1), 2020. e-Pub 2020. PMID: 32411819.
Candelaria, RP, Adrada, BE, Hess, KR, Santiago, L, Lane, DL, Thompson, A, Moulder, S, Huang, ML, Arribas, E, Rauch, GM, Leung, J, Symmans, WF, Valero, V, Ravenberg, EE, White, JB, Yang, WT. Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. European Journal of Radiology 130, 2020. e-Pub 2020. PMID: 32777736.
Yee, D, DeMichele, A, Yau, C, Isaacs, C, Symmans, WF, Albain, KS, Chen, YY, Krings, G, Wei, S, Harada, S, Datnow, B, Fadare, O, Klein, M, Pambuccian, S, Chen, B, Adamson, K, Sams, S, Mhawech-Fauceglia, P, Magliocco, AM, Feldman, MM, Rendi, M, Sattar, H, Zeck, JC, Ocal, IT, Tawfik, OW, Lebeau, LG, Sahoo, S, Vinh, T, Chien, AJ, Forero-Torres, A, Stringer-Reasor, E, Wallace, A, Pusztai, L, Boughey, JC, Ellis, ED, Elias, A, Lu, J, Lang, J, Han, HS, Clark, A, Nanda, R, Northfelt, D, Khan, Q, Viscusi, RK, Euhus, D, Edmiston, K, Chui, SY, Kemmer, KA, Park, JW, Liu, MC, Olopade, OI, Leyland-Jones, B, Tripathy, D, Moulder, S, Rugo, H, Schwab, R, Lo, SS, Helsten, T, Beckwith, H, Haugen, P, Hylton, NM, Van't Veer, L, Perlmutter, J, Melisko, ME, Wilson, A, Peterson, G, Asare, A, Buxton, M, Paoloni, M, Clennell, J, Hirst, GL, Singhrao, R, Steeg, K, Matthews, JB, Asare, S, Sanil, A, Berry, S, Esserman, L, Berry, D. Association of Event-Free and Distant Recurrence-Free Survival with Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. JAMA Oncology 6(9):1355-1362, 2020. e-Pub 2020. PMID: 32701140.
Lau, R, Du, L, Chen, E, Fu, C, Gould, R, Marczyk, M, Sinn, BV, Layman, RM, Bedrosian, I, Valero, V, Symmans, WF. Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue. Clinical chemistry 66(7):934-945, 2020. e-Pub 2020. PMID: 32613237.
Allison, KH, Hammond, MH, Dowsett, M, McKernin, SE, Carey, LA, Fitzgibbons, PL, Hayes, DF, Lakhani, S, Chavez Mac Gregor, M, Perlmutter, J, Perou, CM, Regan, MM, Rimm, DL, Symmans, WF, Torlakovic, E, Varella, L, Viale, G, Weisberg, TF, McShane, LM, Wolff, AC. Estrogen and progesterone receptor testing in breast cancer. Archives of Pathology and Laboratory Medicine 144(5):545-563, 2020. e-Pub 2020. PMID: 31928354.
Nanda, R, Liu, MC, Yau, C, Shatsky, R, Pusztai, L, Wallace, A, Chien, AJ, Forero-Torres, A, Ellis, ED, Han, HS, Clark, A, Albain, KS, Boughey, JC, Jaskowiak, NT, Elias, A, Isaacs, C, Kemmer, KA, Helsten, T, Majure, M, Stringer-Reasor, E, Parker, C, Lee, MC, Haddad, T, Cohen, RN, Asare, S, Wilson, A, Hirst, GL, Singhrao, R, Steeg, K, Asare, A, Matthews, JB, Berry, S, Sanil, A, Schwab, R, Symmans, WF, Van't Veer, L, Yee, D, DeMichele, A, Hylton, NM, Melisko, ME, Perlmutter, J, Rugo, H, Berry, D, Esserman, L. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with Early-Stage Breast Cancer. JAMA Oncology 6(5):676-684, 2020. e-Pub 2020. PMID: 32053137.
Allison, KH, Hammond, MH, Dowsett, M, McKernin, SE, Carey, LA, Fitzgibbons, PL, Hayes, DF, Lakhani, S, Chavez Mac Gregor, M, Perlmutter, J, Perou, CM, Regan, MM, Rimm, DL, Symmans, WF, Torlakovic, E, Varella, L, Viale, G, Weisberg, TF, McShane, LM, Wolff, AC. Estrogen and progesterone receptor testing in breast cancer. Journal of Clinical Oncology 38(12):1346-1366, 2020. e-Pub 2020. PMID: 31928404.
Chien, AJ, Tripathy, D, Albain, KS, Symmans, WF, Rugo, H, Melisko, ME, Wallace, A, Schwab, R, Helsten, T, Forero-Torres, A, Stringer-Reasor, E, Ellis, ED, Kaplan, HG, Nanda, R, Jaskowiak, NT, Murthy, RK, Godellas, CV, Boughey, JC, Elias, A, Haley, B, Kemmer, KA, Isaacs, C, Clark, A, Lang, J, Lu, J, Korde, L, Edmiston, K, Northfelt, D, Viscusi, RK, Yee, D, Perlmutter, J, Hylton, NM, Van't Veer, L, DeMichele, A, Wilson, A, Peterson, G, Buxton, M, Paoloni, M, Clennell, J, Berry, S, Matthews, JB, Steeg, K, Singhrao, R, Hirst, GL, Sanil, A, Yau, C, Asare, S, Berry, D, Esserman, L. MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2–positive and/or hormone receptor–negative breast cancers in the I-SPY 2 trial. Journal of Clinical Oncology 38(10):1059-1069, 2020. e-Pub 2020. PMID: 32031889.
Di Cosimo, S, Appierto, V, Pizzamiglio, S, Silvestri, M, Baselga, J, Piccart, MJ, Huober, J, Izquierdo, M, de la Peña, L, Hilbers, FS, De Azambuja, E, Untch, M, Pusztai, L, Pritchard, KI, Nuciforo, PG, Vincent-Salomon, A, Symmans, WF, Apolone, G, De Braud, F, Iorio, MV, Verderio, P, Daidone, MG. Early modulation of circulating microRNAs levels in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. International journal of molecular sciences 21(4), 2020. e-Pub 2020. PMID: 32085669.
Sinn, BV, Weber, KE, Schmitt, WD, Fasching, PA, Symmans, WF, Blohmer, JU, Karn, T, Taube, ET, Klauschen, F, Marme, F, Schem, C, Stickeler, E, Ataseven, B, Huober, J, von Minckwitz, G, Seliger, B, Denkert, C, Loibl, S. Human leucocyte antigen class i in hormone receptor-positive, HER2-negative breast cancer. Breast Cancer Research 21(1), 2019. e-Pub 2019. PMID: 31829264.
Marczyk, M, Fu, C, Lau, R, Du, L, Trevarton, AJ, Sinn, BV, Gould, R, Pusztai, L, Hatzis, C, Symmans, WF. The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues. BMC cancer 19(1), 2019. e-Pub 2019. PMID: 31805884.
Sinn, BV, Fu, C, Lau, R, Litton, J, Tsai, TH, Murthy, RK, Tam, AL, Andreopoulou, E, Gong, Y, Murthy, R, Gould, R, Zhang, Y, King, TA, Viale, A, Andrade, VP, Giri, D, Salgado, R, Laïos, I, Sotiriou, C, Marginean, EC, Kwiatkowski, DN, Layman, RM, Booser, DJ, Hatzis, C, Vicente Valero, V, Symmans, WF. SETER/PR. npj Breast Cancer 5(1), 2019. e-Pub 2019. PMID: 31231679.
Hurvitz, S, Martin, M, Jung, KH, Huang, CS, Harbeck, N, Valero, V, Stroiakovski, D, Wildiers, H, Campone, M, Boileau, JF, Fasching, PA, Afenjar, K, Spera, G, Lopez-Valverde, V, Song, C, Trask, PC, Boulet, T, Sparano, JA, Symmans, WF, Thompson, A, Slamon, DJ. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer. Journal of Clinical Oncology 37(25):2206-2216, 2019. e-Pub 2019. PMID: 31157583.
Candelaria, RP, Adrada, BE, Wei, W, Thompson, A, Santiago, L, Lane, DL, Huang, ML, Arribas, E, Rauch, GM, Symmans, WF, Gilcrease, M, Huo, L, Lim, B, Ueno, NT, Moulder, S, Yang, WT. Imaging features of triple-negative breast cancers according to androgen receptor status. European Journal of Radiology 114:167-174, 2019. e-Pub 2019. PMID: 31005169.
Echeverria, GV, Ge, Z, Seth, S, Zhang, X, Jeter-Jones, S, Zhou, X, Cai, S, Tu, Y, McCoy, A, Peoples, M, Sun, Y, Qiu, H, Chang, Q, Bristow, C, Carugo, A, Shao, J, Ma, X, Harris, A, Mundi, P, Lau, R, Ramamoorthy, V, Wu, Y, Alvarez, MJ, Califano, A, Moulder, S, Symmans, WF, Marszalek, JR, Heffernan, TP, Chang, JT, Piwnica-Worms, H. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Science translational medicine 11(488), 2019. e-Pub 2019. PMID: 30996079.
Luen, SJ, Salgado, R, Dieci, MV, Vingiani, A, Curigliano, G, Gould, R, Castaneda, CA, D'Alfonso, TM, Sanchez, J, Cheng, E, Andreopoulou, E, Castillo, M, Adams, S, Demaria, S, Symmans, WF, Michiels, S, Loi, S. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Annals of Oncology 30(2):236-242, 2019. e-Pub 2019. PMID: 30590484.
Shinn, EH, Broderick, G, Fellman, B, Johnson, A, Wieland, E, Moulder, S, Symmans, WF. Simulating time-dependent patterns of nonadherence by patients with breast cancer to adjuvant oral endocrine therapy. JCO Clinical Cancer Informatics 3, 2019. e-Pub 2019. PMID: 31002563.
Echeverria, GV, Powell, E, Seth, S, Ge, Z, Carugo, A, Bristow, C, Peoples, M, Robinson, FS, Qiu, H, Shao, J, Jeter-Jones, S, Zhang, X, Ramamoorthy, V, Cai, S, Wu, W, Draetta, G, Moulder, S, Symmans, WF, Chang, JT, Heffernan, TP, Piwnica-Worms, H. High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. Nature communications 9(1), 2018. e-Pub 2018. PMID: 30498242.
Powell, E, Shao, J, Picon, HM, Bristow, C, Ge, Z, Peoples, M, Robinson, FS, Jeter-Jones, S, Schlosberg, C, Grzeskowiak, CL, Yang, F, Wu, Y, Wistuba, II, Moulder, S, Symmans, WF, Scott, KL, Edwards, JR, Liang, H, Heffernan, TP, Piwnica-Worms, H. A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis. npj Breast Cancer 4(1), 2018. e-Pub 2018. PMID: 29736411.
Reddy, JP, Atkinson, RL, Larson, R, Burks, JK, Smith, D, Debeb, BG, Ruffell, B, Creighton, CJ, Bambhroliya, A, Reuben, JM, Van Laere, S, Krishnamurthy, S, Symmans, WF, Brewster, A, Woodward, W. Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer. Breast Cancer Research and Treatment 171(2):283-293, 2018. e-Pub 2018. PMID: 29858753.
Cha, J, Yang, W, Xia, W, Wei, Y, Chan, LC, Lim, S, Li, C, Kim, T, Chang, S, Lee, H, Hsu, JL, Wang, HL, Kuo, CW, Chang, W, Hadad, SM, Purdie, CA, McCoy, A, Cai, S, Tu, Y, Litton, J, Mittendorf, EA, Moulder, S, Symmans, WF, Thompson, A, Piwnica-Worms, H, Chen, CH, Khoo, KH, Hung, MC. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Molecular cell 71(4):606-620.e7, 2018. e-Pub 2018. PMID: 30118680.
Ding, Q, Wang, Y, Zuo, Z, Gong, Y, Krishnamurthy, S, Li, C, Lai, YJ, Wei, W, Wang, J, Manyam, GC, Diao, L, Zhang, X, Lin, F, Symmans, WF, Sun, L, Liu, C, Liu, X, Debeb, BG, Ueno, NT, Harano, K, Alvarez, RH, Wu, Y, Cristofanilli, M, Huo, L. Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Human Pathology 77:121-129, 2018. e-Pub 2018. PMID: 29689244.
Goetz, MP, Sangkuhl, K, Guchelaar, HJ, Schwab, M, Province, M, Whirl-Carrillo, M, Symmans, WF, McLeod, HL, Ratain, MJ, Zembutsu, H, Gaedigk, A, van Schaik, RH, Ingle, JN, Caudle, KE, Klein, TE. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clinical pharmacology and therapeutics 103(5):770-777, 2018. e-Pub 2018. PMID: 29385237.
Loibl, S, O'Shaughnessy, J, Untch, M, Sikov, W, Rugo, H, McKee, M, Huober, J, Golshan, M, von Minckwitz, G, Maag, D, Sullivan, D, Wolmark, N, McIntyre, K, Ponce Lorenzo, JJ, Metzger-Filho, O, Rastogi, P, Symmans, WF, Liu, X, Geyer, C. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess). The lancet oncology 19(4):497-509, 2018. e-Pub 2018. PMID: 29501363.
Wulfkuhle, JD, Yau, C, Wolf, D, Vis, DJ, Gallagher, RI, Brown-Swigart, L, Hirst, GL, Voest, EE, DeMichele, A, Hylton, NM, Symmans, WF, Yee, D, Esserman, L, Berry, D, Liu, MC, Park, JW, Wessels, LF, Van't Veer, L, Petricoin, E. Evaluation of the HER/PI3K/AKT family signaling network as a predictive biomarker of pathologic complete response for patients with breast cancer treated with Neratinib in the I-SPY 2 TRIAL. JCO Precision Oncology 2:1-20, 2018. e-Pub 2018. PMID: 32914002.
Li, J, Fu, C, Speed, TP, Wang, W, Symmans, WF. Accurate RNA sequencing from formalin-fixed cancer tissue to represent high-quality transcriptome from frozen tissue. JCO Precision Oncology(2):1-9, 2018. e-Pub 2018. PMID: 29862382.
Criscitiello, C, Bayar, MA, Curigliano, G, Symmans, WF, Desmedt, C, Bonnefoi, H, Sinn, BV, Pruneri, G, Vicier, C, Pierga, JY, Denkert, C, Loibl, S, Sotiriou, C, Michiels, S, Andre, F. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. Annals of Oncology 29(1):162-169, 2018. e-Pub 2018. PMID: 29077781.
Hurvitz, S, Martin, M, Symmans, WF, Jung, KH, Huang, CS, Thompson, A, Harbeck, N, Valero, V, Stroiakovski, D, Wildiers, H, Campone, M, Boileau, JF, Beckmann, MW, Afenjar, K, Fresco, R, Helms, HJ, Xu, J, Lin, YG, Sparano, JA, Slamon, DJ. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE). The lancet oncology 19(1):115-126, 2018. e-Pub 2018. PMID: 29175149.
Boughey, JC, Ballman, KV, McCall, LM, Mittendorf, EA, Symmans, WF, Julian, TB, Byrd, DR, Hunt, KK. Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Annals of surgery 266(4):667-676, 2017. e-Pub 2017. PMID: 28657941.
Hunt, KK, Karakas, C, Ha, MJ, Biernacka, A, Yi, M, Sahin, AA, Adjapong, O, Hortobagyi, GN, Bondy, ML, Thompson, PA, Cheung, KL, Ellis, I, Bacus, S, Symmans, WF, Do, K, Keyomarsi, K. Cytoplasmic cyclin E predicts recurrence in patients with breast cancer. Clinical Cancer Research 23(12):2991-3002, 2017. e-Pub 2017. PMID: 27881578.
Varga, Z, Lebeau, A, Bu, H, Hartmann, A, Penault-Llorca, F, Guerini-Rocco, E, Schraml, P, Symmans, WF, Stoehr, R, Teng, X, Turzynski, A, Von Wasielewski, R, Gürtler, C, Laible, M, Schlombs, K, Joensuu, H, Keller, T, Sinn, HP, Sahin, U, Bartlett, JM, Viale, G. An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®. Breast Cancer Research 19(1), 2017. e-Pub 2017. PMID: 28490348.
Hayashi, N, Iwamoto, T, Qi, Y, Niikura, N, Santarpia, L, Yamauchi, H, Nakamura, S, Hortobagyi, GN, Pusztai, L, Symmans, WF, Ueno, NT. Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. Journal of Cancer 8(6):1045-1052, 2017. e-Pub 2017. PMID: 28529618.
Candelaria, RP, Bassett Jr, R, Symmans, WF, Ramineni, M, Moulder, S, Kuerer, HM, Thompson, A, Yang, WT. Performance of mid-treatment breast ultrasound and axillary ultrasound in predicting response to neoadjuvant chemotherapy by breast cancer subtype. Oncologist 22(4):394-401, 2017. e-Pub 2017. PMID: 28314842.
Symmans, WF, Wei, C, Gould, R, Yu, X, Zhang, Y, Liu, M, Walls, A, Bousamra, A, Ramineni, M, Sinn, BV, Hunt, KK, Buchholz, TA, Valero, V, Buzdar, AU, Yang, WT, Brewster, A, Moulder, S, Pusztai, L, Hatzis, C, Hortobagyi, GN. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. Journal of Clinical Oncology 35(10):1049-1060, 2017. e-Pub 2017. PMID: 28135148.
Wolf, D, Yau, C, Sanil, A, Glas, AM, Petricoin, E, Wulfkuhle, JD, Severson, TM, Linn, SC, Brown-Swigart, L, Hirst, GL, Buxton, M, DeMichele, A, Hylton, NM, Symmans, WF, Yee, D, Paoloni, M, Esserman, L, Berry, D, Rugo, H, Olopade, OI, Van't Veer, L. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. npj Breast Cancer 3(1), 2017. e-Pub 2017. PMID: 28948212.
Jiang, T, Shi, W, Wali, VB, Pongor, LS, Li, C, Lau, R, Györffy, B, Lifton, RP, Symmans, WF, Pusztai, L, Hatzis, C. Predictors of Chemosensitivity in Triple Negative Breast Cancer. PLoS Medicine 13(12), 2016. e-Pub 2016. PMID: 27959926.
Park, JW, Liu, MC, Yee, D, Yau, C, Van't Veer, L, Symmans, WF, Paoloni, M, Perlmutter, J, Hylton, NM, Hogarth, M, DeMichele, A, Buxton, M, Chien, AJ, Wallace, A, Boughey, JC, Haddad, T, Chui, SY, Kemmer, KA, Kaplan, HG, Isaacs, C, Nanda, R, Tripathy, D, Albain, KS, Edmiston, K, Elias, A, Northfelt, D, Pusztai, L, Moulder, S, Lang, J, Viscusi, RK, Euhus, D, Haley, B, Khan, Q, Wood, WC, Melisko, ME, Schwab, R, Helsten, T, Lyandres, J, Davis, SE, Hirst, GL, Sanil, A, Esserman, L, Berry, D. Adaptive randomization of neratinib in early breast cancer. New England Journal of Medicine 375(1):11-22, 2016. e-Pub 2016. PMID: 27406346.
Rugo, H, Olopade, OI, DeMichele, A, Yau, C, Van't Veer, L, Buxton, M, Hogarth, M, Hylton, NM, Paoloni, M, Perlmutter, J, Symmans, WF, Yee, D, Chien, AJ, Wallace, A, Kaplan, HG, Boughey, JC, Haddad, T, Albain, KS, Liu, MC, Isaacs, C, Khan, Q, Lang, J, Viscusi, RK, Pusztai, L, Moulder, S, Chui, SY, Kemmer, KA, Elias, A, Edmiston, K, Euhus, D, Haley, B, Nanda, R, Northfelt, D, Tripathy, D, Wood, WC, Ewing, CA, Schwab, R, Lyandres, J, Davis, SE, Hirst, GL, Sanil, A, Berry, D, Esserman, L. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. New England Journal of Medicine 375(1):23-34, 2016. e-Pub 2016. PMID: 27406347.
Mittendorf, EA, Vila, J, Tucker, SL, Chavez Mac Gregor, M, Smith, B, Symmans, WF, Sahin, AA, Hortobagyi, GN, Hunt, KK. The neo-bioscore update for staging breast cancer treated with neoadjuvant chemotherapy incorporation of prognostic biologic factors into staging after treatment. JAMA Oncology 2(7):929-936, 2016. e-Pub 2016. PMID: 26986538.
Pietilae, MP, Vijay, GV, Soundararajan, R, Yu, X, Symmans, WF, Sphyris, N, Mani, S. FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition. Scientific reports 6, 2016. e-Pub 2016. PMID: 27064522.
Mougalian, SS, Hernandez, M, Lei, X, Lynch, SP, Kuerer, HM, Symmans, WF, Theriault, RL, Fornage, BD, Hsu, L, Buchholz, TA, Sahin, AA, Hunt, KK, Yang, WT, Hortobagyi, GN, Valero, V. Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. JAMA Oncology 2(4):508-516, 2016. e-Pub 2016. PMID: 26720612.
Huo, L, Wang, Y, Gong, Y, Krishnamurthy, S, Wang, J, Diao, L, Liu, C, Liu, X, Lin, F, Symmans, WF, Wei, W, Zhang, X, Sun, L, Alvarez, RH, Ueno, NT, Fouad, TM, Harano, K, Debeb, BG, Wu, Y, Reuben, J, Cristofanilli, M, Zuo, Z. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Modern Pathology 29(4):330-346, 2016. e-Pub 2016. PMID: 26916073.
Hatzis, C, Symmans, WF, Zhang, Y, Gould, R, Moulder, S, Hunt, KK, Abu-Khalaf, M, Hofstatter, EW, Lannin, DR, Chagpar, AB, Pusztai, L. Relationship between complete pathologic response to neoadjuvant chemotherapy and survival in triple-negative breast cancer. Clinical Cancer Research 22(1):26-33, 2016. e-Pub 2016. PMID: 26286912.
Agarwal, D, Qi, Y, Jiang, T, Liu, X, Shi, W, Wali, VB, Turk, BE, Ross, JS, Symmans, WF, Pusztai, L, Hatzis, C. Characterization of DNA variants in the human kinome in breast cancer. Scientific reports 5, 2015. e-Pub 2015. PMID: 26420498.
Van Poznak, CH, Somerfield, MR, Bast Jr, RC, Cristofanilli, M, Goetz, MP, González-Angulo, AM, Hicks, DG, Hill, EG, Liu, MC, Lucas, W, Mayer, IA, Mennel, RG, Symmans, WF, Hayes, DF, Harris, LN. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer. Journal of Clinical Oncology 33(24):2695-2704, 2015. e-Pub 2015. PMID: 26195705.
Peintinger, F, Sinn, BV, Hatzis, C, Albarracin, C, Downs-Kelly, E, Morkowski, JJ, Gould, R, Symmans, WF. Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. Modern Pathology 28(7):913-920, 2015. e-Pub 2015. PMID: 25932963.
Qi, Y, Liu, X, Liu, C, Wang, B, Hess, KR, Symmans, WF, Shi, W, Pusztai, L. Reproducibility of variant calls in replicate next generation sequencing experiments. PloS one 10(7), 2015. e-Pub 2015. PMID: 26136146.
Bossuyt, V, Provenzano, E, Symmans, WF, Boughey, JC, Coles, CE, Curigliano, G, Dixon, JM, Esserman, L, Fastner, G, Kühn, T, Peintinger, F, von Minckwitz, G, White, J, Yang, WT, Badve, S, Denkert, C, MacGrogan, G, Penault-Llorca, F, Viale, G, Cameron, D, Davidson, NE, Piccart-Gebhart, MJ, Norton, L, Earl, H, Alba, E, Lluch, A, Albanell, J, Amos, KD, Becette, V, Biernat, W, Bonnefoi, H, Buzdar, AU, Cane, P, Pinder, SE, Carson, L, Dickson-Witmer, D, Gong, G, Green, J, Hsu, CY, Tseng, LM, Kroep, J, Leitch, AM, Sarode, V, Mamounas, EP, Marcom, PK, Nuciforo, PG, Paik, S, Peg, V, Peston, D, Pierga, JY. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Annals of Oncology 26(7):1280-1291, 2015. e-Pub 2015. PMID: 26019189.
DeMichele, A, Yee, D, Berry, D, Albain, KS, Benz, C, Boughey, JC, Buxton, M, Chia, S, Chien, AJ, Chui, SY, Clark, A, Edmiston, K, Elias, A, Forero-Torres, A, Haddad, T, Haley, B, Haluska, P, Hylton, NM, Isaacs, C, Kaplan, HG, Korde, L, Leyland-Jones, B, Liu, MC, Melisko, ME, Minton, S, Moulder, S, Nanda, R, Olopade, OI, Paoloni, M, Park, JW, Parker, BA, Perlmutter, J, Petricoin, E, Rugo, H, Symmans, WF, Tripathy, D, Van't Veer, L, Viscusi, RK, Wallace, A, Wolf, D, Yau, C, Esserman, L. The neoadjuvant model is still the future for drug development in breast cancer. Clinical Cancer Research 21(13):2911-2915, 2015. e-Pub 2015. PMID: 25712686.
Amoroso, V, Generali, D, Buchholz, TA, Cristofanilli, M, Pedersini, R, Curigliano, G, Daidone, MG, Di Cosimo, S, Dowsett, M, Fox, SB, Harris, A, Makris, A, Vassalli, L, Ravelli, A, Cappelletti, MR, Hatzis, C, Hudis, C, Pedrazzoli, P, Sapino, A, Semiglazov, V, von Minckwitz, G, Simoncini, EL, Jacobs, MA, Barry, P, Kühn, T, Darby, SC, Hermelink, K, Symmans, WF, Gennari, A, Schiavon, G, Dogliotti, L, Berruti, A, Bottini, A. International expert consensus on primary systemic therapy in the management of early breast cancer. Journal of the National Cancer Institute - Monographs 2015(51):90-96, 2015. e-Pub 2015. PMID: 26063896.
Khan, SS, Karn, T, Symmans, WF, Rody, A, Müller, V, Holtrich, U, Becker, S, Pusztai, L, Hatzis, C. Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers. Breast Cancer Research and Treatment 149(3):789-797, 2015. e-Pub 2015. PMID: 25651779.
Sheri, A, Smith, IE, Johnston, S, A'hern, R, Nerurkar, A, Jones, RL, Hills, M, Detre, S, Pinder, SE, Symmans, WF, Dowsett, M. Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. Annals of Oncology 26(1):75-80, 2015. e-Pub 2015. PMID: 25361988.
Symmans, WF. Translational research in the national cancer institute’s cooperative groups. Clinical Advances in Hematology and Oncology 12(11):785-787, 2014. e-Pub 2014. PMID: 25674720.
Pusztai, L, Moulder, S, Altan, M, Kwiatkowski, DN, Valero, V, Ueno, NT, Esteva, FJ, Avritscher, R, Qi, Y, Strauss, LC, Hortobagyi, GN, Hatzis, C, Symmans, WF. Gene signature-guided dasatinib therapy in metastatic breast cancer. Clinical Cancer Research 20(20):5265-5271, 2014. e-Pub 2014. PMID: 25172932.
Meric-Bernstam, F, Akcakanat, A, Chen, H, Sahin, AA, Tarco, E, Carkaci, S, Adrada, BE, Singh, G, Do, K, Garces, ZM, Mittendorf, EA, Babiera, G, Bedrosian, I, Hwang, RF, Krishnamurthy, S, Symmans, WF, Gonzalez-Angulo, AM, Mills, GB. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clinical Cancer Research 20(14):3870-3883, 2014. e-Pub 2014. PMID: 24895461.
Fuentes-Mattei, E, Velazquez-Torres, G, Phan, L, Zhang, F, Chou, P, Shin, J, Choi, HH, Chen, JS, Zhao, R, Chen, J, Gully, C, Carlock, C, Qi, Y, Zhang, Y, Wu, Y, Esteva, FJ, Luo, Y, McKeehan, WL, Ensor, J, Hortobagyi, GN, Pusztai, L, Symmans, WF, Lee, M, Yeung, SJ. Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer. Journal of the National Cancer Institute 106(7), 2014. e-Pub 2014. PMID: 24957076.
González-Angulo, AM, Akcakanat, A, Liu, S, Green, MC, Murray III, JL, Chen, H, Palla, S, Koenig, KB, Brewster, A, Valero, V, Ibrahim, NK, Moulder, S, Litton, J, Tarco, E, Moore, JA, Flores, PR, Crawford, DH, Dryden, MJ, Symmans, WF, Sahin, AA, Giordano, SH, Pusztai, L, Do, K, Mills, GB, Hortobagyi, GN, Meric-Bernstam, F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Annals of Oncology 25(6):1122-1127, 2014. e-Pub 2014. PMID: 24669015.
Aktas, B, Sun, H, Yao, H, Shi, W, Hubbard, RE, Zhang, Y, Jiang, T, Ononye, SN, Wali, VB, Pusztai, L, Symmans, WF, Hatzis, C. Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue. Molecular oncology 8(3):717-727, 2014. e-Pub 2014. PMID: 24602449.
Yi, M, Huo, L, Koenig, KB, Mittendorf, EA, Meric-Bernstam, F, Kuerer, HM, Bedrosian, I, Buzdar, AU, Symmans, WF, Crow, JR, Bender, M, Shah, RR, Hortobagyi, GN, Hunt, KK. Which threshold for ER positivity? a retrospective study based on 9639 patients. Annals of Oncology 25(5):1004-1011, 2014. e-Pub 2014. PMID: 24562447.
Shi, W, Balazs, B, Györffy, B, Jiang, T, Symmans, WF, Hatzis, C, Pusztai, L. Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers. Breast Cancer Research and Treatment 144(3):561-568, 2014. e-Pub 2014. PMID: 24619174.
Bertucci, F, Ueno, NT, Finetti, P, Vermeulen, PB, Lucci, A, Robertson, FM, Marsan, M, Iwamoto, T, Krishnamurthy, S, Masuda, H, Van Dam, P, Woodward, W, Cristofanilli, M, Reuben, JM, Dirix, LY, Viens, P, Symmans, WF, Birnbaum, D, Van Laere, SJ. Gene expression profiles of inflammatory breast cancer. Annals of Oncology 25(2):358-365, 2014. e-Pub 2014. PMID: 24299959.
Chavez Mac Gregor, M, Liu, S, Gagliato, DM, Chen, H, Do, K, Pusztai, L, Symmans, WF, Nair, L, Hortobagyi, GN, Mills, GB, Meric-Bernstam, F, González-Angulo, AM. Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiology Biomarkers and Prevention 23(2):316-323, 2014. e-Pub 2014. PMID: 24296856.
Itoh, M, Iwamoto, T, Matsuoka, J, Nogami, T, Motoki, T, Shien, T, Taira, N, Niikura, N, Hayashi, N, Ohtani, S, Higaki, K, Fujiwara, T, Doihara, H, Symmans, WF, Pusztai, L. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers. Breast Cancer Research and Treatment 143(2):403-409, 2014. e-Pub 2014. PMID: 24337596.
Torikoshi, Y, Gohda, K, Davis, ML, Symmans, WF, Pusztai, L, Kazansky, A, Nakayama, S, Yoshida, T, Matsushima, T, Hortobagyi, GN, Ishihara, H, Kim, SJ, Noguchi, S, Ueno, NT. Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient. Journal of Cancer 4(9):697-702, 2014. e-Pub 2014. PMID: 24312139.
Vasan, N, Yelensky, R, Wang, K, Moulder, S, Dzimitrowicz, H, Avritscher, R, Wang, B, Wu, Y, Cronin, M, Palmer, G, Symmans, WF, Miller, VA, Stephens, PJ, Pusztai, L. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers. Oncologist 19(5):453-458, 2014. e-Pub 2014. PMID: 24710307.
Polley, MC, Leung, SC, McShane, LM, Gao, D, Hugh, JC, Mastropasqua, MG, Viale, G, Zabaglo, LA, Penault-Llorca, F, Bartlett, JM, Gown, AM, Symmans, WF, Piper, T, Mehl, E, Enos, RA, Hayes, DF, Dowsett, M, Nielsen, TO. An international ki67 reproducibility study. Journal of the National Cancer Institute 105(24):1897-1906, 2013. e-Pub 2013. PMID: 24203987.
Haibe-Kains, B, Desmedt, C, Di Leo, A, De Azambuja, E, Larsimont, D, Selleslags, J, Delaloge, S, Duhem, C, Kains, JP, Carly, B, Maerevoet, M, Vindevoghel, A, Rouas, G, Lallemand, F, Durbecq, V, Cardoso, F, Salgado, R, Rovere, R, Bontempi, G, Michiels, S, Buyse, M, Nogaret, JM, Qi, Y, Symmans, WF, Pusztai, L, D'Hondt, V, Piccart-Gebhart, MJ, Sotiriou, C. Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients. Genomics Data 1:7-10, 2013. e-Pub 2013. PMID: 26484051.
Masuda, H, Baggerly, KA, Wang, Y, Iwamoto, T, Brewer, T, Pusztai, L, Kai, K, Kogawa, T, Finetti, P, Birnbaum, D, Dirix, LY, Woodward, W, Reuben, JM, Krishnamurthy, S, Symmans, WF, Van Laere, SJ, Bertucci, F, Hortobagyi, GN, Ueno, NT. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Research 15(6), 2013. e-Pub 2013. PMID: 24274653.
Boughey, JC, Suman, VJ, Mittendorf, EA, Ahrendt, GM, Wilke, LG, Taback, B, Leitch, AM, Kuerer, HM, Bowling, M, Flippo-Morton, TS, Byrd, DR, Ollila, DW, Julian, TB, McLaughlin, SA, McCall, LM, Symmans, WF, Le-Petross, H, Haffty, BG, Buchholz, TA, Nelson, H, Hunt, KK. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer. JAMA 310(14):1455-1461, 2013. e-Pub 2013. PMID: 24101169.
Masuda, H, Baggerly, KA, Wang, Y, Zhang, Y, González-Angulo, AM, Meric-Bernstam, F, Valero, V, Lehmann, BD, Pietenpol, JA, Hortobagyi, GN, Symmans, WF, Ueno, NT. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clinical Cancer Research 19(19):5533-5540, 2013. e-Pub 2013. PMID: 23948975.
Bianchini, G, Pusztai, L, Karn, T, Iwamoto, T, Rody, A, Kelly, CM, Müller, V, Schmidt, M, Qi, Y, Holtrich, U, Becker, S, Santarpia, L, Fasolo, A, Del Conte, G, Zambetti, M, Sotiriou, C, Haibe-Kains, B, Symmans, WF, Gianni, L. Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. Breast Cancer Research 15(5), 2013. e-Pub 2013. PMID: 24060333.
Saura, C, Tseng, LM, Chan, S, Chacko, RT, Campone, M, Manikhas, A, Nag, S, Leichman, CG, Dasappa, L, Fasching, PA, De Mendoza, FH, Symmans, WF, Liu, D, Mukhopadhyay, P, Horak, C, Xing, G, Pusztai, L. Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker. Oncologist 18(7):787-794, 2013. e-Pub 2013. PMID: 23853246.
Saura, C, Tseng, LM, Chan, S, Chacko, RT, Campone, M, Manikhas, A, Nag, S, Leichman, CG, Dasappa, L, Fasching, PA, De Mendoza, FH, Symmans, WF, Liu, D, Mukhopadhyay, P, Horak, C, Xing, G, Pusztai, L. Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker. Oncologist 18(7):787-794, 2013. e-Pub 2013. PMID: 23853246.
Yu, KD, Zhu, R, Zhan, M, Rodriguez, AA, Yang, WT, Wong, ST, Makris, A, Lehmann, BD, Chen, X, Mayer, IA, Pietenpol, JA, Shao, Z, Symmans, WF, Chang, J. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clinical Cancer Research 19(10):2723-2733, 2013. e-Pub 2013. PMID: 23549873.
Szekely, B, Iwamoto, T, Szasz, AM, Qi, Y, Matsuoka, J, Symmans, WF, Tokes, AM, Kulka, J, Swanton, C, Pusztai, L. A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories. Breast Cancer Research and Treatment 138(3):691-698, 2013. e-Pub 2013. PMID: 23504136.
Azim, HA, Michiels, S, Zagouri, F, Delaloge, S, Filipits, M, Namer, M, Neven, P, Symmans, WF, Thompson, A, Andre, F, Loi, S, Swanton, C. Utility of prognostic genomic tests in breast cancer practice. Annals of Oncology 24(3):647-654, 2013. e-Pub 2013. PMID: 23337633.
Holder, AM, González-Angulo, AM, Chen, H, Akcakanat, A, Do, K, Symmans, WF, Pusztai, L, Hortobagyi, GN, Mills, GB, Meric-Bernstam, F. High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Research and Treatment 137(1):319-327, 2013. e-Pub 2013. PMID: 23208590.
Santarpia, L, Iwamoto, T, Leo, AD, Hayashi, N, Bottai, G, Stampfer, M, Andre, F, Turner, N, Symmans, WF, Hortobagyi, GN, Pusztai, L, Bianchini, G. DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. Oncologist 18(10):1063-1073, 2013. e-Pub 2013. PMID: 24072219.
Bayraktar, S, Gutierrez-Barrera, AM, Liu, D, Pusztai, L, Litton, J, Valero, V, Hunt, KK, Hortobagyi, GN, Wu, Y, Symmans, WF, Arun, BK. USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer Journal (United States) 19(1):10-17, 2013. e-Pub 2013. PMID: 23337751.
Shen, K, Song, N, Kim, YC, Tian, C, Rice, SD, Gabrin, MJ, Symmans, WF, Pusztai, L, Lee, JK. A Systematic Evaluation of Multi-Gene Predictors for the Pathological Response of Breast Cancer Patients to Chemotherapy. PloS one 7(11), 2012. e-Pub 2012. PMID: 23185353.
Santarpia, L, Qi, Y, Hale, K, Wang, B, Young, E, Booser, DJ, Holmes, FA, O'Shaughnessy, J, Hellerstedt, BA, Pippen, JE, Vidaurre, T, Gomez, HL, Valero, V, Hortobagyi, GN, Symmans, WF, Bottai, G, Di Leo, A, González-Angulo, AM, Pusztai, L. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Research and Treatment 134(1):333-343, 2012. e-Pub 2012. PMID: 22538770.
McGovern, SL, Qi, Y, Pusztai, L, Symmans, WF, Buchholz, TA. Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Research 14(3), 2012. e-Pub 2012. PMID: 22559056.
Chen, W, Yousef, WA, Gallas, BD, Hsu, ER, Lababidi, S, Tang, R, Pennello, GA, Symmans, WF, Pusztai, L. Uncertainty estimation with a finite dataset in the assessment of classification models. Computational Statistics and Data Analysis 56(5):1016-1027, 2012. e-Pub 2012.
Kaufmann, M, von Minckwitz, G, Mamounas, EP, Cameron, D, Carey, LA, Cristofanilli, M, Denkert, C, Eiermann, W, Gnant, M, Harris, JR, Karn, T, Liedtke, C, Mauri, D, Rouzier, R, Ruckhaeberle, E, Semiglazov, V, Symmans, WF, Tutt, A, Pusztai, L. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Annals of surgical oncology 19(5):1508-1516, 2012. e-Pub 2012. PMID: 22193884.
Liu, JC, Voisin, V, Bader, GD, Deng, T, Pusztai, L, Symmans, WF, Esteva, FJ, Egan, SE, Zacksenhaus, E. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2 +:ERα - breast cancer. Proceedings of the National Academy of Sciences of the United States of America 109(15):5832-5837, 2012. e-Pub 2012. PMID: 22460789.
Dutta, B, Pusztai, L, Qi, Y, Andre, F, Lazar, V, Bianchini, G, Ueno, NT, Agarwal, R, Wang, B, Shiang, CY, Hortobagyi, GN, Mills, GB, Symmans, WF, Balazsi, G. A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. British journal of cancer 106(6):1107-1116, 2012. e-Pub 2012. PMID: 22343619.
Iwamoto, T, Booser, DJ, Valero, V, Murray III, JL, Koenig, KB, Esteva, FJ, Ueno, NT, Zhang, J, Shi, W, Qi, Y, Matsuoka, J, Yang, EJ, Hortobagyi, GN, Hatzis, C, Symmans, WF, Pusztai, L. Estrogen Receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. Journal of Clinical Oncology 30(7):729-734, 2012. e-Pub 2012. PMID: 22291085.
González-Angulo, AM, Iwamoto, T, Liu, S, Chen, H, Do, K, Hortobagyi, GN, Mills, GB, Meric-Bernstam, F, Symmans, WF, Pusztai, L. Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clinical Cancer Research 18(4):1109-1119, 2012. e-Pub 2012. PMID: 22235097.
Shen, K, Qi, Y, Song, N, Tian, C, Rice, SD, Gabrin, MJ, Brower, SL, Symmans, WF, O'Shaughnessy, J, Holmes, FA, Asmar, L, Pusztai, L. Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer. BMC medical genomics 5, 2012. e-Pub 2012. PMID: 23158478.
Chang, C, Wang, J, Zhao, C, Fostel, J, Tong, W, Bushel, PR, Deng, Y, Pusztai, L, Symmans, WF, Shi, T. Maximizing biomarker discovery by minimizing gene signatures. BMC genomics 12(SUPPL. 5), 2011. e-Pub 2011. PMID: 22369133.
Zhao, C, Shi, LM, Tong, W, Shaughnessy, JD, Oberthür, A, Pusztai, L, Deng, Y, Symmans, WF, Shi, T. Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile. BMC genomics 12(SUPPL. 5), 2011. e-Pub 2011. PMID: 22369035.
Hess, KR, Wei, C, Qi, Y, Iwamoto, T, Symmans, WF, Pusztai, L. Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems. BMC bioinformatics 12, 2011. e-Pub 2011. PMID: 22132775.
Iwamoto, T, Lee, J, Bianchini, G, Hubbard, RE, Young, E, Matsuoka, J, Kim, SB, Symmans, WF, Hortobagyi, GN, Pusztai, L. First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. Breast Cancer Research and Treatment 130(1):155-164, 2011. e-Pub 2011. PMID: 21833625.
Generali, D, Symmans, WF, Berruti, A, Fox, SB. Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer. Journal of the National Cancer Institute - Monographs(43):99-102, 2011. e-Pub 2011. PMID: 22043052.
Li, Q, Eklund, AC, Birkbak, NJ, Desmedt, C, Haibe-Kains, B, Sotiriou, C, Symmans, WF, Pusztai, L, Brunak, S, Richardson, AL, Szallasi, Z. Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response. BMC bioinformatics 12, 2011. e-Pub 2011. PMID: 21798043.
Hatzis, C, Pusztai, L, Valero, V, Booser, DJ, Esserman, L, Lluch, A, Vidaurre, T, Holmes, FA, Souchon, EA, Wang, H, Martin, M, Cotrina, J, Gomez, HL, Hubbard, RE, Chacón, JI, Ferrer-Lozano, J, Dyer, R, Buxton, M, Gong, Y, Wu, Y, Ibrahim, NK, Andreopoulou, E, Ueno, NT, Hunt, KK, Yang, WT, Nazario, A, DeMichele, A, O'Shaughnessy, J, Hortobagyi, GN, Symmans, WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305(18):1873-1881, 2011. e-Pub 2011. PMID: 21558518.
Desmedt, C, Di Leo, A, De Azambuja, E, Larsimont, D, Haibe-Kains, B, Selleslags, J, Delaloge, S, Duhem, C, Kains, JP, Carly, B, Maerevoet, M, Vindevoghel, A, Rouas, G, Lallemand, F, Durbecq, V, Cardoso, F, Salgado, R, Rovere, R, Bontempi, G, Michiels, S, Buyse, M, Nogaret, JM, Qi, Y, Symmans, WF, Pusztai, L, D'Hondt, V, Piccart-Gebhart, MJ, Sotiriou, C. Multifactorial approach to predicting resistance to anthracyclines. Journal of Clinical Oncology 29(12):1578-1586, 2011. e-Pub 2011. PMID: 21422418.
Coutant, C, Rouzier, R, Qi, Y, Lehmann-Che, J, Bianchini, G, Iwamoto, T, Hortobagyi, GN, Symmans, WF, Uzan, S, Andre, F, De Thé, H, Pusztai, L. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clinical Cancer Research 17(8):2591-2601, 2011. e-Pub 2011. PMID: 21248301.
Yi, M, Kronowitz, S, Meric-Bernstam, F, Feig, BW, Symmans, WF, Lucci, A, Ross, MI, Babiera, G, Kuerer, HM, Hunt, KK. Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer 117(5):916-924, 2011. e-Pub 2011. PMID: 20945319.
Yi, M, Buchholz, TA, Meric-Bernstam, F, Bedrosian, I, Hwang, RF, Ross, MI, Kuerer, HM, Luo, S, Gonzalez-Angulo, AM, Buzdar, AU, Symmans, WF, Feig, BW, Lucci, A, Huang, EH, Hunt, KK. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Annals of surgery 253(3):572-579, 2011. e-Pub 2011. PMID: 21209588.
Iwamoto, T, Bianchini, G, Booser, DJ, Qi, Y, Coutant, C, Ya-Hui Shiang, C, Santarpia, L, Matsuoka, J, Hortobagyi, GN, Symmans, WF, Holmes, FA, O'Shaughnessy, J, Hellerstedt, BA, Pippen, JE, Andre, F, Simon, R, Pusztai, L. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. Journal of the National Cancer Institute 103(3):264-272, 2011. e-Pub 2011. PMID: 21191116.
Iwamoto, T, Bianchini, G, Qi, Y, Cristofanilli, M, Lucci, A, Woodward, W, Reuben, JM, Matsuoka, J, Gong, Y, Krishnamurthy, S, Valero, V, Hortobagyi, GN, Robertson, FM, Symmans, WF, Pusztai, L, Ueno, NT. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Research and Treatment 125(3):785-795, 2011. e-Pub 2011. PMID: 21153052.
González-Angulo, AM, Hennessy, BT, Meric-Bernstam, F, Sahin, AA, Liu, W, Ju, Z, Carey, M, Myhre, S, Speers, C, Deng, L, Broaddus, R, Lluch, A, Aparicio, SA, Brown, PH, Pusztai, L, Symmans, WF, Alsner, J, Overgaard, J, Borresen-Dale, A, Hortobagyi, GN, Coombes, KR, Mills, GB. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clinical Proteomics 8(1), 2011. e-Pub 2011. PMID: 21906370.
Kuerer, HM, Buzdar, AU, Mittendorf, EA, Esteva, FJ, Lucci, A, Vence, LM, Radvanyi, L, Meric-Bernstam, F, Hunt, KK, Symmans, WF. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 117(1):39-47, 2011. e-Pub 2011. PMID: 20740500.
Hatzis, C, Sun, H, Yao, H, Hubbard, RE, Meric-Bernstam, F, Babiera, G, Wu, Y, Pusztai, L, Symmans, WF. Effects of tissue handling on rna integrity and microarray measurements from resected breast cancers. Journal of the National Cancer Institute 103(24):1871-1883, 2010. e-Pub 2010. PMID: 22034635.
Bianchini, G, Iwamoto, T, Qi, Y, Coutant, C, Shiang, CY, Wang, B, Santarpia, L, Valero, V, Hortobagyi, GN, Symmans, WF, Gianni, L, Pusztai, L. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. Cancer Research 70(21):8852-8862, 2010. e-Pub 2010. PMID: 20959472.
Shinde, SS, Forman, MR, Kuerer, HM, Yan, K, Peintinger, F, Hunt, KK, Hortobagyi, GN, Pusztai, L, Symmans, WF. Higher parity and shorter breastfeeding duration. Cancer 116(21):4933-4943, 2010. e-Pub 2010. PMID: 20665494.
Tabchy, A, Valero, V, Vidaurre, T, Lluch, A, Gomez, HL, Martin, M, Qi, Y, Barajas-Figueroa, LJ, Souchon, EA, Coutant, C, Doimi, F, Ibrahim, NK, Gong, Y, Hortobagyi, GN, Hess, KR, Symmans, WF, Pusztai, L. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clinical Cancer Research 16(21):5351-5361, 2010. e-Pub 2010. PMID: 20829329.
Shiang, CY, Qi, Y, Wang, B, Lazar, V, Wang, J, Symmans, WF, Hortobagyi, GN, Andre, F, Pusztai, L. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Research and Treatment 123(3):747-755, 2010. e-Pub 2010. PMID: 20024612.
Bianchini, G, Qi, Y, Alvarez, RH, Iwamoto, T, Coutant, C, Ibrahim, NK, Valero, V, Cristofanilli, M, Green, MC, Radvanyi, L, Hatzis, C, Hortobagyi, GN, Andre, F, Gianni, L, Symmans, WF, Pusztai, L. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. Journal of Clinical Oncology 28(28):4316-4323, 2010. e-Pub 2010. PMID: 20805453.
Symmans, WF, Hatzis, C, Sotiriou, C, Andre, F, Peintinger, F, Regitnig, P, Daxenbichler, G, Desmedt, C, Dômont, J, Marth, C, Delaloge, S, Bauernhofer, T, Valero, V, Booser, DJ, Hortobagyi, GN, Pusztai, L. Genomic index of sensitivity to endocrine therapy for breast cancer. Journal of Clinical Oncology 28(27):4111-4119, 2010. e-Pub 2010. PMID: 20697068.
Shi, LM, Campbell, G, Jones, WD, Campagne, F, Wen, Z, Walker, S, Su, Z, Chu, TM, Goodsaid, F, Pusztai, L, Shaughnessy, JD, Oberthür, A, Thomas, RS, Paules, RS, Fielden, M, Barlogie, B, Chen, W, Du, P, Fischer, M, Furlanello, C, Gallas, BD, Ge, X, Megherbi, DB, Symmans, WF, Wang, MD, Zhang, J, Bitter, H, Brors, B, Bushel, PR, Bylesjo, M, Chen, M, Cheng, J, Cheng, J, Chou, J, Davison, TS, Delorenzi, M, Deng, Y, Devanarayan, V, Dix, DJ, Dopazo, J, Dorff, KC, Elloumi, F, Fan, J, Fan, S, Fan, X, Fang, H, Gonzaludo, N, Hess, KR, Hong, H, Huan, J, Irizarry, RA, Judson, R, Juraeva, D, Lababidi, S, Lambert, CG, Li, L, Li, Y, Li, Z, Lin, SM, Liu, G, Lobenhofer, EK, Luo, J, Luo, W, McCall, MN, Nikolsky, Y, Pennello, GA, Perkins, RG, Philip, R, Popovici, V, Price, ND, Qian, F, Scherer, A, Shi, T, Shi, W, Sung, J, Thierry-Mieg, D, Thierry-Mieg, J, Thodima, V, Trygg, J, Vishnuvajjala, L, Wang, SJ, Wu, J, Wu, Y, Xie, Q, Yousef, WA, Zhang, L, Zhang, X, Zhong, S, Zhou, Y, Zhu, S, Arasappan, D, Bao, W, Lucas, A, Berthold, F, Brennan, RJ, Buneß, A, Catalano, JG, Chang, C, Chen, R, Cheng, Y, Cui, J, Czika, W, Demichelis, F, Deng, X, Dosymbekov, D, Eils, R, Feng, Y, Fostel, J, Fulmer-Smentek, S, Fuscoe, J, Gatto, L, Ge, W, Goldstein, DR, Guo, L, Halbert, DN, Han, J, Harris, SC, Hatzis, C, Herman, D, Huang, J, Jensen, R, Jiang, R, Johnson, CD, Jurman, G, Kahlert, Y, Khuder, SA, Kohl, M, Li, J, Lee, L, Li, M, Li, QZ, Li, S, Li, Z, Liu, J, Liu, Y, Liu, Z, Meng, L, Madera, M, Martinez-Murillo, F, Medina, I, Meehan, J, Miclaus, K, Moffitt, RA, Montaner, D, Mukherjee, P, Mulligan, G, Neville, P, Nikolskaya, T, Ning, B, Page, GP, Parker, JS, Parry, RM, Peng, X, Peterson, RL, Phan, JH, Quanz, B, Ren, Y, Riccadonna, S, Roter, AH, Samuelson, FW, Schumacher, MM, Shambaugh, JD, Shi, Q, Shippy, R, Si, S, Smalter, A, Sotiriou, C, Soukup, M, Staedtler, F, Steiner, G, Stokes, TH, Sun, Q, Tan, PY, Tang, R, Tezak, Z, Thorn, B, Tsyganova, M, Turpaz, Y, Vega, SC, Visintainer, R, Von Frese, J, Wang, C, Wang, E, Wang, J, Wang, W, Westermann, F, Willey, J, Woods, M, Wu, S, Xiao, N, Xu, J, Xu, L, Yang, L, Zeng, X, Zhang, J, Zheng, L, Zhang, M, Zhao, C, Puri, RK, Scherf, U, Tong, W, Wolfinger, RD. The Microarray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nature biotechnology 28(8):827-838, 2010. e-Pub 2010. PMID: 20676074.
Loi, S, Haibe-Kains, B, Majjaj, S, Lallemand, F, Durbecq, V, Larsimont, D, González-Angulo, AM, Pusztai, L, Symmans, WF, Bardelli, A, Ellis, P, Tutt, A, Gillett, C, Hennessy, BT, Mills, GB, Phillips, WA, Piccart-Gebhart, MJ, Speed, TP, McArthur, GA, Sotiriou, C. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America 107(22):10208-10213, 2010. e-Pub 2010. PMID: 20479250.
Liedtke, C, Wang, J, Tordai, A, Symmans, WF, Hortobagyi, GN, Kiesel, L, Hess, KR, Baggerly, KA, Coombes, KR, Pusztai, L. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Research and Treatment 121(2):301-309, 2010. e-Pub 2010. PMID: 19603265.
Moulder, S, Yan, K, Huang, F, Hess, KR, Liedtke, C, Lin, F, Hatzis, C, Hortobagyi, GN, Symmans, WF, Pusztai, L. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Molecular cancer therapeutics 9(5):1120-1127, 2010. e-Pub 2010. PMID: 20423993.
Caudle, AS, González-Angulo, AM, Hunt, KK, Liu, P, Pusztai, L, Symmans, WF, Kuerer, HM, Mittendorf, EA, Hortobagyi, GN, Meric-Bernstam, F. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. Journal of Clinical Oncology 28(11):1821-1828, 2010. e-Pub 2010. PMID: 20231683.
Birkbak, NJ, Szallasi, Z, Eklund, AC, Li, Q, Burrell, RA, Gerlinger, M, Valero, V, Andreopoulou, E, Esteva, FJ, Symmans, WF, Desmedt, C, Haibe-Kains, B, Sotiriou, C, Pusztai, L, Swanton, C. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer. The lancet oncology 11(4):358-365, 2010. e-Pub 2010. PMID: 20189874.
Lee, JK, Coutant, C, Kim, YC, Qi, Y, Theodorescu, D, Symmans, WF, Baggerly, KA, Rouzier, R, Pusztai, L. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clinical Cancer Research 16(2):711-718, 2010. e-Pub 2010. PMID: 20068086.
Popovici, V, Chen, W, Gallas, BD, Hatzis, C, Shi, W, Samuelson, FW, Nikolsky, Y, Tsyganova, M, Ishkin, A, Nikolskaya, T, Hess, KR, Valero, V, Booser, DJ, Delorenzi, M, Hortobagyi, GN, Shi, LM, Symmans, WF, Pusztai, L. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Research 12(1), 2010. e-Pub 2010. PMID: 20064235.
Lehmann-Che, J, Andre, F, Desmedt, C, Mazouni, C, Giacchetti, S, Turpin, E, Espié, M, Plassa, LF, Marty, M, Bertheau, P, Sotiriou, C, Piccart-Gebhart, MJ, Symmans, WF, Pusztai, L, De Thé, H. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist 15(3):246-252, 2010. e-Pub 2010. PMID: 20228131.
Symmans WF. Abstracts of Breast Cancer Research 2010. London, United Kingdom. May 18, 2010. Breast Cancer Res 12 Suppl 1(Suppl 1):L1-3, O1-6, P1-59, 2010. e-Pub 2010. PMID: 20492635.
Leng, X, Ding, T, Lin, H, Wang, Y, Hu, L, Hu, J, Feig, BW, Zhang, W, Pusztai, L, Symmans, WF, Wu, Y, Arlinghaus, R. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Research 69(22):8579-8584, 2009. e-Pub 2009. PMID: 19887608.
Pusztai, L, Jeong, JH, Gong, Y, Ross, JS, Kim, C, Paik, S, Rouzier, R, Andre, F, Hortobagyi, GN, Wolmark, N, Symmans, WF. Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. Journal of Clinical Oncology 27(26):4287-4292, 2009. e-Pub 2009. PMID: 19667268.
Gong, Y, Sweet, W, Duh, YJ, Greenfield, L, Tarco, E, Trivedi, S, Symmans, WF, Isola, J, Sneige, N. Performance of chromogenic in situ hybridization on testing HER2 status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) HercepTest results. American journal of clinical pathology 132(2):228-236, 2009. e-Pub 2009. PMID: 19605817.
Liedtke, C, Hatzis, C, Symmans, WF, Desmedt, C, Haibe-Kains, B, Valero, V, Kuerer, HM, Hortobagyi, GN, Piccart-Gebhart, MJ, Sotiriou, C, Pusztai, L. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. Journal of Clinical Oncology 27(19):3185-3191, 2009. e-Pub 2009. PMID: 19364972.
Gong, Y, Sweet, W, Duh, YJ, Greenfield, L, Fang, Y, Zhao, J, Tarco, E, Symmans, WF, Isola, J, Sneige, N. Chromogenic in situ hybridization is a reliable method for detecting her2 gene status in breast cancer a multicenter study using conventional scoring criteria and the new asco/cap recommendations. American journal of clinical pathology 131(4):490-497, 2009. e-Pub 2009. PMID: 19289584.
Lu, J, Tan, M, Huang, W, Li, P, Guo, H, Tseng, LM, Su, X, Yang, W, Treekitkarnmongkol, W, Andreeff, M, Symmans, WF, Yu, D. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to taxoI resistance. Clinical Cancer Research 15(4):1326-1334, 2009. e-Pub 2009. PMID: 19228734.
Andre, F, Job, B, Dessen, P, Tordai, A, Michiels, S, Liedtke, C, Richon, C, Yan, K, Wang, B, Vassal, G, Delaloge, S, Hortobagyi, GN, Symmans, WF, Lazar, V, Pusztai, L. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clinical Cancer Research 15(2):441-451, 2009. e-Pub 2009. PMID: 19147748.
Liedtke, C, Broglio, K, Moulder, S, Hsu, L, Kau, SW, Symmans, WF, Albarracin, C, Meric-Bernstam, F, Woodward, W, Theriault, RL, Kiesel, L, Hortobagyi, GN, Pusztai, L, González-Angulo, AM. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Annals of Oncology 20(12):1953-1958, 2009. e-Pub 2009. PMID: 19596702.
Wang, J, Wen, S, Symmans, WF, Pusztai, L, Coombes, KR. The bimodality index. Cancer Informatics 7:199-216, 2009. e-Pub 2009. PMID: 19718451.
Moulder, S, Symmans, WF, Booser, DJ, Madden, TL, Lipsanen, C, Yuan, LX, Brewster, A, Cristofanilli, M, Hunt, KK, Buchholz, TA, Zwiebel, J, Valero, V, Hortobagyi, GN, Esteva, FJ. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clinical Cancer Research 14(23):7909-7916, 2008. e-Pub 2008. PMID: 19047121.
Pusztai, L, Broglio, K, Andre, F, Symmans, WF, Hess, KR, Hortobagyi, GN. Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer. Journal of Clinical Oncology 26(28):4679-4683, 2008. e-Pub 2008. PMID: 18662965.
Hale, K, González-Angulo, AM, Lluch, A, Neve, RM, Kuo, WL, Davies, MA, Carey, M, Hu, Z, Guan, Y, Sahin, AA, Symmans, WF, Pusztai, L, Nolden, LK, Horlings, HM, Berns, K, Hung, MC, van de Vijver, MJ, Valero, V, Gray, JW, Bernards, R, Mills, GB, Hennessy, BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Research 68(15):6084-6091, 2008. e-Pub 2008. PMID: 18676830.
Tordai, A, Wang, J, Andre, F, Liedtke, C, Yan, K, Sotiriou, C, Hortobagyi, GN, Symmans, WF, Pusztai, L. Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Research 10(2), 2008. e-Pub 2008. PMID: 18445275.
Khalifeh, I, Albarracin, C, Diaz, LK, Symmans, WF, Edgerton, ME, Hwang, RF, Sneige, N. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. American Journal of Surgical Pathology 32(4):544-552, 2008. e-Pub 2008. PMID: 18300793.
Liedtke, C, Cardone, L, Tordai, A, Yan, K, Gomez, HL, Figureoa, LJ, Hubbard, RE, Valero, V, Souchon, EA, Symmans, WF, Hortobagyi, GN, Bardelli, A, Pusztai, L. PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Research 10(2), 2008. e-Pub 2008. PMID: 18371219.
Liedtke, C, Mazouni, C, Hess, KR, Andre, F, Tordai, A, Mejia, JA, Symmans, WF, González-Angulo, AM, Hennessy, BT, Green, MC, Cristofanilli, M, Hortobagyi, GN, Pusztai, L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology 26(8):1275-1281, 2008. e-Pub 2008. PMID: 18250347.
Andre, F, Mazouni, C, Liedtke, C, Kau, SW, Frye, D, Green, MC, González-Angulo, AM, Symmans, WF, Hortobagyi, GN, Pusztai, L. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Research and Treatment 108(2):183-190, 2008. e-Pub 2008. PMID: 17468948.
Zoubir, M, Mathieu, MC, Mazouni, C, Liedtke, C, Corley, LJ, Geha, S, Bouaziz, J, Spielmann, M, Drusche, F, Symmans, WF, Delaloge, S, Andre, F. Modulation of ER phosphorylation on serine 118 by endocrine therapy. Annals of Oncology 19(8):1402-1406, 2008. e-Pub 2008. PMID: 18436523.
Peintinger, F, Buzdar, AU, Kuerer, HM, Mejia, JA, Hatzis, C, González-Angulo, AM, Pusztai, L, Esteva, FJ, Dawood, S, Green, MC, Hortobagyi, GN, Symmans, WF. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Annals of Oncology 19(12):2020-2025, 2008. e-Pub 2008. PMID: 18667396.
Dawood, S, Broglio, K, Kau, SW, Islam, R, Symmans, WF, Buchholz, TA, McGuire, SE, Meric-Bernstam, F, Cristofanilli, M, Hortobagyi, GN, González-Angulo, AM. Prognostic value of initial clinical disease stage after achieving pathological complete response. Oncologist 13(1):6-15, 2008. e-Pub 2008. PMID: 18245008.
Esteva, FJ, Wang, J, Lin, F, Mejia, JA, Yan, K, Altundaǧ, K, Valero, V, Buzdar, AU, Hortobagyi, GN, Symmans, WF, Pusztai, L. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Research 9(6), 2007. e-Pub 2007. PMID: 18086299.
Vo, T, Xing, Y, Meric-Bernstam, F, Mirza, NQ, Vlastos, G, Symmans, WF, Perkins, GH, Buchholz, TA, Babiera, G, Kuerer, HM, Bedrosian, I, Akins, JS, Hunt, KK. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. American Journal of Surgery 194(4):527-531, 2007. e-Pub 2007. PMID: 17826073.
Symmans, WF, Peintinger, F, Hatzis, C, Rajan, R, Kuerer, HM, Valero, V, Assad, L, Poniecka, A, Hennessy, BT, Green, MC, Buzdar, AU, Singletary, SE, Hortobagyi, GN, Pusztai, L. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. Journal of Clinical Oncology 25(28):4414-4422, 2007. e-Pub 2007. PMID: 17785706.
Williams, SA, Ehlers II, RA, Hunt, KK, Yi, M, Kuerer, HM, Singletary, SE, Ross, MI, Feig, BW, Symmans, WF, Meric-Bernstam, F. Metastases to the breast from nonbreast solid neoplasms. Cancer 110(4):731-737, 2007. e-Pub 2007. PMID: 17582626.
Peintinger, F, Anderson, K, Mazouni, C, Kuerer, HM, Hatzis, C, Lin, F, Hortobagyi, GN, Symmans, WF, Pusztai, L. Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer. Clinical Cancer Research 13(14):4078-4082, 2007. e-Pub 2007. PMID: 17634532.
Mazouni, C, Peintinger, F, Wan-Kau, S, Andre, F, González-Angulo, AM, Symmans, WF, Meric-Bernstam, F, Valero, V, Hortobagyi, GN, Pusztai, L. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. Journal of Clinical Oncology 25(19):2650-2655, 2007. e-Pub 2007. PMID: 17602071.
Mazouni, C, Kau, SW, Frye, D, Andre, F, Kuerer, HM, Buchholz, TA, Symmans, WF, Anderson, K, Hess, KR, González-Angulo, AM, Hortobagyi, GN, Buzdar, AU, Pusztai, L. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Annals of Oncology 18(5):874-880, 2007. e-Pub 2007. PMID: 17293601.
Andre, F, Hatzis, C, Anderson, K, Sotiriou, C, Mazouni, C, Mejia, JA, Wang, B, Hortobagyi, GN, Symmans, WF, Pusztai, L. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clinical Cancer Research 13(7):2061-2067, 2007. e-Pub 2007. PMID: 17404087.
Gong, Y, Yan, K, Lin, F, Anderson, K, Sotiriou, C, Andre, F, Holmes, FA, Valero, V, Booser, DJ, Pippen, JE, Vukelja, S, Gomez, HL, Mejia, JA, Barajas, LJ, Hess, KR, Sneige, N, Hortobagyi, GN, Pusztai, L, Symmans, WF. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma. Lancet Oncology 8(3):203-211, 2007. e-Pub 2007. PMID: 17329190.
Gonzalez, RJ, Buzdar, AU, Symmans, WF, Yen, TW, Broglio, K, Lucci, A, Esteva, FJ, Yin, G, Kuerer, HM. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). Breast Journal 13(1):72-75, 2007. e-Pub 2007. PMID: 17214797.
Buzdar, AU, Valero, V, Ibrahim, NK, Francis, D, Broglio, K, Theriault, RL, Pusztai, L, Green, MC, Singletary, SE, Hunt, KK, Sahin, AA, Esteva, FJ, Symmans, WF, Ewer, MS, Buchholz, TA, Hortobagyi, GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer. Clinical Cancer Research 13(1):228-233, 2007. e-Pub 2007. PMID: 17200359.
Ross, JS, Ross, JS, Symmans, WF, Symmans, WF, Pusztai, L, Pusztai, L, Hortobagyi, GN, Hortobagyi, GN. Personalized medicine for breast cancer. Personalized Medicine 3(4):363-370, 2006. e-Pub 2006. PMID: 29788594.
Peintinger, F, Kuerer, HM, Anderson, K, Boughey, JC, Meric-Bernstam, F, Singletary, SE, Hunt, KK, Whitman, GJ, Moseley, T, Buzdar, AU, Green, MC, Symmans, WF. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Annals of surgical oncology 13(11):1443-1449, 2006. e-Pub 2006. PMID: 17028770.
Hess, KR, Anderson, K, Symmans, WF, Valero, V, Ibrahim, NK, Mejia, JA, Booser, DJ, Theriault, RL, Buzdar, AU, Dempsey, PJ, Rouzier, R, Sneige, N, Ross, JS, Vidaurre, T, Gomez, HL, Hortobagyi, GN, Pusztai, L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. Journal of Clinical Oncology 24(26):4236-4244, 2006. e-Pub 2006. PMID: 16896004.
Kawase, K, Gayed, IW, Hunt, KK, Kuerer, HM, Akins, JS, Yi, M, Grimes, LM, Babiera, G, Ross, MI, Feig, BW, Ames, FC, Singletary, SE, Buchholz, TA, Symmans, WF, Meric-Bernstam, F. Use of Lymphoscintigraphy Defines Lymphatic Drainage Patterns Before Sentinel Lymph Node Biopsy for Breast Cancer. Journal of the American College of Surgeons 203(1):64-72, 2006. e-Pub 2006. PMID: 16798488.
Nahta, R, Yuan, LX, Fiterman, DJ, Zhang, L, Symmans, WF, Ueno, NT, Esteva, FJ. B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells. Molecular cancer therapeutics 5(6):1593-1601, 2006. e-Pub 2006. PMID: 16818519.
Anderson, K, Hess, KR, Kapoor, M, Tirrell, S, Courtemanche, J, Wang, B, Wu, Y, Gong, Y, Hortobagyi, GN, Symmans, WF, Pusztai, L. Reproducibility of gene expression signature-based predictions in replicate experiments. Clinical Cancer Research 12(6):1721-1727, 2006. e-Pub 2006. PMID: 16551855.
Ji, Y, Coombes, KR, Zhang, J, Wen, S, Mitchell, J, Pusztai, L, Symmans, WF, Wang, J. RefSeq refinements of UniGene-based gene matching improve the correlation of expression measurements between two microarray platforms. Applied bioinformatics 5(2):89-98, 2006. e-Pub 2006. PMID: 16722773.
Adepoju, LJ, Symmans, WF, Babiera, G, Singletary, SE, Arun, BK, Sneige, N, Pusztai, L, Buchholz, TA, Sahin, AA, Hunt, KK, Meric-Bernstam, F, Ross, MI, Ames, FC, Kuerer, HM. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 106(1):42-50, 2006. e-Pub 2006. PMID: 16333852.
Symmans, WF, Fiterman, DJ, Anderson, SK, Ayers, M, Rouzier, R, Dunmire, V, Stec, J, Valero, V, Sneige, N, Albarracin, C, Wu, Y, Ross, JS, Wagner, P, Theriault, RL, Arun, BK, Kuerei, H, Hess, KR, Zhang, W, Hortobagyi, GN, Pusztai, L. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocrine-related cancer 12(4):1059-1069, 2005. e-Pub 2005. PMID: 16322343.
Tari, AM, Simeone, AM, Li, YJ, Gutierrez-Puente, Y, Lai, S, Symmans, WF. Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl) retinamide inhibitory effects in breast cancer cells. Laboratory Investigation 85(11):1357-1367, 2005. e-Pub 2005. PMID: 16127422.
Rouzier, R, Perou, CM, Symmans, WF, Ibrahim, NK, Cristofanilli, M, Anderson, K, Hess, KR, Stec, J, Ayers, M, Wagner, P, Morandi, P, Fan, C, Rabiul, I, Ross, JS, Hortobagyi, GN, Pusztai, L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical Cancer Research 11(16):5678-5685, 2005. e-Pub 2005. PMID: 16115903.
Pusztai, L, Wagner, P, Ibrahim, NK, Rivera, E, Theriault, RL, Booser, DJ, Symmans, WF, Wong, FC, Blumenschein, GR, Fleming, DR, Rouzier, R, Boniface, G, Hortobagyi, GN. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104(4):682-691, 2005. e-Pub 2005. PMID: 15986399.
Stec, J, Wang, J, Coombes, KR, Ayers, M, Hoersch, S, Gold, D, Ross, JS, Hess, KR, Tirrell, S, Linette, GP, Hortobagyi, GN, Symmans, WF, Pusztai, L. Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and affymetrix GeneChips. Journal of Molecular Diagnostics 7(3):357-367, 2005. e-Pub 2005. PMID: 16049308.
Rouzier, R, Rajan, R, Wagner, P, Hess, KR, Gold, D, Stec, J, Ayers, M, Ross, JS, Zhang, P, Buchholz, TA, Kuerer, HM, Green, MC, Arun, BK, Hortobagyi, GN, Symmans, WF, Pusztai, L. Microtubule-associated protein tau. Proceedings of the National Academy of Sciences of the United States of America 102(23):8315-8320, 2005. e-Pub 2005. PMID: 15914550.
Yen, TW, Hunt, KK, Ross, MI, Mirza, NQ, Babiera, G, Meric-Bernstam, F, Singletary, SE, Symmans, WF, Giordano, SH, Feig, BW, Ames, FC, Kuerer, HM. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ. Journal of the American College of Surgeons 200(4):516-526, 2005. e-Pub 2005. PMID: 15804465.
Green, MC, Buzdar, AU, Smith, T, Ibrahim, NK, Valero, V, Rosales, MF, Cristofanilli, M, Booser, DJ, Pusztai, L, Rivera, E, Theriault, RL, Carter, C, Frye, D, Hunt, KK, Symmans, WF, Strom, EA, Sahin, AA, Sikov, W, Hortobagyi, GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. Journal of Clinical Oncology 23(25):5983-5992, 2005. e-Pub 2005. PMID: 16087943.
Gianni, L, Zambetti, M, Clark, K, Baker, J, Cronin, M, Wu, J, Mariani, G, Rodriguez Canales, J, Carcangiu, M, Watson, D, Valagussa, P, Rouzier, R, Symmans, WF, Ross, JS, Hortobagyi, GN, Pusztai, L, Shak, S. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. Journal of Clinical Oncology 23(29):7265-7277, 2005. e-Pub 2005. PMID: 16145055.
Rouzier, R, Pusztai, L, Delaloge, S, González-Angulo, AM, Andre, F, Hess, KR, Buzdar, AU, Garbay, JR, Spielmann, M, Mathieu, MC, Symmans, WF, Wagner, P, Atallah, D, Valero, V, Berry, D, Hortobagyi, GN. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. Journal of Clinical Oncology 23(33):8331-8339, 2005. e-Pub 2005. PMID: 16293864.
Ayers, M, Symmans, WF, Stec, J, Damokosh, AI, Clark, EA, Hess, KR, Lecocke, M, Metivier, J, Booser, DJ, Ibrahim, NK, Valero, V, Royce, M, Arun, BK, Whitman, GJ, Ross, JS, Sneige, N, Hortobagyi, GN, Pusztai, L, Miller, KD. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. Women's Oncology Review 4(3):211-213, 2004. e-Pub 2004.
Pusztai, L, Gregory, B, Baggerly, KA, Peng, B, Koomen, JM, Kuerer, HM, Esteva, FJ, Symmans, WF, Wagner, P, Hortobagyi, GN, Laronga, C, Semmes, OJ, Wright, GL, Drake, RR, Vlahou, A. Pharmacoproteomic Analysis of Prechemotherapy and Postchemotherapy Plasma Samples from Patients Receiving Neoadjuvant or Adjuvant Chemotherapy for Breast Carcinoma. Cancer 100(9):1814-1822, 2004. e-Pub 2004. PMID: 15112261.
Rajan, R, Poniecka, A, Smith, T, Yang, Y, Frye, D, Pusztai, L, Fiterman, DJ, Gal-Gombos, E, Whitman, GJ, Rouzier, R, Green, MC, Kuerer, HM, Buzdar, AU, Hortobagyi, GN, Symmans, WF. Change in Tumor Cellularity of Breast Carcinoma after Neoadjuvant Chemotherapy As a Variable in the Pathologic Assessment of Response. Cancer 100(7):1365-1373, 2004. e-Pub 2004. PMID: 15042669.
Hao, X, Sun, B, Hu, L, Lähdesmäki, H, Dunmire, V, Feng, Y, Zhang, SW, Wang, H, Wu, C, Wang, H, Fuller, GN, Symmans, WF, Shmulevich, I, Zhang, W. Differential Gene and Protein Expression in Primary Breast Malignancies and Their Lymph Node Metastases as Revealed by Combined cDNA Microarray and Tissue Microarray Analysis. Cancer 100(6):1110-1122, 2004. e-Pub 2004. PMID: 15022276.
Gong, Y, Symmans, WF, Krishnamurthy, S, Patel, SJ, Sneige, N. Optimal Fixation Conditions for Immunocytochemical Analysis of Estrogen Receptor in Cytologic Specimens of Breast Carcinoma. Cancer 102(1):34-40, 2004. e-Pub 2004. PMID: 14968416.
Ayers, M, Symmans, WF, Stec, J, Damokosh, AI, Clark, EA, Hess, KR, Lecocke, M, Metivier, J, Booser, DJ, Ibrahim, NK, Valero, V, Royce, M, Arun, BK, Whitman, GJ, Ross, JS, Sneige, N, Hortobagyi, GN, Pusztai, L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. Journal of Clinical Oncology 22(12):2284-2293, 2004. e-Pub 2004. PMID: 15136595.
Pusztai, L, Zhen, JH, Arun, BK, Rivera, E, Whitehead, C, Thompson, WJ, Nealy, KM, Gibbs, A, Symmans, WF, Esteva, FJ, Booser, DJ, Murray III, JL, Valero, V, Smith, T, Hortobagyi, GN. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. Journal of Clinical Oncology 21(18):3454-3461, 2003. e-Pub 2003. PMID: 12972520.
Wang, L, Duke, L, Zhang, P, Arlinghaus, R, Symmans, WF, Sahin, AA, Mendez, R, Le Dai, J. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Research 63(15):4724-4730, 2003. e-Pub 2003. PMID: 12907655.
Pusztai, L, Ayers, M, Stec, J, Clark, E, Hess, KR, Stivers, DN, Damokosh, AI, Sneige, N, Buchholz, TA, Esteva, FJ, Arun, BK, Cristofanilli, M, Booser, DJ, Rosales, MF, Valero, V, Adams, C, Hortobagyi, GN, Symmans, WF. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clinical Cancer Research 9(7):2406-2415, 2003. e-Pub 2003. PMID: 12855612.
Symmans, WF, Ayers, M, Clark, EA, Stec, J, Hess, KR, Sneige, N, Buchholz, TA, Krishnamurthy, S, Ibrahim, NK, Buzdar, AU, Theriault, RL, Rosales, MF, Thomas, ES, Gwyn, K, Green, MC, Syed, AR, Hortobagyi, GN, Pusztai, L. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 97(12):2960-2971, 2003. e-Pub 2003. PMID: 12784330.
Zhang, F, Yang, Y, Smith, T, Kau, SW, McConathy, JM, Esteva, FJ, Kuerer, HM, Symmans, WF, Buzdar, AU, Hortobagyi, GN, Pusztai, L. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 97(7):1758-1765, 2003. e-Pub 2003. PMID: 12655533.
Pusztai, L, Sotiriou, C, Buchholz, TA, Meric-Bernstam, F, Symmans, WF, Esteva, FJ, Sahin, AA, Liu, ET, Hortobagi, GN. Molecular profiles of invasive mucinous and ductal carcinomas of the breast. Cancer Genetics and Cytogenetics 141(2):148-153, 2003. e-Pub 2003. PMID: 12606133.
Diaz, LK, Hunt, KK, Ames, FC, Meric-Bernstam, F, Kuerer, HM, Babiera, G, Ross, MI, Singletary, ES, Middleton, LP, Symmans, WF, Krishnamurthy, S, Sahin, AA, Sneige, N, Gilcrease, M. Histologic localization of sentinel lymph node metastases in breast cancer. American Journal of Surgical Pathology 27(3):385-389, 2003. e-Pub 2003. PMID: 12604895.
Buchholz, TA, Davis, DW, McConkey, DJ, Symmans, WF, Valero, V, Jhingran, A, Tucker, SL, Pusztai, L, Cristofanilli, M, Esteva, FJ, Hortobagyi, GN, Sahin, AA. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer Journal 9(1):33-41, 2003. e-Pub 2003. PMID: 12602766.
Buchholz, TA, Stivers, DN, Stec, J, Ayers, M, Clark, E, Bolt, A, Sahin, AA, Symmans, WF, Hess, KR, Kuerer, HM, Valero, V, Hortobagyi, GN, Pusztai, L. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer Journal 8(6):461-468, 2002. e-Pub 2002. PMID: 12500855.
Dunmire, V, Wu, C, Symmans, WF, Zhang, W. Increased yield of total RNA from fine-needle aspirates for use in expression microarray analysis. BioTechniques 33(4):890-896, 2002. e-Pub 2002. PMID: 12398198.
Lee, A, Krishnamurthy, S, Sahin, AA, Symmans, WF, Hunt, KK, Sneige, N. Intraoperative touch imprint of sentinel lymph nodes in breast carcinoma patients. Cancer 96(4):225-231, 2002. e-Pub 2002. PMID: 12209664.
Kronowitz, S, Chang, DW, Robb, GL, Hunt, KK, Ames, FC, Ross, MI, Singletary, SE, Symmans, WF, Kroll, SS, Kuerer, HM. Implications of axillary sentinel lymph node biopsy in immediate autologous breast reconstruction. Plastic and reconstructive surgery 109(6):1888-1896, 2002. e-Pub 2002. PMID: 11994589.
Chhieng, DC, Cangiarella, JF, Symmans, WF, Cohen, JM. Fine-needle aspiration cytology of hodgkin disease. Cancer 93(1):52-59, 2001. e-Pub 2001. PMID: 11241266.
Demaria, S, Volm, MD, Shapiro, RL, Yee, HT, Oratz, R, Formenti, SC, Muggia, FM, Symmans, WF. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clinical Cancer Research 7(10):3025-3030, 2001. e-Pub 2001. PMID: 11595690.
Buchholz, TA, Valero, V, Gilcrease, M, Symmans, WF, Tucker, SL, McConkey, DJ, Pusztai, L, Davis, DW, Hortobagyi, GN, Sahin, AA. Decrease in bcl-2 expression shortly after neoadjuvant chemotherapy predicts primary breast cancer response to treatment. Breast Cancer Research and Treatment 69(3):244, 2001. e-Pub 2001.
Cangiarella, JF, Waisman, J, Cohen, JM, Chhieng, DC, Symmans, WF, Axelrod, D, Gross, J. Radial sclerosing lesion. Breast Journal 7(1):66-67, 2001. e-Pub 2001. PMID: 11348419.
Cangiarella, JF, Waisman, J, Symmans, WF, Gross, J, Cohen, JM, Wu, H, Axelrod, D. Mammotome core biopsy for mammary microcalcification. Cancer 91(1):173-177, 2001. e-Pub 2001. PMID: 11148574.
Symmans, WF, Pusztai, L, Ayers, M, Clark, E, Stec, J, Buchholz, TA, Sneige, N, Hortobagyi, GN. RNA yield from needle biopsies for cDNA microarray analysis of breast cancer prior to neoadjuvant chemotherapy. Breast Cancer Research and Treatment 69(3):301, 2001. e-Pub 2001.
Symmans, WF, Volm, MD, Shapiro, RL, Perkins, AB, Kim, AY, Demaria, S, Yee, HT, McMullen, H, Oratz, R, Klein, P, Formenti, SC, Muggia, FM. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration. Clinical Cancer Research 6(12):4610-4617, 2000. e-Pub 2000. PMID: 11156210.
Chhieng, DC, Yee, HT, Cangiarella, JF, Symmans, WF, Cohen, JM. Use of E-cadherin and CD44 aids in the differentiation between reactive mesothelial cells and carcinoma cells in pelvic washings. Cancer 90(5):299-306, 2000. e-Pub 2000. PMID: 11038427.
Cangiarella, JF, Symmans, WF, Shapiro, RL, Roses, DF, Cohen, JM, Chhieng, DC, Harris, MN, Waisman, J. Aspiration biopsy and the clinical management of patients with malignant melanoma and palpable regional lymph nodes. Cancer 90(3):162-166, 2000. e-Pub 2000. PMID: 10896329.
Chhieng, DC, Fernandez, G, Cangiarella, JF, Cohen, JM, Waisman, J, Harris, MN, Roses, DF, Shapiro, RL, Symmans, WF. Invasive carcinoma in clinically suspicious breast masses diagnosed as adenocarcinoma by fine-needle aspiration. Cancer 90(2):96-101, 2000. e-Pub 2000. PMID: 10794158.
Cangiarella, JF, Gross, J, Symmans, WF, Waisman, J, Petersen, B, D'Angelo, D, Singer, C, Axelrod, D. The incidence of positive margins with breast conserving therapy following mammotome biopsy for microcalcification. Journal of surgical oncology 74(4):263-266, 2000. e-Pub 2000. PMID: 10962457.
Cangiarella, JF, Waisman, J, Cohen, JM, Chhieng, DC, Symmans, WF, Goldenberg, A. Plasmacytoma of the breast. Acta Cytologica 44(1):91-94, 2000. e-Pub 2000. PMID: 10667168.
Moreira, AL, Haslett, PA, Symmans, WF, Tierno, P. Propionibacterium acnes as the cause of endocarditis in a liver transplant recipient. Clinical Infectious Diseases 30(1):224-226, 2000. e-Pub 2000. PMID: 10619770.
Symmans, WF, Cangiarella, JF, Symmans, PJ, Cohen, JM, Yee, HT, Bennett, G, Amorosi, EL, Waisman, J. Apoptotic index from fine needle aspiration cytology as a criterion to predict histologic grade of non-Hodgkin's lymphoma. Acta Cytologica 44(2):194-204, 2000. e-Pub 2000. PMID: 10740606.
Cangiarella, JF, Waisman, J, Weg, N, Tata, M, Gross, J, Symmans, WF. The use of stereotaxic core biopsy and stereotaxic aspiration biopsy as diagnostic tools in the evaluation of mammary calcification. Breast Journal 6(6):366-372, 2000. e-Pub 2000. PMID: 11348394.
Zeng, Z, Melamed, J, Symmans, PJ, Cangiarella, JF, Shapiro, RL, Peralta, H, Symmans, WF. Benign proliferative nipple duct lesions frequently contain CAM 5.2 and anti-cytokeratin 7 immunoreactive cells in the overlying epidermis. American Journal of Surgical Pathology 23(11):1349-1355, 1999. e-Pub 1999. PMID: 10555003.
Symmans, WF, Weg, N, Gross, J, Cangiarella, JF, Tata, M, Mazzo, JA, Waisman, J. A prospective comparison of stereotaxic fine-needle aspiration versus stereotaxic core needle biopsy for the diagnosis of mammographic abnormalities. Cancer 85(5):1119-1132, 1999. e-Pub 1999. PMID: 10091797.
Mangues, R, Corral, T, Lu, S, Symmans, WF, Liu, L, Pellicer, A. NF1 inactivation cooperates with N-Ras in in vivo lymphogenesis activating Erk by a mechanism independent of its Ras-GTPase accelerating activity. Oncogene 17(13):1705-1716, 1998. e-Pub 1998. PMID: 9796699.
Cangiarella, JF, Mercado, CL, Symmans, WF, Newstead, GM, Toth, HK, Waisman, J. Stereotaxic aspiration biopsy in the evaluation of mammographically detected clustered microcalcification. Cancer 84(4):226-230, 1998. e-Pub 1998. PMID: 9723597.
Cangiarella, JF, Symmans, WF, Cohen, JM, Goldenberg, A, Shapiro, RL, Waisman, J. Malignant melanoma metastatic to the breast. A report of seven cases diagnosed by fine-needle aspiration cytology. Cancer 84(3):160-162, 1998. e-Pub 1998. PMID: 9678730.
Mangues, R, Corral, T, Kohl, N, Symmans, WF, Lu, S, Malumbres, M, Gibbs, JB, Oliff, A, Pellicer, A. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Research 58(6):1253-1259, 1998. e-Pub 1998. PMID: 9515813.
Stokes, MB, Kumar, A, Symmans, WF, Scholes, JV, Melamed, J. Pancreatic endocrine tumor with signet ring cell features. Ultrastructural Pathology 22(2):147-152, 1998. e-Pub 1998. PMID: 9615384.
Illei, PB, Feiner, HD, Symmans, WF, Mitnick, JS, Roses, DF, Perle, MA. Numerical abnormalities of chromosomes 7, 18, and X in precancerous breast disease defined by fluorescent in situ hybridization. Breast Journal 4(4):252-257, 1998. e-Pub 1998. PMID: 21223444.
Cangiarella, JF, Weg, N, Symmans, WF, Waisman, J. Aspiration cytology of signet-ring cell lymphoma. Acta Cytologica 41(6):1828-1832, 1997. e-Pub 1997. PMID: 9390152.
Zhau, HY, Zhou, J, Symmans, WF, Chen, BQ, Chang, SM, Sikes, RA, Chung, LW. Transfected neu oncogene induces human prostate cancer metastasis. Prostate 28(2):73-83, 1996. e-Pub 1996. PMID: 8604395.
Mangues, R, Symmans, WF, Lu, S, Schwartz, S, Pellicer, A. Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis. Oncogene 13(5):1053-1063, 1996. e-Pub 1996. PMID: 8806695.
Symmans, WF, Liu, J, Knowles, DM, Inghirami, G. Breast cancer heterogeneity. Human Pathology 26(2):210-216, 1995. e-Pub 1995. PMID: 7860051.
Symmans, WF, Katz, RL, Ordonez, NG, Dalton, H, Romaguera, JE, Cabanillas, F. Transformation of follicular lymphoma. Expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation. Acta Cytologica 39(4):673-682, 1995. e-Pub 1995. PMID: 7631541.
Zhau, HE, Zhao, LS, Chung, LW, Chen, BQ, Troncoso, P, Kao, C, Kojima, M, Symmans, WF, Zheng, N, Palmer, JL, Moul, JW, Davis, R, Ye, MF, Xiao, LS, Craig Hall, M. Comparative studies of prostate cancers among United States, Chinese, and Japanese patients. Urologic Oncology: Seminars and Original Investigations 1(2):51-63, 1995. e-Pub 1995. PMID: 21224092.
Dodd, L, Evans, DB, Symmans, WF, Katz, RL. Fine‐needle aspiration of pancreatic extramedullary plasmacytoma. Diagnostic Cytopathology 10(4):371-374, 1994. e-Pub 1994. PMID: 7924813.
Avellino, AM, Hair, LS, Symmans, WF, Gold, AP, Carmel, P, Powers, JM. Meningeal meningiomatosis in a child. Clinical neuropathology 13(2):82-87, 1994. e-Pub 1994. PMID: 8205731.
Symmans, WF, Nielsen, H, Dell, R, Rose, E, Marbor, CC. Cardiac allograft pathology. Cardiovascular Pathology 3(4):249-256, 1994. e-Pub 1994. PMID: 25991018.
Colombel, M, Symmans, WF, Gil, S, O'Toole, KM, Chopin, DK, Benson, MC, Olsson, CA, Korsmeyer, SJ, Buttyan, R. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. American Journal of Pathology 143(2):390-400, 1993. e-Pub 1993. PMID: 7688182.
Hair, LS, Symmans, WF, Powers, JM, Carmel, P. Immunohistochemistry and proliferative activity in Lhermitte-Duclos disease. Acta neuropathologica 84(5):570-573, 1992. e-Pub 1992. PMID: 1462769.
Symmans, WF, Mechanic, L, Mac Connell, P, Da Silva, K, Stricker, B, Nuovo, G. Correlation of cervical cytology and human papillomavirus DNA detection in postmenopausal women. International Journal of Gynecological Pathology 11(3):204-209, 1992. e-Pub 1992. PMID: 1328078.
Despommier, D, Symmans, WF, Dell, R. Changes in nurse cell nuclei during synchronous infection with Trichinella spiralis. Journal of Parasitology 77(2):290-295, 1991. e-Pub 1991. PMID: 2010862.
Koulos, J, Symmans, WF, Chumas, J, Nuovo, G. Human papillomavirus detection in adenocarcinoma of the anus. J Parasitol 4(1):58-61, 1991. e-Pub 1991. PMID: 1850518.

Invited Articles

Kim T, Li Y, Calhoun BC, Thennavan A, Carey LA, Symmans W, Troester MA, Perou CM, Marron J. Stain SAN. J Med Imaging (Bellingham) 11(4):044006, 2024. e-Pub 2024. PMID: 39185474.
Bossuyt, V, Symmans, WF. Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy. Annals of surgical oncology 23(10):3153-3161, 2016. e-Pub 2016. PMID: 27380637.
Pusztai, L, Rouzier, R, Symmans, WF. CCR 20th anniversary commentary. Clinical Cancer Research 21(16):3575-3577, 2015. e-Pub 2015. PMID: 26275950.
Niikura, N, Odisio, BC, Tokuda, Y, Symmans, WF, Hortobagyi, GN, Ueno, NT. Latest biopsy approach for suspected metastases in patients with breast cancer. Nature Reviews Clinical Oncology 10(12):711-719, 2013. e-Pub 2013. PMID: 24145987.
Kelly, CM, Symmans, WF, Andreopoulou, E, Bianchini, G. Breast cancer genomics. Oncologist 18(4):e11-e12, 2013. e-Pub 2013. PMID: 23633449.
Symmans, WF. A perspective on genomic tests for breast cancer. Oncology (Williston Park) 26(4):364-365, 369, 2012. e-Pub 2012. PMID: 22655530.
Ross, JS, Slodkowska, EA, Symmans, WF, Pusztai, L, Ravdin, PM, Hortobagyi, GN. The HER-2 receptor and breast cancer. Oncologist 14(4):320-368, 2009. e-Pub 2009. PMID: 19346299.
Ross, JS, Hatzis, C, Symmans, WF, Pusztai, L, Hortobagyi, GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 13(5):477-493, 2008. e-Pub 2008. PMID: 18515733.
Diaz, LK, Cryns, VL, Symmans, WF, Sneige, N. Triple negative breast carcinoma and the basal phenotype. Advances in anatomic pathology 14(6):419-430, 2007. e-Pub 2007. PMID: 18049131.
Gong, Y, Symmans, WF, Pusztai, L. Gene-expression microarrays provide new prognostic and predictive test for breast cancer. Pharmacogenomics 8(10):1359-1368, 2007. e-Pub 2007. PMID: 17979510.
Ross, JS, Ross, JS, Symmans, WF, Symmans, WF, Pusztai, L, Pusztai, L, Hortobagyi, GN, Hortobagyi, GN. Standardizing slide-based assays in breast cancer. Clinical Cancer Research 13(10):2831-2835, 2007. e-Pub 2007. PMID: 17504980.
Symmans, WF. A Pathologist's Perspective on Emerging Genomic Tests for Breast Cancer. Seminars in oncology 34(SUPPL. 3):S4-S9, 2007. e-Pub 2007. PMID: 17512433.
Pusztai, L, Mazouni, C, Anderson, K, Wu, Y, Symmans, WF. Molecular classification of breast cancer. Oncologist 11(8):868-877, 2006. e-Pub 2006. PMID: 16951390.
Ross, JS, Symmans, WF, Pusztai, L, Hortobagyi, GN. Pharmacogenomics and clinical biomarkers in drug discovery and development. American journal of clinical pathology 124 Suppl:S29-41, 2005. e-Pub 2005. PMID: 16468416.
Ross, JS, Symmans, WF, Pusztai, L, Hortobagyi, GN. Breast Cancer Biomarkers 40:99-125, 2005. e-Pub 2005. PMID: 16355921.
Pusztai, L, Symmans, WF, Hortobagyi, GN. Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Breast Cancer 12(2):73-85, 2005. e-Pub 2005. PMID: 15858436.
Pusztai, L, Rouzier, R, Wagner, P, Symmans, WF. Individualized chemotherapy treatment for breast cancer. Drug Resist Updat 7(6):325-331, 2004. e-Pub 2004. PMID: 15790543.
Symmans, WF. Breast cancer prognostic and predictive factors. Semin Breast Dis 7(3):91-100, 2004. e-Pub 2004.
Rajan, R, Esteva, FJ, Symmans, WF. Pathologic changes in breast cancer following neoadjuvant chemotherapy. Clin Breast Cancer 5(3):235-238, 2004. e-Pub 2004. PMID: 15335458.
Ross, JS, Fletcher, JA, Bloom, KJ, Linette, GP, Stec, J, Symmans, WF, Pusztai, L, Hortobagyi, GN. Targeted therapy in breast cancer. Molecular and Cellular Proteomics 3(4):379-398, 2004. e-Pub 2004. PMID: 14762215.
Ross, JS, Linette, GP, Stec, J, Clark, EA, Ayers, M, Leschly, N, Symmans, WF, Hortobagyi, GN, Pusztai, L. Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn 4(2):169-188, 2004. e-Pub 2004. PMID: 14995904.
Ross, JS, Schenkein, DP, Pietrusko, R, Rolfe, M, Linette, GP, Stec, J, Stagliano, NE, Ginsburg, GS, Symmans, WF, Pusztai, L, Hortobagyi, GN. Targeted therapies for cancer 2004. Am J Clin Pathol 122(4):598-609, 2004. e-Pub 2004. PMID: 15487459.
Ross, JS, Schenkein, DP, Kashala, O, Linette, GP, Stec, J, Symmans, WF, Pusztai, L, Hortobagyi, GN. Pharmacogenomics. Advances in anatomic pathology 11(4):211-220, 2004. e-Pub 2004. PMID: 15220824.
Ross, JS, Fletcher, JA, Bloom, KJ, Linette, GP, Stec, J, Clark, E, Ayers, M, Symmans, WF, Pusztai, L, Hortobagyi, GN. HER-2/neu testing in breast cancer. Am J Clin Pathol 120 Suppl:S53-71, 2003. e-Pub 2003. PMID: 15298144.
Symmans, WF. Breast cancer response to paclitaxel in vivo. Drug Resist Updat 4(5):297-302, 2001. e-Pub 2001. PMID: 11991683.
Esteva, FJ, Pusztai, L, Symmans, WF, Sneige, N, Hortobagyi, GN. Clinical relevance of HER-2 amplification and overexpression in human cancers. Ref Gynecol Obstet 7(4-5):267-276, 2000. e-Pub 2000.
Formenti, SC, Symmans, WF, Volm, MD, Skinner, K, Cohen, D, Spicer, DV, Danenberg, PV. Concurrent paclitaxel and radiation therapy for breast cancer. Semin Radiat Oncol 9(2 SUPPL 1):34-42, 1999. e-Pub 1999. PMID: 10210538.

Review Articles

Page, DB, Broeckx, G, Jahangir, CA, Verbandt, S, Gupta, R, Thagaard, J, Khiroya, R, Kos, Z, AbdulJabbar, K, Acosta-Haab, G, Acs, B, Akturk, G, Almeida, J, Alvarado-Cabrero, I, Azmoudeh-Ardalan, F, Badve, S, Baharun, NB, Bellolio, E, Bheemaraju, V, Blenman, KR, Botinelly Mendonça Fujimoto, L, Bouchmaa, N, Burgues, O, Cheang, M, Ciompi, F, Cooper, LA, Coosemans, A, Corredor, G, Dantas Portela, FL, Deman, F, Demaria, S, Dudgeon, S, Elghazawy, M, Ely, SA, Fernandez-Martín, C, Fineberg, S, Fox, SB, Gallagher, WM, Giltnane, J, Gnjatic, S, Gonzalez-Ericsson, PI, Grigoriadis, A, Halama, N, Hanna, MG, Harbhajanka, A, Hardas, A, Hart, S, Hartman, J, Hewitt, SM, Hida, AI, Horlings, HM, Husain, Z, Hytopoulos, E, Irshad, S, Janssen, EA, Kahila, MM, Kataoka, TR, Kawaguchi, K, Kharidehal, D, Khramtsov, AI, Kiraz, U, Kirtani, P, Kodach, LL, Korski, K, Kovács, A, Lænkholm, AV, Lang-Schwarz, C, Larsimont, D, Lennerz, JK, Lerousseau, M, Li, X, Ly, A, Madabhushi, A, Maley, SK, Manur Narasimhamurthy, V, Marks, DK, McDonald, ES, Mehrotra, R, Michiels, S, Minhas, FA, Mittal, S, Moore, DA, Mushtaq, S, Nighat, H, Papathomas, T, Penault-Llorca, F, Perera, RD, Pinard, CJ, Pinto-Cardenas, JC, Pruneri, G, Pusztai, L, Rahman, A, Rajpoot, N, Rapoport, B, Rau, TT, Reis-Filho, JS, Ribeiro, JM, Rimm, DL, Vincent-Salomon, A, Salto-Tellez, M, Saltz, J, Sayed, S, Siziopikou, KP, Sotiriou, C, Stenzinger, A, Sughayer, M, Sur, D, Symmans, WF, Tanaka, S, Taxter, T, Tejpar, S, Teuwen, J, Thompson, EA, Tramm, T, Tran, WT, van der Laak, J, van Diest, P, Verghese, GE, Viale, G, Vieth, M, Wahab, N, Walter, T, Waumans, Y, Wen, HY, Yang, W, Yuan, Y, Adams, S, Bartlett, JS, Loibl, S, Denkert, C, Savas, P, Loi, S, Salgado, R, Specht Stovgaard, E. Spatial analyses of immune cell infiltration in cancer. Journal of Pathology 260(5):514-532, 2023. e-Pub 2023. PMID: 37608771.
Thagaard, J, Broeckx, G, Page, DB, Jahangir, CA, Verbandt, S, Kos, Z, Gupta, R, Khiroya, R, AbdulJabbar, K, Acosta-Haab, G, Acs, B, Akturk, G, Almeida, J, Alvarado-Cabrero, I, Amgad, M, Azmoudeh-Ardalan, F, Badve, S, Baharun, NB, Balslev, E, Bellolio, E, Bheemaraju, V, Blenman, KR, Botinelly Mendonça Fujimoto, L, Bouchmaa, N, Burgues, O, Chardas, A, Chon U Cheang, M, Ciompi, F, Cooper, LA, Coosemans, A, Corredor, G, Dahl, AB, Dantas Portela, FL, Deman, F, Demaria, S, Doré Hansen, J, Dudgeon, S, Ebstrup, T, Elghazawy, M, Fernandez-Martín, C, Fox, SB, Gallagher, WM, Giltnane, J, Gnjatic, S, Gonzalez-Ericsson, PI, Grigoriadis, A, Halama, N, Hanna, MG, Harbhajanka, A, Hart, S, Hartman, J, Hauberg, S, Hewitt, SM, Hida, AI, Horlings, HM, Husain, Z, Hytopoulos, E, Irshad, S, Janssen, EA, Kahila, MM, Kataoka, TR, Kawaguchi, K, Kharidehal, D, Khramtsov, AI, Kiraz, U, Kirtani, P, Kodach, LL, Korski, K, Kovács, A, Lænkholm, AV, Lang-Schwarz, C, Larsimont, D, Lennerz, JK, Lerousseau, M, Li, X, Ly, A, Madabhushi, A, Maley, SK, Manur Narasimhamurthy, V, Marks, DK, McDonald, ES, Mehrotra, R, Michiels, S, Minhas, FA, Mittal, S, Moore, DA, Mushtaq, S, Nighat, H, Papathomas, T, Penault-Llorca, F, Perera, RD, Pinard, CJ, Pinto-Cardenas, JC, Pruneri, G, Pusztai, L, Rahman, A, Rajpoot, N, Rapoport, B, Rau, TT, Reis-Filho, JS, Ribeiro, JM, Rimm, DL, Roslind, A, Vincent-Salomon, A, Salto-Tellez, M, Saltz, J, Sayed, S, Scott, E, Siziopikou, KP, Sotiriou, C, Stenzinger, A, Sughayer, M, Sur, D, Fineberg, S, Symmans, WF, Tanaka, S, Taxter, T, Tejpar, S, Teuwen, J, Thompson, EA, Tramm, T, Tran, WT, van der Laak, J, van Diest, P, Verghese, GE, Viale, G, Vieth, M, Wahab, N, Walter, T, Waumans, Y, Wen, HY, Yang, W, Yuan, Y, Zin, RM, Adams, S, Bartlett, JS, Loibl, S, Denkert, C, Savas, P, Loi, S, Salgado, R, Specht Stovgaard, E. Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer. Journal of Pathology 260(5):498-513, 2023. e-Pub 2023. PMID: 37608772.
Amgad, M, Stovgaard, ES, Balslev, E, Thagaard, J, Chen, W, Dudgeon, S, Sharma, A, Kerner, J, Denkert, C, Yuan, Y, AbdulJabbar, K, Wienert, S, Savas, P, Voorwerk, L, Beck, AH, Madabhushi, A, Hartman, J, Sebastian, MM, Horlings, HM, Hudeček, J, Ciompi, F, Moore, DA, Singh, R, Roblin, E, Balancin, ML, Mathieu, MC, Lennerz, JK, Kirtani, P, Chen, IC, Braybrooke, J, Pruneri, G, Demaria, S, Adams, S, Schnitt, SJ, Lakhani, S, Rojo, F, Comerma, L, Badve, S, Khojasteh, M, Symmans, WF, Sotiriou, C, Gonzalez-Ericsson, PI, Pogue-Geile, KL, Kim, RS, Rimm, DL, Viale, G, Hewitt, SM, Bartlett, JM, Lazar, A, Yang, W. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. npj Breast Cancer 6(1), 2022. e-Pub 2022. PMID: 32411818.
Asad, S, Kananen, K, Mueller, KR, Symmans, WF, Wen, Y, Perou, CM, Blachly, JS, Chen, JL, Vincent, BG, Stover, DG. Challenges and Gaps in Clinical Trial Genomic Data Management. JCO Clinical Cancer Informatics 6(1), 2022. e-Pub 2022. PMID: 35404674.
El Bairi, K, Haynes, HR, Blackley, EF, Fineberg, S, Shear, J, Turner, S, de Freitas, JR, Sur, D, Amendola, LC, Gharib, M, Kallala, A, Arun, I, Azmoudeh-Ardalan, F, Fujimoto, L, Sua, LF, Liu, SW, Lien, HC, Kirtani, P, Balancin, ML, El Attar, H, Guleria, P, Yang, W, Shash, E, Chen, IC, Bautista, V, Do Prado Moura, JF, Rapoport, B, Castaneda, CA, Spengler, E, Acosta-Haab, G, Frahm, I, Sanchez, J, Castillo, M, Bouchmaa, N, Md Zin, RR, Shui, R, Onyuma, T, Yang, W, Husain, Z, Willard-Gallo, K, Coosemans, A, Perez, EA, Provenzano, E, Ericsson, PG, Toi, M, Yang, W, Symmans, WF, Sebastian, MM, Yuan, Y, Lazar, A. The tale of TILs in breast cancer. npj Breast Cancer 7(1), 2021. e-Pub 2021. PMID: 34853355.
Hudeček, J, Voorwerk, L, van Seijen, M, Nederlof, I, de Maaker, M, van den Berg, J, Van De Vijver, K, Sikorska, K, Adams, S, Demaria, S, Viale, G, Nielsen, TO, Badve, S, Michiels, S, Symmans, WF, Sotiriou, C, Rimm, DL, Hewitt, SM, Denkert, C, Loibl, S, Loi, S, Bartlett, JM, Pruneri, G, Dillon, D, Cheang, M, Tutt, A, Hall, JA, Kos, Z, Salgado, R, Kok, M, Horlings, HM, Hyytiäinen, A, Hida, AI, Thompson, A, Lefevre, A, Lazar, A, Gown, AM, Lo, A, Sapino, A, Madabhushi, A, Moreira, A, Richardson, AL, Vingiani, A, Beck, AH, Bellizzi, AM, Guerrero, A, Grigoriadis, A, Sebastian, MM, Yang, W, Yuan, Y. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. npj Breast Cancer 6(1), 2020. e-Pub 2020. PMID: 32436923.
Gonzalez-Ericsson, PI, Stovgaard, ES, Sua, LF, Reisenbichler, E, Kos, Z, Carter, J, Michiels, S, Le Quesne, J, Nielsen, TO, Lænkholm, AV, Fox, SB, Adam, J, Bartlett, JM, Rimm, DL, Quinn, C, Peeters, D, Dieci, MV, Vincent-Salomon, A, Cree, IA, Hida, AI, Balko, JM, Haynes, HR, Frahm, I, Acosta-Haab, G, Balancin, ML, Bellolio, E, Yang, W, Kirtani, P, Sugie, T, Ehinger, A, Castaneda, CA, Kok, M, McArthur, HL, Siziopikou, KP, Badve, S, Fineberg, S, Gown, AM, Viale, G, Schnitt, SJ, Pruneri, G, Penault-Llorca, F, Hewitt, SM, Thompson, EA, Allison, KH, Symmans, WF, Bellizzi, AM, Brogi, E, Moore, DA, Larsimont, D, Dillon, D, Lazar, A, Lien, HC, Goetz, MP, Broeckx, G, El Bairi, K, Harbeck, N, Cimino-Mathews, A, Sotiriou, C, Adams, S, Liu, Sw, Loibl, S, Chen, IC, Lakhani, S, Juco, J, Denkert, C, Blackley, EF, Demaria, S, Leon-Ferre, R, Gluz, O, Zardavas, D, Emancipator, K, Ely, SA, Loi, S, Salgado, R, Sanders, ME. The path to a better biomarker. Journal of Pathology 250(5):667-684, 2020. e-Pub 2020. PMID: 32129476.
Boughey, JC, Alvarado, M, Lancaster, RB, Symmans, WF, Mukhtar, RA, Wong, JM, Ewing, CA, Potter, DA, Tuttle, TM, Hieken, TJ, Carter, J, Jakub, J, Kaplan, HG, Buchanan, CL, Jaskowiak, NT, Sattar, H, Mueller, J, Nanda, R, Isaacs, C, Pohlmann, PR, Lynce, F, Tousimis, EA, Zeck, JC, Lee, MC, Lang, J, Mhawech-Fauceglia, P, Rao, R, Taback, B, Chen, M, Kalinsky, K, Hibshoosh, H, Killelea, B, Sanft, T, Hirst, GL, Asare, S, Matthews, JB, Perlmutter, J, Esserman, L, Chien, AJ, Forero-Torres, A, Yee, D, Ellis, ED, Han, HS, Lu, J, Wallace, A, Albain, KS, Elias, A, Clark, A, Kemmer, KA. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. npj Breast Cancer 4(1), 2018. e-Pub 2018. PMID: 30131975.
Dieci, MV, Radosevic-Robin, N, Fineberg, S, Van Den Eynden, GG, Ternes, N, Penault-Llorca, F, Pruneri, G, D'Alfonso, TM, Demaria, S, Castaneda, CA, Sanchez, J, Badve, S, Michiels, S, Bossuyt, V, Rojo, F, Singh, B, Nielsen, TO, Viale, G, Kim, SR, Hewitt, SM, Wienert, S, Loibl, S, Rimm, DL, Symmans, WF, Denkert, C, Adams, S, Loi, S, Salgado, R. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ. Seminars in cancer biology 52:16-25, 2018. e-Pub 2018. PMID: 29024776.
Klauschen, F, Müller, KR, Binder, A, Bockmayr, M, Hägele, M, Seegerer, P, Wienert, S, Pruneri, G, de Maria, S, Badve, S, Michiels, S, Nielsen, TO, Adams, S, Savas, P, Symmans, WF, Willis, S, Gruosso, T, Park, M, Haibe-Kains, B, Gallas, BD, Thompson, A, Cree, IA, Sotiriou, C, Solinas, C, Preusser, M, Hewitt, SM, Rimm, DL, Viale, G, Loi, S, Loibl, S, Salgado, R, Denkert, C. Scoring of tumor-infiltrating lymphocytes. Seminars in cancer biology 52:151-157, 2018. e-Pub 2018. PMID: 29990622.
Sandberg, LJ, Clemens, MW, Symmans, WF, Valero, V, Caudle, AS, Smith, B, Kuerer, HM, Hsu, L, Kronowitz, S. Molecular Profiling Using Breast Cancer Subtype to Plan for Breast Reconstruction. Plastic and reconstructive surgery 139(3):586e-596e, 2017. e-Pub 2017. PMID: 28234813.
Hendry, S, Salgado, R, Gevaert, T, Russell, P, John, T, Thapa, B, Christie, M, Van De Vijver, K, Estrada, MV, Gonzalez-Ericsson, PI, Sanders, ME, Solomon, BJ, Solinas, C, Van Den Eynden, GG, Allory, Y, Preusser, M, Hainfellner, JA, Pruneri, G, Vingiani, A, Demaria, S, Symmans, WF, Nuciforo, PG, Comerma, L, Thompson, EA, Lakhani, S, Kim, SR, Schnitt, SJ, Colpaert, C, Sotiriou, C, Scherer, SJ, Ignatiadis, M, Badve, S, Pierce, RH, Viale, G, Sirtaine, N, Penault-Llorca, F, Sugie, T, Fineberg, S, Paik, S, Srinivasan, A, Richardson, AL, Wang, Y, Chmielik, E, Brock, JE, Johnson, DB, Balko, JM, Wienert, S, Bossuyt, V, Michiels, S, Ternes, N, Burchardi, N, Luen, SJ, Savas, P, Klauschen, F, Watson, PH, Nelson, B, Criscitiello, C, O'Toole, S, Larsimont, D, De Wind, R, Curigliano, G, Andre, F, Lacroix-Triki, M, van de Vijver, MJ, Rojo, F, Floris, G, Bedri, S, Sparano, JA, Rimm, DL, Nielsen, TO, Kos, Z, Hewitt, SM, Singh, B, Farshid, G, Loibl, S, Allison, KH, Tung, N, Adams, S, Willard-Gallo, K, Horlings, HM, Gandhi, L, Moreira, A, Hirsch, F, Dieci, MV, Urbanowicz, M, Brcic, I, Korski, K, Gaire, F, Koeppen, H, Lo, A, Giltnane, J, Rebelatto, MC, Steele, KE, Zha, J, Emancipator, K, Juco, J, Denkert, C, Reis-Filho, JS, Loi, S, Fox, SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors. Advances in anatomic pathology 24(6):311-335, 2017. e-Pub 2017. PMID: 28777143.
Hendry, S, Salgado, R, Gevaert, T, Russell, P, John, T, Thapa, B, Christie, M, Van De Vijver, K, Estrada, MV, Gonzalez-Ericsson, PI, Sanders, ME, Solomon, BJ, Solinas, C, Van Den Eynden, GG, Allory, Y, Preusser, M, Hainfellner, JA, Pruneri, G, Vingiani, A, Demaria, S, Symmans, WF, Nuciforo, PG, Comerma, L, Thompson, EA, Lakhani, S, Kim, SR, Schnitt, SJ, Colpaert, C, Sotiriou, C, Scherer, SJ, Ignatiadis, M, Badve, S, Pierce, RH, Viale, G, Sirtaine, N, Penault-Llorca, F, Sugie, T, Fineberg, S, Paik, S, Srinivasan, A, Richardson, AL, Wang, Y, Chmielik, E, Brock, JE, Johnson, DB, Balko, JM, Wienert, S, Bossuyt, V, Michiels, S, Ternes, N, Burchardi, N, Luen, SJ, Savas, P, Klauschen, F, Watson, PH, Nelson, B, Criscitiello, C, O'Toole, S, Larsimont, D, De Wind, R, Curigliano, G, Andre, F, Lacroix-Triki, M, van de Vijver, MJ, Rojo, F, Floris, G, Bedri, S, Sparano, JA, Rimm, DL, Nielsen, TO, Kos, Z, Hewitt, SM, Singh, B, Farshid, G, Loibl, S, Allison, KH, Tung, N, Adams, S, Willard-Gallo, K, Horlings, HM, Gandhi, L, Moreira, A, Hirsch, F, Dieci, MV, Urbanowicz, M, Brcic, I, Korski, K, Gaire, F, Koeppen, H, Lo, A, Giltnane, J, Rebelatto, MC, Steele, KE, Zha, J, Emancipator, K, Juco, J, Denkert, C, Reis-Filho, JS, Loi, S, Fox, SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors. Advances in anatomic pathology 24(5):235-251, 2017. e-Pub 2017. PMID: 28777142.
Strasser-Weippl, K, Chavarri-Guerra, Y, Symmans, WF, Bychkovsky, BL, Debiasi, M, Liedke, PE, Soto-Perez-de-Celis, E, Dizon, DS, Cazap, E, Lopes, G, Touya, D, Nunes, JS, Louis, JS, Vail, C, Bukowski, A, Ramos-Elias, P, Unger-Saldaña, K, Brandao, DF, Ferreyra, M, Luciani, S, Nogueira-Rodrigues, A, de Carvalho Calabrich, AF, Del Carmen, MG, Rauh-Hain, JA, Schmeler, KM, Sala, R, Goss, PE. Progress and remaining challenges for cancer control in Latin America and the Caribbean. The lancet oncology 16(14):1405-1438, 2015. e-Pub 2015. PMID: 26522157.
Provenzano, E, Bossuyt, V, Viale, G, Cameron, D, Badve, S, Denkert, C, MacGrogan, G, Penault-Llorca, F, Boughey, JC, Curigliano, G, Dixon, JM, Esserman, L, Fastner, G, Kühn, T, Peintinger, F, von Minckwitz, G, White, J, Yang, WT, Symmans, WF. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer. Modern Pathology 28(9):1185-1201, 2015. e-Pub 2015. PMID: 26205180.
Salgado, R, Denkert, C, Demaria, S, Sirtaine, N, Klauschen, F, Pruneri, G, Wienert, S, Van Den Eynden, GG, Baehner, FL, Penault-Llorca, F, Perez, EA, Thompson, EA, Symmans, WF, Richardson, AL, Brock, JE, Criscitiello, C, Bailey, H, Ignatiadis, M, Floris, G, Sparano, JA, Kos, Z, Nielsen, TO, Rimm, DL, Allison, KH, Reis-Filho, JS, Loibl, S, Sotiriou, C, Viale, G, Badve, S, Adams, S, Willard-Gallo, K, Loi, S. The evaluation of tumor-infiltrating lymphocytes (TILS) in breast cancer. Annals of Oncology 26(2):259-271, 2015. e-Pub 2015. PMID: 25214542.
Kuerer, HM, Albarracin, C, Yang, WT, Cardiff, RD, Brewster, A, Symmans, WF, Hylton, NM, Middleton, LP, Krishnamurthy, S, Perkins, GH, Babiera, G, Edgerton, ME, Czerniecki, BJ, Arun, BK, Hortobagyi, GN. Ductal carcinoma in situ. Journal of Clinical Oncology 27(2):279-288, 2009. e-Pub 2009. PMID: 19064970.
Peintinger, F, Kuerer, HM, McGuire, SE, Bassett Jr, R, Pusztai, L, Symmans, WF. Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer. British Journal of Surgery 95(4):433-437, 2008. e-Pub 2008. PMID: 18161887.
Gralow, J, Burstein, HJ, Wood, WC, Hortobagyi, GN, Gianni, L, von Minckwitz, G, Buzdar, AU, Smith, IE, Symmans, WF, Singh, B, Winer, EP. Preoperative therapy in invasive breast cancer. Journal of Clinical Oncology 26(5):814-819, 2008. e-Pub 2008. PMID: 18258991.
Dawood, S, González-Angulo, AM, Peintinger, F, Broglio, K, Symmans, WF, Kau, SW, Islam, R, Hortobagyi, GN, Buzdar, AU. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin. Cancer 110(6):1195-1200, 2007. e-Pub 2007. PMID: 17647266.
Peintinger, F, Symmans, WF, González-Angulo, AM, Boughey, JC, Buzdar, AU, Yu, TK, Hunt, KK, Singletary, SE, Babiera, G, Lucci, A, Meric-Bernstam, F, Kuerer, HM. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 107(6):1248-1254, 2006. e-Pub 2006. PMID: 16862596.
Ross, JS, Linette, GP, Stec, J, Clark, EA, Ayers, M, Leschly, N, Symmans, WF, Hortobagyi, GN, Pusztai, L. Breast cancer biomarkers and molecular medicine. Expert Review of Molecular Diagnostics 3(5):573-585, 2003. e-Pub 2003. PMID: 14510178.
Ross, JS, Fletcher, JA, Linette, GP, Stec, J, Clark, E, Ayers, M, Symmans, WF, Pusztai, L, Bloom, KJ. The HER-2/neu gene and protein in breast cancer 2003. Oncologist 8(4):307-325, 2003. e-Pub 2003. PMID: 12897328.
Symmans, WF, Cangiarella, JF, Gottlieb, S, Newstead, GM, Waisman, J. What is the role of cytopathologists in stereotaxic needle biopsy diagnosis of nonpalpable mammographic abnormalities?. Diagnostic Cytopathology 24(4):260-270, 2001. e-Pub 2001. PMID: 11285624.
Symmans WF. p53 and non-Hodgkin's lymphoma. Diag Oncol 4:22-25, 1994. e-Pub 1994.

Editorials

Symmans WF. Interpreting the Complex Landscape of Immune-Tumor Interface. Clin Cancer Res 27(20):5446-5448, 2021. PMID: 34389608.
Symmans, WF, Hortobagyi, GN. Fingerprinting lymph node metastases. Annals of surgical oncology 15(5):1275-1276, 2008. PMID: 18340490.
Symmans, WF. Genomic testing for sensitivity of breast cancer to hormonal therapy. Clinical Cancer Research 12(7 I):1954-1955, 2006. PMID: 16609001.
Symmans WF. Editorial on “Percutaneous Core Needle Biopsy of Radial Scars of the Breast". Breast Diseases: A Yearbook Quarterly 14:291-292, 2003.
Symmans WF. Editorial on “Core biopsy of the breast with atypical ductal hyperplasia" Breast Diseases: A Yearbook Quarterly, 2002.
Symmans WF. Editorial on “E-cadherin as a Prognostic Indicator in Primary Breast Cancer". Breast Diseases: A Yearkbook Quarterly, 2002.
Symmans WF. Editorial on “VEGF-B expression in human primary breast cancers is". Breast Diseases: A Yearbook Quarterly 12:291-292, 2002.
Symmans WF. Using fine needle aspiration samples to predict breast cancer 12:263-265, 2001.

Abstracts

Stover DG, Salgado R, Savenkov O, Ballman KV, Magbanua MJM, Loi S, Mayer EL, Vater M, Glover K, Watson MA, Wen Y, Symmans WF, Perou C, Carey LA, Partridge AH, Rugo HS. Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents, 2023. e-Pub 2023.
Rugo HS, Wolf DM, Yau C, Petricoin E, Pohlmann PR, Pusztai L, Symmans WF, Borowsky A, Finestone S, Yee D, Hylton N, van't Veer L, Esserman L, DeMichele A. Correlation of HER2 low status in I-SPY 2 with molecular subtype, response, and survival, 2023. e-Pub 2023.
Rothschild HT, Clelland E, Patterson A, Molina-Vega J, Kaur M, Abel MK, Symmans WF, Schwartz CJ, Mukhtar R. HER2-14 HER-2 low status in early stage invasive lobular carcinoma of the brease, 2023. e-Pub 2023.
Isaacs C, Nanda R, Chien J, Trivedi MS, Stringer-Reasor E, Vaklavas C, Boughey JC, Sanford A, Wallace A, Clark AS, Thomas A, Albain KS, Kennedy LC, Sanft TB, Kalinsky K, Han HS, Williams N, Aurora M, Elias A, Flakson C, Asare S, Lu R, Pitsouni M, Wilson A, Perlmutter J, Rugo H, Schwab R, Symmans WF, Hylton NM, van't Veer L, Yee D, DeMichele A, Berry D, Esserman LJ, I-SPY Investigators. Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer, 2023. e-Pub 2023.
Loibl S, Denkert C, Liu Y, Knudsen ES, DeMichele A, Zhang Z, Teply-Szymanksi J, Filipits M, Fasching PA, Gnant M, Deng S, Balic M, Rojo F, Watson M, Deshpande C, Turner N, Metzger O, Theall KP, Witkiewicz A, Valota O, Symmans WF, Mayer EL. Development and validation of a composite biomarker predictive of Palbociclib + endocrine treatment benefit in early breast cancer, 2023. e-Pub 2023.
Clelland E, Rothschild HT, Patterson A, Molina-Vega J, Kaur M, Abel MK, Symmans WF, Chien J, Schwartz CJ, Mukhtar R. Quantifying estrogen and progesterone receptor status in early-stage invasive lobular carcinoma of the breast, 2023. e-Pub 2023.
Zakon DB, Poncet C, Cardoso F, Anouk N, Valero V, Aebi S, Benstead K, Bogler O, Dal Lago L, Fraser J, Caballero C, Hedenfalk IA, Korde LA, Linderholm B, Martens JWM, Middleton LP, Murray M, Kelly CM, Nilsson C, Nowaczyk M, Peeters S, Beauvois M, Porter P, Schroder CP, Rubio IT, Ruddy K, van Asperen C, Van Den Wengaert D, van Deurzen CHM, van Leeuwen-Stok E, Vermeij JM, Barlett JMS, Wolff AC, Giordano SH, Symmans WF. PD6-11 evaluation of the sensitivity to endocring therapy index (SET2,3) in early male breast cancer, 2023. e-Pub 2023.
Stringer-Reasor E, Shatsky RA, Chien J, Wallace A, Boughey JC, Albain KS, Han HS, Nanda R, Isaacs C, Kalinsky K, Mitri Z, Clark AS, Vaklavas C, Trivedi MS, Lu J, Asare S, Lu R, Pitsouni M, Wilson A, Perlmutter J, Rugo H, Schwab R, Symmans WF, Hylton NM, van't Veer L, Yee D, DeMichele A, Berry D, Esserman LJ, I-SPY Investigators. PD-11-01 evaluation of the PD-1 inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer, 2023. e-Pub 2023.
Rinkenbaugh AL, Sinha VC, Singh P, Qi Y, Shao J, Zhang X, Echeverria GV, Symmans WF, Moulder SL, Piwnica-Worms H. Analysis of spatiotemporal phenotypic heterogeneity in chemoresistant triple-negative breast cancer using imaging mass cytometry, 2022. e-Pub 2022.
Mittempergher L, Kuilman MM, Barcaru A, Nota B, Delahaye LJMJ, Audeh MW, Wolf DM, Yau C, Brown-Swigart L, Hirst GL, Symmans WF, Lu R, Liu MC, Nanda R, Esserman L, van't Veer LJ, Glas AM. The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY 2, 2022. e-Pub 2022.
Metzger O, Ballman KV, Campbell J, Liu MC, Ligibel JA, Chen E, Du L, Symmans WF. Measurement of endocrine activity (SET2,3) related to prognosis and prediction of benefit from dose-dense (DD) chemotherapy in estrogen receptor-positive (ER+) cancer, 2022. e-Pub 2022.
Cha J, Warner P, Hiatt R, Gomez SL, van't Veer L, Stover-Fiscalini A, Borowsky A, Symmans WF, Wolf DM, Yau C, Yee D, DeMichele A, Berry DA, Esserman L, Audeh WM, Modh S. Distribution of breast cancer molecular subtypes within receptor classifications, 2022. e-Pub 2022.
Potter DA, Roesch E, Yau C, Lu R, Wolf D, Samson S, Stafford D, Albain KS, Isaacs C, Trivedi M, Yee D, Boughey J, Thomas A, Chien AJ, Hylton N, Li W, DeMichele A, Perlmutter J, Symmans WF, Hershman DL, Melisko M, van't Veer L, Wilson A, Asare SM, Berry DA, Schwab R, Rugo HS, Esserman LJ. Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positing (HER2+) stage II/III breast cancer, 2022. e-Pub 2022.
Kyalwazi B, Yau C, Olopade O, Chien AJ, Wallace A, Forero-Torres A, Pusztai L, Ellis E, Albain K, Blaes A, Haley B, Boughey J, Elias A, Clark A, Isaacs C, Nanda R, Han H, Yung R, Tripathy D, Edmiston K, Viscusi R, Northfelt D, Khan Q, Sanil A, Berry S, Asare S, Wilson A, Hirst G, Hylton N, Melisko M, Perlmutter J, Rugo H, Symmans WF, van't Veer L, Berry D, Esserman L. Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial, 2022. e-Pub 2022.
Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, Symmans WF, Park BH, Burnette BL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Brown-Glaberman U, Flaum LE, Mayer EL, Sikov WM, Rodler ET, DeMichele AM, Sparano JA, Wolff AC, Miller KD, Wagner LI. Patient-reported outcomes in EA1131, 2022. e-Pub 2022.
Grimm SL, Gu G, Herzog SK, Gonzalez TL, Lin H, Beyer AR, Rechoum Y, Bawa-Khalfe T, Khan AF, Du L, Symmans WF, Kittler R, Coarfa C, Fuqua SAW. Mutant ESR1 receptors antagonize the tumor suppressor function of androgen receptors, 2022. e-Pub 2022.
Onishi N, Gibbs JE, Li W, Newitt DC, Price ER, LeStage B, Symmans WF, DeMichele AM, Yau C, The I-SPY 2 TRIAL Consortium, Esserman LJ, Hylton NM. Functional tumor volume at 3 and 6-week MRI as an indicator of patients with inferior outcome after neoadjuvant chemotherapy, 2022. e-Pub 2022.
Speers CW, Symmans WF, Barlow WE, Trevarton A, The S, Du L, Rae JM, Shak S, Bahner FL, Sharma P, Pusztai L, Horobagyi GN, Hayes DF, Albain KS, Godwin A, Thompson A. Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence Score® assay in node-positive postmenopausal breast cancer, 2022. e-Pub 2022.
Symmans WF, Du L, Hoskin T, Anurag M, Ma C, Bedrosian I, Hunt KK, Ellis M, Suman VJ. Evaluation of sensitivity to endocrine therapy index (SET2,3) for response to neoadjuvant endocrine therapy (NET) and subsequent prognosis. 2021 Asco Annual Meeting, 2021. e-Pub 2021.
Litton JK, Beck JT, Jones JM, Andersen J, Blum JL, Mina LA, Brig R, Danso MA, Yuan Y, Abbattista A, Noonan K, Chakrabarti J, Czibere A, Symmans WF, Telli ML. Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (B), 2021. e-Pub 2021.
Telli ML, Litton JK, Beck JT, Jones JM, Andersen J, Mina LA, Brig R, Danso MA, Yuan Y, Symmans WF, Abbattista A, Noonan K, Mata M, Laird D, Blum JL. Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC), 2021. e-Pub 2021.
Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele A, Sparano JA, Wolff AC, Miller K. A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC), 2021. e-Pub 2021.
Beckwith H, Schwab R, Yau C, Stringer-Reasor E, Wei S, Chien AJ, Albain KS, Kalinsky K, Wallace A, Elias A, Yee D, Clark AS, Boughey JC, Han H, Nanda R, Isaacs C, Mitri Z, Lang JE, Thomas A, Sanft T, DeMichele A, Perlmutter J, Rugo HS, Hylton NM, Symmans WF, Melisko ME, van't Veer LJ, I-SPY 2 Consortium, Wilson A, Asare SM, Sanil A, Berry DA, Esserman LJ. Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer, 2021. e-Pub 2021.
Hurvitz SA, Fresco R, Afenjar K, Stroyakovskiy D, Huang C-S, Wildiers H, Jung KH, Boileau J-F, Campone M, Martin M, Valero V, Sparano JA, Symmans WF, Fasching PA, Thompson AM, Harbeck N, Lopez-Valverde V, Song C, Boulet T, Restuccia E, Slamon DJ. Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial, 2021. e-Pub 2021.
Shad S, van der Noordaa M, Osdoit M, de Croze D, Hamy A-S, Lae M, Reyal F, Martin M, Del Monte-Millan M, Lopez-Tarruella S, I-SPY 2 TRIAL Consortium, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Sonke G, Steenbruggen TG, van Seijen M, Wesseling J, Bartlett J, Edge S, Kim M-O, Abraham J, Caldas C, Earl H, Provenzano E, Sammut S-J, Cameron D, Graham A, Hall P, Mackintosh L, Fang F, Godwin AK, Schwensen K, Sharma P, DeMichele A, Dunn J, Hiller L, Hayward L, Thomas J, Cole K, Pusztai L, van't Veer L, Symmans WF, Esserman L, Yau C. Site of recurrence after neoadjuvant therapy, 2021. e-Pub 2021.
Venters SJ, Li W, Wolf DM, Carter JM, Klein ME, Singh K, Rabe K, Ocal IT, Newitt D, Yau C, Onishi N, Gibbs J, Sahoo S, Harada S, Khazai L, Harigopal M, Borowsky AD, Krings G, Balassanian R, Chen Y-Y, Cole K, Shad S, LeStage B, Delson A, Finestone S, Brown-Swigart L, I-SPY 2 Imaging Working Group, I-SPY 2 Consortium, Esserman L, van't Veer L, Symmans WF, Hylton NM. Serial MRI and pathology combined to select candidates for therapy de-escalation in the I-SPY 2 TRIAL, 2021. e-Pub 2021.
Onishi N, Li W, Venters SJ, Wolf DM, Newitt DC, Price ER, Gibbs J, LeStage B, the I-SPY 2 Pathology Working Group, the I-SPY 2 Consortium, Symmans WF, Hylton NM. Radilogic review to refine selection of candidates for de-escalation of neoadjuvant therapy, 2021. e-Pub 2021.
Carter JM, Klein ME, Venters SJ, Rabe K, Ocal IT, Singh K, Wolf DM, Sahoo S, Harada S, Khazai L, Harigopal M, Borowsky AD, Krings G, Balassanian R, Chen Y-Y, Cole K, Shad S, Delson A, Brown-Swigart L, I-SPY 2 TRIAL Consortium, Esserman L, van't Veer L, Symmans WF. Pathologic features of the inter-regiment biopsy predict response to neoadjuvant therapy in the I-SPY 2 TRIAL, 2021. e-Pub 2021.
Yee D, Haluska P, Wolf DM, Yau C, I-SPY 2 Consortium, DeMichele A, Isaacs C, Perlmutter J, Venticinque J, Rugo HS, Schwab R, Hylton NM, Symmans WF, Melisko ME, Helsten TL, van't Veer LJ, Berry DA, Esserman LJ. Biomarker analysis of paclitaxel, ganitumab, and metformin (PGM) therapy in the I-SPY 2 neoadjuvant clinical trial, 2021. e-Pub 2021.
van der Noordaa MEM, Yau C, Shad S, Osdoit M, Steenbruggen TG, de Croze D, Hamy A-S, Lae M, Reyal F, Del Monte-Millan M, Martin M, Tarruella SL, I-SPY 2 TRIAL Consortium, Boughey JC, Goetz M, Hoskin T, Gould R, Valero V, Sonke G, van Seijen M, Wesseling J, Bartlett J, Edge S, Kim M-O, Abraham J, Caldas C, Earl H, Provenzano E, Sammut S-J, Cameron D, Graham A, Hall P, MacKintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele A, Dunn J, Hiller L, Hayward L, Thomas J, Cole K, Pusztai L, van't Veer L, Symmans WF, Esserman L. Assessing prognosis after neoadjuvant therapy, 2021. e-Pub 2021.
Seth S, Rauch GM, Adrada B, Piwnica-Worms H, Hou L, Thompson AM, Symmans WF, Lim B, White J, Draetta GF, Futreal A, Chang J, Moulder S. A tiered algorithm using mid-therapy ultrasound (US) response assessment and a novel gene expression signature (GES) improves the prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple-negative brast cancer (TNBC), 2021. e-Pub 2021.
Pusztai L, Han HS, Yau C, Wolf D, Wallace AM, Shatsky R, Helsten T, Boughey JC, Haddad T, Stringer-Reasor E, Falkson C, Chien AJ, Mukhtar R, Elias A, Virginia B, Nanda R, Yee D, Kalinsky K, Albain KS, Muller AS, Kemmer K, Clark AS, Isaacs C, Thomas A, Hylton N, Symmans WF, Perlmutter J, Melisko M, Rugo HS, Schwab R, Wilson A, Singhrao R, Asare S, van't Veer LJ, DeMichele AM, Sanil Ashish, Berry DA, Esserman LJ, Trial Consortium I-SPY 2. Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer, 2020. e-Pub 2020.
Lim B, Seth S, Huo L, Layman RM, Valero V, Thompson AM, White JB, Litton JK, Damodaran S, Candelaria RP, Arun B, Rauch GM, Murthy RK, Ding Q, Symmans WF, Zhao L, Zhang J, Tripathy D, Moulder SL, Ueno NT. Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide, 2020. e-Pub 2020.
Yam C, Alatrash G, Yen E-Y, Garber H, Philips AV, Huo L, Yang F, Bassett RL, Sun X, Parra Cuentas ER, Symmans WF, Seth S, White JB, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Moulder SL, Mittendorf EA. Immune phenotype and response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC), 2020. e-Pub 2020.
Goetz MP, Suman VJ, Reid JM, Kuffel M, Buhrow SA, McGovern RM, Black J, Dockter T, Symmans WF, Liu MC, Hawse JR, Doroshow J, Storniolo AM, Collins JM, Streicher H, Ames MM, Ingle JN, Partridge A, Carey L. A randomized phase II trial of tamoxifen versus Z-endoxifen HCL in postmenopausal women with metastatic estrogen receptor positive, HER2 negative breast cancer, 2020. e-Pub 2020.
Pohlmann PR, Yau C, DeMichele A, Claudine I, Boughey JC, Hylton N, Melisko ME, Perlmutter J, Rugo HS, Symmans WF, I-SPY 2 TRIAL Consortium, Berry DA, Esserman L. Amsterdam 70-gene profile (MammaPrint) low risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy, 2020. e-Pub 2020.
Li W, Onishi N, Newitt DC, Gibbs J, Wilmes LJ, Jones EF, Joe BN, Sit LS, Yau C, Chien AJ, Price Elissa, Albain KS, Kuritza T, Morley K, Boughey JC, Brandt K, Choudhery S, Clark AS, Rosen M, McDonald ES, Elias AD, Wolverton D, Fountain K, Euhus DM, Han HS, Niell B, Drukteinis J, Lang JE, Lu J, Meisel JL, Mitri Zaha, Nanda Rita, Northfelt RW, Sanft T, Stringer-Reasor E, Viscusi RK, Wallace AM, Yee D, Yung R, Asare SM, Melisko ME, Perlmutter J, Ruho HS, Schwab R, Symmans WF, van't Veer L, Berry DA, DeMichele A, Abe H, Sheth D, Edmiston KK, Ellis ED, Ha R, Wynn R, Crane EP, Dillis C, Nelson M, Church A, Isaacs C, Khan QJ, Oh KY, Jafarian N, Bang DH, Mullins C, Woodard S, Zamora KW, Ojeda-Fornier H, Sheth P, Hovanessian-Larsen L, Eghtedari M, Spektor M, Giurescu M, Newell MS, Cohen MA, Berman E, Lehman C, Smith W, Fitzpatrick, Borders MH, Yang W, Dogan B, Goudreau S, Brown T, Esserman LJ, Hylton NM. Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial, 2020. e-Pub 2020.
Venters SJ, Wolf DM, Brown-Swigart L, Yau C, Delson AL, Parker B, Balassanian R, Carter J, Chen Y-Y, Cole K, Khazai L, Klein M, Kokh D, Krings G, Sahoo S, Wei J, I-SPY 2 TRIAL Consortium, Esserman LJ, van't Veer L, Symmans WF. Assessing biomarkers to inform treatment de-escalation, 2020. e-Pub 2020.
Osdoit M, Yau C, Symmans WF, Boughey JC, Asare SM, Balassanian R, Carter JM, Chen Y-Y, Cole K, Khazai L, Klein M, Kokh D, Krings G, Sahoo S, Ahrendt G, Chiba A, Ewing C, Godellas C, Jaskowiak N, Killelea B, Krontiras H, Lancaster R, Lang J, Lee MC, Naik A, Rao R, Tchou J, Tierney S, Tousimis E, Tuttle T, Wallace A, I-SPY 2 TRIAL Consortium, Parker B, Esserman LJ, Mukhtar RA. The impact of residual ductal carcinoma in situ on breast cancer recurrence in the neoadjuvant I-SPY 2 TRIAL, 2020. e-Pub 2020.
Li W, Onishi N, Newitt DC, Harnish R, Jones EF, Wilmes LJ, Bibbs J, Price E, Joe BN, Chien AJ, Berry DA, Boughey JC, Albain KS, Clark AS, Edmiston KK, Elias AD, Ellis ED, Euhus DM, Han HS, Isaacs C, Khan QJ, Lang JE, Lu J, Meisel JL, Mitri Z, Nanda R, Northfelt DW, Sanft T, Stringer-Reasor E, Viscusi RK, Wallace AM, Yee D, Yung R, Melisko ME, Perlmutter J, Rugo HS, Schwab R, Symmans WF, van't Veer L, Yau C, Asare SM, DeMichele A, Goudreau S, Abe H, Sheth D, Wolverton D, Fountain K, Ha R, Wynn R, Crance EP, Dillis C, Kuritza T, Morely K, Nelson M, Church A, Niell B, Durkteinis J, Oh KY, Jafarian N, Brandt K, Choudhery S, Bang DH, Mullins C, Woodard S, Zamora KW, Ojeda-Fornier H, Eghedari M, Sheth P, Hovanessian-Larsen L, Rosen M, McDonald ES, Spektor M, Giurescu M, Newell MS, Cohen MA, Berman E, Lehman C, Smith W, Fitzpatrick K, Borders MH, Yang W, Dogan B, Esserman LJ, Hylton NM. The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI, 2020. e-Pub 2020.
Yau C, DeMichele A, Symmans WF, Pusztai L, Yee D, Clark AS, Hatzis C, Matthews JB, Carter J, Chen Y-Y, Cole K, Khazai L, Klein M, Kokh D, Krings G, Sahoo S, Albain KS, Chien AJ, Edmiston KK, Elias AD, Ellis ED, Euhus DM, Han HS, Isaacs C, Khan QJ, Lang JE, Lu J, Meisel JL, Mitri Z, Nanda R, Northfelt DW, Sanft T, Stringer-Reasor E, Viscusi RK, Wallace AM, Yung R, Hylton NM, Boughey JC, Melisko ME, Perlmutter J, Rugo HS, Schwab R, van't Veer LJ, Berry DA, Esserman LJ. Site of recurrence after neoadjuvant therapy, 2020. e-Pub 2020.
Abuhadra N, Hess K, Litton J, Rauch G, Thompson A, Lim B, Adrada B, Mittendorf E, Damodaran S, Candelaria R, Arun B, Yang WT, Ueno N, Santiago L, Murthy R, Ibrahim N, Aysegul S, Symmans WF, Huo L, Moulder S. Serial TILs, 2020. e-Pub 2020.
Garber H, Rauch G, Adrada B, Candelaria R, Mittendorf E, Thompson A, Litton J, Damodaran S, Lim B, Arun B, Ueno N, Valero V, Ibrahim N, Murthy R, Tripathy D, Piwnica-Worms H, Symmans WF, Huo L, Moulder S. Residual cancer burden in patients with early stage triple-negative breast cancer who progress on anthracycline-based neoadjuvant chemotherapy in an ongoing clinical trial (ARTEMIS), 2020. e-Pub 2020.
King TA, Liu MC, McClure MB, Hinoue T, Kelly BJ, Creighton CJ, Bowen J, Leraas K, Burns RT, Coppens S, Rezk S, Garrett AL, Balko JM, Parker JS, Park BH, Krop I, Anders C, Hoadley KA, Gastier-Foster J, Rimawi MF, Nanda R, Lin NU, Isaacs C, Marcom PK, Storniolo AM, Couch FJ, Mardis ER, Lee AV, Chandran U, Laird PW, Hilsenbeck SG, Norton L, Richardson AL, Symmans WF, Carey LA, Wolff AC, Davidson NE, Perou CM, the AURORA US Network. Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network, 2020. e-Pub 2020.
Seth S, Huo L, Vasaikar S, Rauch G, Lim B, White J, Adrada B, Piwnica-Worms H, Ueno NT, Thompson AM, Mittendorf E, Tripathy D, Litton JK, Symmans WF, Draetta G, Futreal A, Chang J, Moulder S. Longitudinal response and selection under neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC), 2020. e-Pub 2020.
Onishi N, Li W, Newitt DC, Harnish R, Gibbs J, Jones Ella F, Nguyen A, Wilmes L, Joe BN, Campbell MJ, Basu A, van't Veer L, DeMichelle A, Yee D, Berry DA, Albain KS, Boughey JC, Chien AJ, Clark AS, Edmiston KK, Elias AD, Ellis ED, Euhus DM, Han HS, Isaacs C, Khan QJ, Lang JE, Lu J, Meisel JL, Mitri Z, Nanda R, Northfelt DW, Sanft T, Stringer-Reasor E, Viscusi RK, Wallace AM, Yung R, Melisko ME, Perlmutter J, Rugo HS, Symmans WF, Asare SM, Yau JE, Yau C, Esserman LJ, Hylton NM. Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer, 2020. e-Pub 2020.
Echeverria GV, Xu M, Shao J, Zhang X, Jeter-Jones S, Zhou X, Moulder SL, Marszalek JR, Heffernan TP, Symmans WF, Chang JT, Piwnica-Worms H. Investigating genomic and phenotypic evolution of triple-negative breast cancer chemoresistance and metastasis in patient-derived xenografts, 2020. e-Pub 2020.
Helsten TL, Lo SS, Yau C, Kalinky K, Elias AD, Wallace AM, Chien AJ, Lu J, Lang JE, Albain KS, Stringer-Reasor E, Clark AS, Boughey JC, Ellis ED, Yee D, DeMichele A, Isaacs C, Perlmutter J, Rugo HS, Schwab R, Hylton NM, Symmans WF, Melisko ME, van't Veer L, Wilson A, Singhrao R, Asare SM, Sanil Ashish, Berry DA, Esserman LJ. Evaluation of patritumab/paclitaxel//trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer, 2020. e-Pub 2020.
Liu MC, Robinson PA, Yau C, Wallace AM, Chien AJ, Stringer-Reasor E, Nanda R, Yee D, Albain KS, Boughey JC, Han HS, Elias AD, Kalinsky K, Clark AS, Kemmer K, Isaacs C, Lang JE, Lu J, Sanft T, DeMichele A, Hylton NM, Melisko ME, Perlmutter J, Rugo HS, Schwab R, Symmans WF, van't Veer L, Haugen PK, Wilson A, Singhrao R, Asare S, Sanil A, Berry DA, Esserman LJ. Ecaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer, 2020. e-Pub 2020.
Singh P, Bedrosian I, Ha MJ, Shen Y, Du L, Gould R, Symmans WF. Association of a genomic index of sensitivity to endocrine therapy with disease-free survival in breast cancer, 2020. e-Pub 2020.
Schwab R, Clark AS, Yau C, Hylton N, Li W, Wolfe D, Chien AJ, Wallace AM, Forero-Torres A, Stringer-Reasor E, Nanda R, Jaskowiak N, Boughey J, Haddad T, Han HS, Lee C, Albain K, Isaacs C, Elias AD, Ellis ED, Shah P, Lang JE, Lu J, Tripathy D, Kemmer K, Yee D, Haley B, Majure M, Roesch E, Vaklavas C, Ewing C, Helsten T, Symmans WF, Perlmutter J, Rugo HS, Melisko M, Wilson A, Singhrao R, van't Veer L, DeMichele A, Asare S, Berry D, Esserman LJ. Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer, 2019. e-Pub 2019.
Echeverria GV, Ge Z, Seth S, Powell E, Zhang X, Jeter-Jones S, Zhou X, Jiang Y, McCoy A, Cai S, Tu Y, Peoples M, Sun Y, Qiu H, Bristow C, Carugo A, Shao J, Moulder SL, Symmans WF, Heffernan TP, Chang JT, Piwnica-Worms H. Clonal dynamics and phenotypic evolution during chemoresistance and metastasis revealed by patient-derived xenograft models of triple-negative breast cancer, 2019. e-Pub 2019.
den Hollander P, Shah S, Zhou X, Redwood A, Cai S, Sobieski M, Brunell D, Stephan C, Davies P, Piwnica-Worms H, Moulder S, Symmans WF, Mani SA. Overcoming therapy resistance in stem cell-rich triple-negative breast cancer through p38 MAP kinase inhibition, 2019. e-Pub 2019.
Filho OM, Stover DG, Asad S, Ansell PJ, Watson M, Loibl S, Geyer CE, O'Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, Von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Symmans WF. Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC, 2019. e-Pub 2019.
Seth S, Huo L, Rauch GM, Adrada BE, Piwnica-Worms H, Thompson AM, Mittendorf EA, Litton JK, Symmans WF, Draetta GF, Futreal A, Moulder SL, Chang J. Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) triple-negative breast cancer (TNBC), 2019. e-Pub 2019.
Thompson PA, Brewster A, Tsavachidis S, Armstrong G, Do K-A, Ha M-J, Gutierrez C, Symmans WF, Bondy M. Cumulative copy number imbalances after neoadjuvant chemotherapy residual breast tumor is an independent predictor of relapse, 2019. e-Pub 2019.
Seth S, Huo L, Rauch G, Lau R, Gilcrease M, Adrada B, Piwnica-Worms H, Symmans WF, Draetta G, Futreal AP, Moulder S, Chang JT. Towards a therapeutically relevant subtyping scheme for triple-negative breast cancer (TNBC), profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival rates (ARTEMIS), 2019. e-Pub 2019.
van der Noorda ME, Esserman L, Yau C, Mukhtar R, Price E, Hylton N, Abe H, Wolverton D, Crane EP, Ward KA, Nelson M, Niell BL, Oh K, Brandt KR, Bang DH, Ojeda-Fournier H, Eghtedari M, Sheth PA, Bernreuter WK, Umphrey H, Rosen MA, Dogan B, Yang W, Joe B, van't Veer L, Hirst G, Lancaster R, Wallace A, Alvaredo M, Symmans WF, Asare S, Boughey JC, I-SPY 2 Consortium. Role of breast MRI in predicting pathologically negative nodes after neoadjuvant chemotherapy in cN0 patients in the I-SPY 2 trial, 2019. e-Pub 2019.
Echeverria GV, Ge Z, Seth S, Jeter-Jones SL, Zhang X, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Lau R, Shao J, Sun Y, Bristow C, Carugo A, Ma X, Harris A, Wu Y, Moulder S, Symmans WF, Marszalek JR, Heffernan TP, Chang JT, Piwnica-Worms H. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state, 2019. e-Pub 2019.
Hylton NM, Symmans WF, Yau C, Li W, Hatzis C, Isaacs C, Albain KS, Chen Y-Y, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal I, Tawfik O, Grasso-LeBeau L, Sahoo S, Vinh T, Yang S, Adams A, Chien AJ, Ferero-Torres A, Stringer-Reasor E, Wallace A, Boughey JC, Ellis ED, Elias AD, Lang JE, Lu J, Han HS, Clark AS, Korde L, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Wood WC, Park JW, Liu MC, Olopade O, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen PK, van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennel JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Sanil A, Berry SM, Abe H, Wolverton D, Crane EP, Ward KA, Nelson M, Niell BL, Oh K, Brandt KR, Bang DH, Ojeda-Fournier H, Eghtedari M, Sheth PA, Bernreuter WK, Umphrey H, MA Rosen, Dogan B, Yang W, Joe B, I-SPY 2 TRIAL Consortium, Yee D, Pusztai L, DeMichele A, Asare SM, Berry DA, Esserman LJ. Refining neoadjuvant predictors of three year distant metastasis free survival, 2019. e-Pub 2019.
Marczyk M, Fu C, Lau R, Du L, Trevarton AJ, Sinn BV, Gould RE, Symmans WF, Hatzis C. Pre-analytical effects of FFPE extraction methods on targeted and whole transcriptome sequencing assays for endocrine sensitivity in metastatic breast cancer. San Antonio Breast Cancer Symposium, 2019. e-Pub 2019.
Yam C, Raghavendra A, Hess KR, Adrada BE, Candelaria RP, Damodaran S, Gilcrease MZ, Helgason T, Hortobagyi GN, Huo L, Layman RM, Lim B, Litton JK, Mittendorf EA, Murthy RK, Piwnica-Worms H, Rauch GM, Santiago L, Symmans WF, Thompson AM, Tripathy D, Ueno NT, Valero V, Barcenas CH, Moulder SL, Yang W. Impact of serial biopsies in triple-negative breast cancer patients receiving neoadjuvant systemic therapy, 2019. e-Pub 2019.
Wolf DM, Yau C, Wulfkuhle, Petricoin E, Campbell M, Brown-Swigart L, Hirst G, Asare S, Zhu Z, Lee EP, Delson A, Pohlmann P, I-SPY 2 TRIAL Consortium, Hylton N, Liu MC, Symmans WF, DeMichele A, Yee D, Berry D, Esserman L, van't Veer L. Identifying breast cancer molecular phenotypes to predict response ina modern treatment landscape, 2019. e-Pub 2019.
Litton J, Symmans WF, Gogineni K, Saltzman M, Telli ML, Usha L, Chakrabarti J, Tudor IC, Quek RG, Czibere A. A phase 2, open-label, single-arm, multi-center study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple-negative breast cancer (TNBC). San Antonio Breast Cancer Symposium, 2019. e-Pub 2019.
Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Spera G, Lopez-Valverde V, Song C, Boulet T, Sparano J, Symmans WF, Thompson AM, Slamon D. Neoadjuvant trastuzumab (H), pertuzumab (P) and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), 2019. e-Pub 2019.
Du L, Yau C, Brown-Swigart L, Hirst G, I-SPY 2 Consortium, van der Noordaa M, Bedrosian I, Layman RM, Valero V, van't Veer L, Esserman L, Symmans WF. Prognostic contribution of predicted sensitivity to endocrine therapy (SET) prior to neoadjuvant chemotherapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer, 2019. e-Pub 2019.
Yau C, van der Noordaa M, Wei J, Osdoit M, Reyal F, Hamy A, Lae M, Martin M, del Monte M, I-SPY 2 TRIAL Consortium, Boughey JC, Gould R, Wesseling J, Steenbruggen T, van Seijen M, Sonke G, Edge S, Sammut S, Provenzano E, Abraham J, Hall P, Graham A, Mackintosh L, Cameron D, Wang A, Sharma A, Cole K, Pusztai L, Kim M, van't Veer L, Esserman L, Symmans WF. Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer, 2019. e-Pub 2019.
Marczyk M, Fu C, Lau R, Du L, Trevarton AJ, Sinn BV, Gould RE, Symmans WF, Hatzis C. Pre-analytical effects of FFPE extraction methods on targeted and whole transcriptome sequencing assays for endocrine sensitivity in metastatic breast cancer. San Antonio Breast Cancer Symposium, 2018. e-Pub 2018.
Litton J, Symmans WF, Citron M, Gogineni K, Saltzman M, Telli ML, Usha L, Chakrabarti J, Tudor IC, Quek RGW, Czibere A. A phase 3, nonrandomized, open-label, single-arm, multi-center study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early triple-negative breast cancer, 2018. e-Pub 2018.
Symmans WF, Yau C, Chen Y, Datnow B, Wei S, Feldman MD, Ritter J, Duan X, Chen B, Tickman R, Sattar H, Magliocco AM, Kallakury B, Troxell M, Asare S, Liu MC, DeMichele A, Yee D, Berry DA, Esserman L on behalf of I-SPY 2 TRIAL Investigators and Pathologists. Residual cancer burden (RCB) is prognostic in the I-SPY 2 trial. 2018 ASCO Annual Meeting, 2018. e-Pub 2018.
Bayar M, Criscitiello C, Curigliano G, Symmans WF, Desmedt C, Bonnefoi H, Sinn BV, Pruneri G, Vicier C, Pierga JY, Denkert C, Loibl S, Sotiriou C, Michels S, Andre F. A gene signature of chemo-immunization to predict outcome in patients with triple-negative breast cancer treated with neoadjuvant chemotherapy, 2017. e-Pub 2017.
Yam C, Hess K, Litton JK, Yang WT, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Krishnamurthy R, Damodaran SK, Helgason T, Huo L, Thompson AM, Gilcrease M, Santiago L, Candelaria RP, Rauch G, Adrada B, Symmans WF, Moulder SL. A randomized, triple-negative breast cancer enrolling trial to confirm molecular profiling improves survival rates (ARTEMIS), 2017. e-Pub 2017.
Sinn BV, Tsai T-H, Lau R, Fu C, Gould R, Murthy R, King TA, Hatzis C, Kwiatkowski DN, Valero V, Symmans WF. A robust 18-gene predictor of sensitivity to endocrine therapy in metastatic breast cancer, 2016. e-Pub 2016.
Moulder S, Hess K, Rauch M, Astrada B, Litton J, Mittendorf E, Ueno N, Tripathy D, Lim B, Piwnica-Worms H, Thompson A, Symmans WF. A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients (pts) with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT), 2016. e-Pub 2016.
Echeverria GV, Chang JT, Cai S, Tu Y, McCoy A, Lau R, Redwood A, Kaffiabasabadi S, Rauch GM, Astrada BE, Jennifer L, Moulder SL, Symmans WF, Piwnica-Worms H. An annotated collection of pre- and post-therapy breast cancer patient derived xenograft models built from fine needle aspiration samples aligned with ongoing clinical trials documenting response to treatment, 2016. e-Pub 2016.
Wolf DM, Yau C, Sanil A, Glas A, Petricoin C, Wulfkuhle J, Brown-Swigart L, Hirst G, I-Spy 2 TRIAL Investigators, Buxton M, DeMichele A, Hylton N, Symmans WF, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olapade O, van't Veer L. DNA repair deficiency biomarkers and MammaPrint High1/(Ultra)High2 risk as predictors of veliparib/carboplatin response, 2016. e-Pub 2016.
Forero A, Yee D, Buxton MB, Symmans WF, Chien AJ, Boughey JC, Elias AD, DeMichele A, Moulder S, Minton S, Kaplan HG, Albain KS, Wallace AM, Haley BB, Isaacs C, Korde LA, Nanda R, Lang JE, Kemmer KA, Hylton NM, Paoloni M, van't Veer L, Lyandres J, Perlmutter J, Hogarth M, Yau C, Sanil A, Berry DA, Esserman LJ. Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer, 2016. e-Pub 2016.
Fujii T, Lim B, Helgason T, Hess KR, Gilcrease MZ, Willey JS, Tripathy D, Litton JK, Moulder S, Krishnamurthy S, Yang W, Reuben JM, Symmans WF, Ueno NT. A fase IIB study of neoadjuvant ZT regimen (enzalutamide therapy in combination with weekly paclitaxel) for androgen receptor (AR)-positive triple-negative breast cancer (TNBC), 2016. e-Pub 2016.
Hurvitz SA, Symmans WF, Jung KH, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Anfenjar K, Fresco R, Helms HJ, Xu J, Ling YG, Sparano JA, Slamon D. Pathologic complete response rates after neoadjuvant trastuzumab emtansince (T-DM1) + pertuzumab vs. docetaxel + carboplatin + trastuzumab + pertuzumab (TCH+P) treatment in patients with HER2-positive (HER2+) early breast cancer, 2016. e-Pub 2016.
Reddy JP, Atkinson RL, Larson RA, Burks JK, Smith D, Debeb BG, Ruffell B, Creighton C, Reuben JM, Krishnamurthy S, Symmans WF, Brewster A, Van Laere SJ. Stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer, 2016. e-Pub 2016.
Yee D, Paoloni M, van't Veer L, Sanil A, Yau C, Forero A, Chien AJ, Wallace AM, Moulder S, Albain KS, Kaplan HG, Elias AD, Haley BB, Boughey JC, Kemmer KA, Korde LA, Isaacs C, Minton S, Nanda R, DeMichele A, Lang JE, Buxton MB, Hylton NM, Symmans WF, Lyandres J, Hogarth M, Perlmutter J, Esserman LF, Berry DA. The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer, 2016. e-Pub 2016.
Shah M, Jensen R, Yau C, Straehley I, Berry DA, DeMichele A, Buxton MB, Hylton NM, Perlmutter J, Symmans WF, Tripathy D, Yee D, Wallace A, Kaplan HG, Clark A, Chien AJ, I-SPY Investigators, Esserman LJ, Melisko ME. Trajectory of patient (pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial, 2016. e-Pub 2016.
Litton JK, Moulder S, Helgason T, Clayborn AR, Rauch GM, Gilcrease M, Adrada BE, Huo L, Hess KR, Symmans WF, Thompson A, Tripathy D, Mittendorf EA. Triple-negative first-line study, 2016. e-Pub 2016.
Tripathy D, Chien AJ, Hylton N, Buxton MB, Ewing CA, Wallace AM, Forero A, Kapla HG, Nanda R, Albain KS, Moulder SL, Haley BB, DeMichelle A, Symmans WF, van't Veer L, Paoloni M, Esserman L, Berry D, Yee D. Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206, 2015. e-Pub 2015.
Mitri ZI, Ueno NT, Yang W, Valero V, Litton J, Murth RK, Ibrahim NK, Arun BK, Mittendorf EA, Hunt KK, Meric-Bernstam F, Thompson A, Piwnica-Worms H, Tripathy D, Symmans WF, Moulder-Thompson S. Women's triple-negative, first-line treatment, 2015. e-Pub 2015.
Moulder S, Ueno NT, Yang WT, Ensor J, Valero V, Litton JK, Krishnamurthy R, Ibrahim NK, Arun B, Mittendorf EA, Hunt K, Meric-Bernstam F, Thompson AM, Piwnica-Worms H, Tripathy D, Symmans WF. Women's triple-negative, first line treatment, 2015. e-Pub 2015.
Albain KS, Leyland-Jones B, Symmans WF, Paoloni M, van't Veer L, DeMichele A, Buxton M, Hylton N, Yee D, Lyandres Clennel J, Yau C, Sanil A. The evaluation of trebananib plus standard neoadjuvant therapy in high-rise breast cancer, 2015. e-Pub 2015.
Liu MC, Symmans WF, Yau C, Chen Y-Y, Rugo HS, Olopade OF, Datnow B, Chen B, Feldman M, Kallakury B, Hasteh F, Tickman R, Ritter J, Troxel M, Mhawech-Fauceglia P, Duan X, Berry D, Esserman L, DeMichele A. Residual cancer burden (RCB) with veliparib/carboplatin in the I-SPY 2 trial, 2015. e-Pub 2015.
Mater E, DeMIchele A, Dubsky P, Barry W, Metzger O, Symmans WF, Burstein H, Miller K, Wolff A, Rastogi P, Loibl S, von Minckwitz G, Goulioti T, Zardavas D, Fesl C, Koehler M, Huang-Bartlett C, Chen L, Piccart M, Winer E, Gnant M. PALLAS: Palbociclib Collaborative Adjuvant Study, 2015. e-Pub 2015.
Haddad TC, Shah MD, Symmans WF, Hylton N, Yau C, Lyandres J, Melisko ME, Forero A, Albain KS, Kaplan HG, Viscusi RK, Berry DA, Esserman L, Chien AJ. I-SPY 2 low risk registry, 2015. e-Pub 2015.
Echeverria GV, Seth S, Moulder S, Symmans WF, Chang J, Cai S, Heffernan T, Piwnica-Worms H. Investigating clonal dynamics in triple negative breast cancer chemoresistance, 2015. e-Pub 2015.
Mittendorf EA, Bila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK. Bioscore, 2015. e-Pub 2015.
Buxton MB, Natashura K, DeMichele A, Perlmutter J, Hylton NM. Transforming the clinical trial process 32(5S), 2014. e-Pub 2014.
Buxton MB, Matsuhara K, DeMichele A, Perlmutter J, Hylton NM, Yee D, van't Veer L, Symmans WF, Hogarth M, Lyandres J, Davis SE, Flynn S, Paoloni M, Berry DA, Esserman L. Transforming the clinical trial process, 2014. e-Pub 2014.
Murthy R, Ueno NT, Symmans WF, Litton J, Arun BK, Ibrahim NK, Alvarez RH, Gilcrease MZ, Valero V, Tripathy D, Moulder S. Phase II single arm study of liposomal doxorubicin (D), bevacizumab (A), and temsirolimus (T) for treatment of triple negative early breast cancer refractory to standard neoadjuvant chemotherapy, 2014. e-Pub 2014.
Geyer C, O'Shaughnessy J, Untch M, Sikov W, Rugo HS, McKee MD, Huober JB, Golshan M, Giranda VL, Von Minckwitz GV, Maag D, Sullivan DM, Wolmark N, McIntyre K, Ponce Lorenzo J, Metzger O, Rastogi P, Symmans WF, Liu X, Loibl S. Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early-stage triple-negative breast cancer (TNBC), 2014. e-Pub 2014.
Kammerer S, Sokolowski A, Hackl H, Jahn S, Asslaber M, Symmans WF, Peintinger R, Regitnig P, Schreibmater W, Bauernhofer T. Overexpression of G protein-activated inward rectifier potassium channel 1 (GIRK1) is associated with lymph node metastasis and poor prognosis in breast cancer 25(Suppl 1):i8-i16, 2014. e-Pub 2014.
Boughey JC, Ballman KV, Symmans WF, McCall LM, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Hunt K. Methods impacting the false negative rate of sentinel lymph node surgery in patients presenting with node positive bread cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy, 2014. e-Pub 2014.
Wolf DM, Yau C, Sanil A, Chien J, Wallas A, DeMichele A, Kaplan H, Yee D, Isaacs C, Albain K, Viscuzi R, Boughey J, Moulder S, Chui S, Khan Q, Stylbo T, Edmiston K, Northfelt D, Elias A, Haley B, Tripathy D, Brown-Swigart L, Flynn S, Hirst G, Buxton M, Hylton N, Paoloni M, Symmans WF, Esserman L, Berry D, Rugo H, Olopade OI, van't Veer L. MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL, 2014. e-Pub 2014.
Yau C, Wolf D, Sanil A, Chien J, Wallace A, Boughey J, Yee D, Tripathy D, DeMichele A, Nanda R, Chiu S, Isaacs C, Albain K, Kaplan H, Moulder S, Viscusi R, Northfelt D, Edmiston K, Elias A, Styblo T, Haley B, Brown-Swigart L, Flynn S, Hirst GL, Buxton M, Hylton N, Paoloni M, Symmans WF, Esserman L, Berry D, Liu MC, Park JW, van't Veer L. MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL, 2014. e-Pub 2014.
Yau C, Wolf D, Sanil A, van't Veer L, Petricoin EF, Buxton M, Gray J, DeMichele A, Hogarth M, Hylton N, Perlmutter J, Symmans WF, Yee D, Berry D, Esserman L. I-SPY 2 qualifying biomarker evaluation (QBE), 2014. e-Pub 2014.
Moulder S, Yang W, Ueno NT, Ensor J, Valero V, Alvarez R, Litton J, Murthy R, Ibrahim N, Arun B, Mittendorf EA, Hunt K, Meric-Bernstam F, Piwnica-Worms H, Candelaria R, Tripathy D, Symmans WF. Improving outcomes in triple-negative breast cancer (TNBC) using molecular triaging and diagnostic imaging to guide neoadjuvant therapy, 2014. e-Pub 2014.
Fournier MV, Margulis A, Reid K, Brumbaugh S, Anderson R, Symmans WF, Esserman L, Hylton N. Gene expression profiles accompanying phenotypic changes during non-malignant breast epithelial cells acini formation to explain MRI phenotypes, 2014. e-Pub 2014.
Wulfkuhle JD, Yau C, Wolf DM, Gallagher RI, Sanil A, Brown-Swigart L, Flynn S, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans WF, van't Veer L, Yee D, Paoloni M, Esserman L, Berry D, Liu MC, Park JW, Petricoin EF. Evaluation of HER family protein signaling network as a predictive biomarker for pCR for breast cancer patients treated with neratinib in the I-SPY 2 trial, 2014. e-Pub 2014.
Wolf DM, Yau C, Sanil A, Daemen A, Heiser L, Gray J, Brown-Swigart L, Flynn S, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans WF, Yee D, Paoloni M, Esserman L, Berry D, Rugo H. Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-rise breast cancer, 2014. e-Pub 2014.
Jiang T, Shi W, Symmans WF, Li C, Platt J, Lau R, Wali V, Lifton R, Pusztai L, Hatzis C. Broad exonic DNA diversity is associated with resistance to taxane-FAC chemotherapy in triple negative breast cancer, 2014. e-Pub 2014.
Schermann C, Zurl B, Regitnig P, Moinfar F, Symmans WF, Bjelic-Radisc V, Schrenk P, Peintinger F. Agreement between predicted response by imaging methods and pathological response by RCB in breast cancer patients treated with neoadjuvant chemotherapy 25(Suppl 1):i19-i20, 2014. e-Pub 2014.
Hatzis C, Gould RE, Zhang Y, Abu-Khalaf M, Chung G, Sanft T, Hofstatter E, DiGiovanna M, Shi W, Chagpar A, Symmans WF, Pusztai L. Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypes 73(Suppl 24):P6-06-37, 2013. e-Pub 2013.
Iwamoto T, Matsuoka J, Nogami T, Motoki T, Shien T, Taira N, Niikura N, Hayashi N, Doihara H, Symmans WF, Pusztai L. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in breast cancers that are ER-negative but progesterone receptor-positive by immunohistochemistry 73(Suppl 24):P4-05-09, 2013. e-Pub 2013.
Symmans WF, Wei C, Gould R, Zhang Y, Hunt KK, Buchholz TA, Valero V, Hortobagyi GN, Pusztai L. Long-term prognostic value of residual cancer burden (RCB) classification following neoadjuvant chemotherapy 73(Suppl 24):S6-02, 2013. e-Pub 2013.
Sheri A, A'Hern R, Jones R, Symmans WF, Nerurkar A, et al. Integration of Ki67 with residual cancer burden (RCB) compared to Ki67 or RCB alone to predict long-term outcome following neoadjuvant chemotherapy 31:535, 2013. e-Pub 2013.
Shi W, Balazs B, Qi Y, Gyorffy B, Wang B, Lie C-G, Shiang CY, Valero V, Moulder-Thompson S, Avritscher R, Powis G, Hortobagyi GN, Natoqicz R, Wali V, Weinstein J, Symmans WF, Pusztai L. Obesity induces functional transcriptomic changes enhancing the cancer hallmarks of estrogen receptor-positive breast cancer 73(Suppl 24), 2013. e-Pub 2013.
Masuda H, Baggerly K, Wang Y, Zhang Y, Gonzalez-Angulo A, et al. Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer 31:1005, 2013. e-Pub 2013.
Natowicz R, Jiang T, Shi W, Qi Y, Delpech Y, Symmans WF. Correlation of intratumor gene expression heterogeneity with chemotherapy sensitivity in breast cancer 31:1013, 2013. e-Pub 2013.
Lau R, Sun H, Gould R, Hatzis C, Symmans WF. Contribution of analytical, pre-analytical and intra-tumoral heterogeneity to variance in gene expression measurements from human breast cancers 24(3), 2013. e-Pub 2013.
. Breast cancer evaluation and targeted investigational therapy (BEAT-IT): a pilot prospective tissue testing to guide clinical trial selection 31:532, 2013. e-Pub 2013.
Mougalian S, Xiudong L, Hsu L, Hortobagyi G, Kuerer HM, Symmans WF. 10-year outcomes of breast cancer patients with histologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy 31:1017, 2013. e-Pub 2013.
Karn T, Hatzis C, Symmans WF, Pusztai L, Ruckhaberle E, Schmidt M, Muller V, Holtrich U, Rody A, Kaufmann M. Independent blinded validation of the genomic index of sensitivity to endocrine therapy 23(Suppl 2):120-PR, 2012. e-Pub 2012.
Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada B, Singh G, Anh-Do KM, Garces Z, Mittendorf EA, Babiera G, Wagner J, Bedrosian I, Krishnamurthy S, Symmans WF, Gonzalez-Angulo AM, Mills G. Effect of biospecimen variables on proteomic biomarker assessment in breast cancer, 2012. e-Pub 2012.
Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, Symmans WF, Le-Petross HT, Haffty BG, Buckhholz TA, Hunt KK. The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy, 2012. e-Pub 2012.
Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Berstam F, Kuerer HM, Bedrosian I, Symmans WF, Hortobagyi GN, Crow JR, Shah RR, Hunt KK. Estrogen receptor positivity: 10% or 1%? 72(Suppl 24), 2012. e-Pub 2012.
Gonzalez-Angulo AM, Green MC, Murray FL, Palla SL, Koenig H, Brewster AM, Valero V, Ibrahim NK, Moulder SL, Litton JK, Crawford DJ, Flores PR, Dryden MF, Symmans WF, Giordano SH, Pusztai L, Buzdar A, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC) 29:2016, 2011. e-Pub 2011.
Symmans WF, Andre F, Llu MC, Delacruz J, Peintinger F, Borstnar S, Wang H, Regitnig P, Ota M, Seevaratnam S, Delaloge S, Hatzis C. Blinded validation study of genomic predictions for survival following adjuvant sequential anthracycline-docetaxel chemotherapy with or without endocrine therapy 29:1030, 2011. e-Pub 2011.
Symmans WF. Protein kinase mutation patterns in human breast cancer, 2011. e-Pub 2011.
Bianchini G, Pusztai L, Iwamoto T, Kelly CM, Zambetti M, Fasolo A, Del Conte G, Santarpia L, Symmans WF, Gianni L. Molecular tumor characteristics influence adjuvant endocrine treatment outcome 71(Suppl 24), 2011. e-Pub 2011.
Santarpia L, Gonzalez-Angulo AM, Qi Y, Stemke-Hale K, et al. Use of mutation profiling of breast cancer using sequenom technology to detect distinct mutation patters in triple-negative compared to receptor-positive cancers 28(15S):1039, 2010. e-Pub 2010.
Guarneri V, Chavez-MacGregor M, Hsu L, Symmans WF, Litton JK, Mittendfor EA, Conte PF, Hortobagyi A, Gonzalez-Angulo M. Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients 28(15S):621, 2010. e-Pub 2010.
Chavez-MacGregor M, Hubbard G, Bernstam F, et al. Residual cancer burden (RCB) in breast cancer patients treated with taxane- and anthracycline-based neoadjuvant chemotherapy: the effect of race 28(15S), 2010. e-Pub 2010.
Pusztai L, Moulder SL, Litton JK, Valero V, et al. Gene-signature-based patient selection of dasatanib therapy in metastatic breast cancer (MBC) 28(15S), 2010. e-Pub 2010.
Hunt K, Le-Petross HT, Suman V, Haffty BG, Leitch AM, Ollila D, Byrd DR, Buchholz TA, Symmans WF, Boughey JC. A phase II study evaluating the role of sentinel lymph node surgery and axillary lymph node dissection following preoperative chemotherapy in women with node-positive breast cancer (T1-4, 2.M0) at initial diagnosis 28(15S), 2010. e-Pub 2010.
Caudle AS, Gonzalez-Angulo AM, Kelly HK, Liu P, Pusztai L, Symmans WF, Kuere HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer 27(15S):603, 2009. e-Pub 2009.
Andreopoulou E, Hatzis C, Booser D, Valero V, Wallace MJ, Sotiriou C, Hortobagyi G, Pusztai L, Symmans WF. Correlations of estrogen receptor (ER) related genomic transcription and ER gene expression with increasing AJCC stage of ER-positive breast cancer 27(15S):1044, 2009. e-Pub 2009.
Dean-Colomb W, Yan K, Liedtke C, Symmans WF, Holmes FA, O'Shaughnessy J, Asmar L, Hortobagyi G, Pusztai L, Gonzalez-Angulo AM. Transcriptional profiles of triple receptor-negative breast cancer: are Caucasian, Hispanic and African-American women different?, 2008. e-Pub 2008.
Gong Y, Sweet W, Duh Y-J, Greenfield L, Trivedi S, Symmans WF, Isola J, Sneige N. Residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy is independently prognostic in every phenotypic subset of breast cancer, 2008. e-Pub 2008.
Hubbard R, Peintinger F, Liedtke C, Hatzis C, Kuerer HM, Valero V, Buzdar AU, Hortobagyi GN, Pusztai L, Symmans WF. Prognostic value of residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy in phenotypic subsets of breast cancer, 2008. e-Pub 2008.
Broglio K, Moulder SL, Hsu L, Kau S, Pusztai L, Symmans WF, Hortobagyi GN, Gonzalez-Angulo AM, Liedtke C. Prognostic impact of discordance/concordance of triple-receptor expression between primary tumor and metastasis in patients with metastatic breast cancer, 2008. e-Pub 2008.
Zoubir M, Mathieu M, Liedtke C, Bidard F, Delaloge S, Corley L, Spielmann M, Pusztai L, Andre F, Symmans WF. Predictive biomarkers for preoperative endocrine therapy of stage II-III breast cancer by tissue microarrays, 2008. e-Pub 2008.
Peintinger F, Hatzis C, Morkowski J, Hubbard R, Albarracin CT, Qureshi G, Pusztai L, Symmans WF. Inter-pathologist agreement of residual cancer burden (RCB) assessment in breast cancer after treatment with preoperative chemotherapy, 2008. e-Pub 2008.
Gong Y, Sweet W, Duh Y-J, Greenfield L, Symmans WF, Isola J, Sneige N. Impact of chromosome 17/HER-2 polysomy on reliability of chromogenic in situ hybridization (CISH): a study of two institutions, 2008. e-Pub 2008.
Lazar, Andre F, Liedtke C, Job B, Symmans WF, Levy A, Delaloge S, Dessens P, Michiels S, Pusztai L. High resolution oligonucleotide array-CGH to identify therapeutic targets in breast cancer, 2008. e-Pub 2008.
Hatzis C, Symmans WF, Lin F, Zheng B, Yan K, Booser DJ, Gong Y, Valero V, Hortobagyi GN, Pusztai L. Genomic predictors of pathologic response to preoperative chemotherapy for triple-negative and ER-positive/HER2-negative breast cancers, 2008. e-Pub 2008.
Symmans WF. Functional proteomic-based predictor of pathologic complete response to neoadjuvant chemotherapy with paclitaxel/FAC-FEC in breast cancer, 2008. e-Pub 2008.
Gong Y, Sweet W, Duh Y-J, Greenfield L, Tarco E, Symmans WF, Isola J, Esteva FJ. Chromogenic in situ hybridization (CISH) is a reliable method for detecting HER-2 gene status in breast cancer" a multicenter study with comparison of three methods, 2008. e-Pub 2008.
Symmans WF. Combined use of genomic prognostic and treatment response predictors in breast cancer, 2008. e-Pub 2008.
Symmans WF, Hatzis C, Liedtke C, Desmedt C, Valero V, Kuerer HM, Hortobagyi GN, Piccart-Gebhart M, Pusztai L, Sotiriou C. Use of genomic grade index (GGI) to predict pathologic response to preoperative chemotherapy in breast cancer, 2008. e-Pub 2008.
Pusztai L, Holmes FA, Wang J, Hellerstedt B, Pippen J, Vukelja S, Kocs D, Asmar L, Yan K, Lin F, Symmans WF, O'Shaughnessy J. Pharmacogenomic analysis of needle biopsies obtained before preoperative docetaxel/capecitabine and 5-flourouracil/epirubicin/cyclophosphamide chemotherapy for breast cancer, 2007. e-Pub 2007.
Peintinger F, Buzdar A, Kuerer H, Gonzalez-Angulo AM, Hatzis C, Pusztai L, Esteva FJ, Green M, Hortobagyi GN, Symmans WF. The impact of hormone receptor status on pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy with or without trastuzumab, 2007. e-Pub 2007.
Symmans WF. Prospective study of changes in spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes, 2007. e-Pub 2007.
Wu S, Chasalow S, Lee H, Xu L, Paul B, Mokliatchouk O, Symmans WF, Zerba KE, Pusztai L, Clark E. Identification of predictive markers to differentiate ixabepilone from paclitaxel activity in ER-negative breast cancer patients, 2007. e-Pub 2007.
Harris LN, Eklund AC, Carter S, Li X, Winer EP, Hilsenbeck S, Esteva FJ, Symmans WF, Pusztai L, Szallasi Z, Chang J. HER2 tumors are heterogeneous, clinically, molecularly, and in response to preoperative trastuzumab: pathway analysis of gene expression profiles from three breast cancer datasets, 2007. e-Pub 2007.
Pusztai L, Andre F, Mazouni C, Liedtke C, Kau S, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN. HER2 expression and efficacy of preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, 2007. e-Pub 2007.
Liedtke C, Mazouni C, Hess KR, Tordai A, Andre F, Symmans WF, Gonzalez-Angulo AM, Green M, Hortobagyi GN, Pusztai L. Differential response to primary chemotherapy and long-term survival in patients with triple-negative breast cancer 25(18S), 2007. e-Pub 2007.
Symmans WF. Comparison of prediction results from single gene expression and multigene signatures in matched clinical fine-needle aspiration (FNA) and core biopsy (CBX) samples from patients with breast cancer, 2007. e-Pub 2007.
Shaye AN, Gong Y, Yan K, Sneige N, Esteva FJ, Hortobagyi GN, Pusztai L, Symmans WF. Application of the ASCO/CAP guidelines for HER2 testing to mRNA expression values from microarrays, 2007. e-Pub 2007.
Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Lu Y, Symmans WF, Hortobagyi G, Mills GB. Activation of the PI3K/AKT signal transduction pathway is inversely associated with estrogen receptor levels and correlates with survival in hormone receptor-positive HER2/neu-negative breast cancer, 2007. e-Pub 2007.
Symmans WF, Hatzis C, Sotiriou C, Anderson SK, Valero V, Booser DJ, Buzdar AU, Hess KR, Hortobagyi GN, Pusztai L. A genomic index of estrogen receptor reporter genes predicts benefit from adjuvant endocrine therapy independent of baseline prognosis. 28th San Antonio Breast Cancer Symposium, 2006. e-Pub 2006.
Marginean C, Rajan R, Pusztai L, Whitman G, Kuerer H, Zhang P, Buzdar A, Valero V, Hortobagyi GN, Symmans WF. Predictive biomarkers of breast cancer response to neoadjuvant chemotherapy and their relationship to pathologic assessment of residual disease. 95th Annual Meeting, 2006. e-Pub 2006.
Peintinger F, Whitman GJ, Stephens TW, Anderson K, Phelps M, Symmans WF. Predicting residual tumor size in breast cancer patients treated with neoadjuvant chemotherapy: do we need mammography or sonography or both modalities?, 2006. e-Pub 2006.
Symmans WF. Pharmacogenomic predictor of complete response to preoperative paclitaxel and 5-fluourouracil, doxorubicin, cyclophosphamide chemotherapy in breast cancer, 2006. e-Pub 2006.
Symmans WF, Peintinger F, Hatzis C, Kuerer H, Valero V, Hennessy B, Green M, Singletary E, Hortobagyi GN, Pusztai L. A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy, 2006. e-Pub 2006.
Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Vukelja S, Kocs D, Asmar L, Fenske E, Lin F, Symmans WF, Pusztai L. Pharmacogenomic analysis of needle biopsies obtained before preoperative docetaxel/capecitabine/FEC (TX/FEC) chemotherapy for breast cancer, 2006. e-Pub 2006.
Esteva FJ, Anderson K, Lin F, Nahta R, Mejia J, Altundag K, Buzdar AU, Hortobagyi GN, Symmans WF, Pusztai L. Pharmacogenomic analysis of HER2 amplified breast cancer treated with preoperative trastuzumab and paclitaxel, 5-fluorouracil, epirubicin, cyclophosphamide (T/FEC) chemotherapy, 2006. e-Pub 2006.
Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule associated protein (MAP)-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in ER- positive breast cancer, 2006. e-Pub 2006.
Hatzis C, Peintinger F, Valero V, Booser DJ, Mejia J, Hortobagyi G, Pusztai L, Symmans WF. Genomic predictor of benefit from endocrine therapy also predicts response to chemotherapy, 2006. e-Pub 2006.
Peintinger F, Anderson K, Mazouni C, Kuerer HM, Symmans WF, Pusztai L. Correlation between residual cancer volume and MDACC genomic response predictor score in breast cancer patients treated with preoperative chemotherapy, 2006. e-Pub 2006.
Ibrahim NK, Nguyen G, Suki D, Hennessy B, Montero A, Sarriera JE, Symmans WF, Valero V, Sawaya R, Aldape K. Clinicopathological correlation (CC) and outcome of breast cancer patients (pts) with resected brain metastasis (BM), 2006. e-Pub 2006.
Symmans WF, Ayers M, Clark E, Stec J, Hess K, Buchholz T, Sneige N, Hortobagyi G, Pusztai L. Comparison of fine needle and core needle biopsies of breast cancers for cDNA microarray analyses of gene expression 63, 2002. e-Pub 2002.
Symmans WF. Gene expression profiling of fine needle aspirations of breast cancer identifies genes associated with complete pathologic response to neoadjuvant taxol/FAC chemotherapy 76:220A, 2002. e-Pub 2002.
Poniecka A, Gal-Gambos E, Symmans WF. Change in tumor cell density following neoadjuvant chemotherapy 82(1):46A, 2002. e-Pub 2002.
Leon-Ferre RA, Dimitroff K, Yau C, Giridhar K, Mukhtar RA, Hirst GL, Hylton N, Symmans W, Goetz MP, Esserman L, Boughey JC. Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial. 2024 ASCO Annual Meeting.
Sura GH, Tran K, Fu C, Du L, Marczyk M, Gould RE, Chen E, Symmans WF. Pre-Analytical Effects on Targeted and Whole Transcriptome RNA Sequencing Analysis in Cytology. USCAP 113th Annual Meeting.
Rugo HS, Wolf DM, Yau C, Petricoin E, Pohlmann PR, Pusztai L, Symmans W, Borowsky A, Finestone S, Yee D, Hylton N, 't Veer LV, Esserman L, DeMichele A. Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival. 2023 ASCO Annual Meeting.
Stover D, Hlauschek D, Mayer E, Symmans W, Watson M, Barozzi I, Filipits M, Ballman K, Ezquerra MB, Balko J, Rubovszky G, Zdenkowski N, Brufsky A, Steger G, Isaacs C, Loibl S, Henao F, Regan M, Liu Y, Fesl C, O'Brien P, DeMichele A, Gnant M, Metzger O. Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial. San Antonio Breast Cancer Symposium.
Ye Q, Klippel D, Albarracin C, Chen H, Contreras A, Ding Q, Huo L, Laila, Khazai, Middleton L, Resetkova E, Sahin A, Sun H, Sweeney K, Symmans W, Yun, Wu, Krishnamurthy S. A Prospective Study of Real Time Whole Slide Imaging of Frozen Sections for Intraoperative Evaluation of Axillary Sentinel Lymph Nodes in Breast Cancer. USCAP 113th Annual Meeting.
Sura G, Tran K, Trevarton A, Marczyk M, Fu C, Lili D, Qu J, Tasto A, Agata, Tinnirello, Lau R, Gould R, Sinn B, Lajos MD, DPhil, Hatzis C, Symmans W. Comparison of Ficoll-Hypaque Enrichment versus the Cytolyt Method for Clearing Blood from Malignant Effusions: Effects on RNA Quality, Sequencing, and Analysis. USCAP 113th Annual Meeting.
Chien AJ, Mukhtar RA, Giridhar K, Olopade OI, Kalinsky K, Vaklavas C, Elias AD, Wei M, Goetz MP, Van't Veer L, Alkhafaji S, Rugo HS, Chen N, Symmans W, Borowsky AD, Swigart LB, Onishi N, Yee D, Hylton N, Esserman L. I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC). 2024 ASCO Annual Meeting.
Metzger O, Ballman KV, Gnant M, Watson M, Chen E, Tran K, O'Brien P, Hlauschek D, Martin M, Balko JM, Nowecki Z, Hahn OM, Denkert C, Curtis C, Liu Y, Dueck AC, Fesl C, Mayer EL, DeMichele A, Symmans W. Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer. 2024 ASCO Annual Meeting.
Penault-Llorca FM, Lusque A, Filleron T, Tran K, Du L, Baehner F, Dalenc F, Lacroix-Triki M, Bachelot T, Andre F, Boucher P, Lemonnier J, Symmans W. Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the Recurrence Score in node-positive breast cancer: Independent validation in the PACS-01 trial. 2024 ASCO Annual Meeting.
Zakon DB, Poncet C, Cardoso F, Anouk N, Valero V, Aebi S, Benstead K, Bogler O, Dal Lago L, Fraser J, Caballero C, Hedenfalk I, Korde L, Linderholm B, Martens JWM, Middleton L, Murray M, Kelly C, Nilsson C, Nowaczyk M, Peeters S, Beauvois M, Porter P, Schröder C, Rubio IT, Ruddy KJ, van Asperen C, Van Den Weyngaert D, van Deurzen CHM, van Leeuwen-Stok E, Vermeij J, Bartlett JMS, Wolff AC, Giordano SH, Symmans WF. Evaluation of the Sensitivity to Endocrine Therapy Index (SET2,3) in Early Male Breast Cancer. San Antonio Breast Cancer Symposium.
Helsten TL, Lo SS, Yau C, Kalinsky K, Elias AD, Wallace AM, Chien A, Lu J, Lang JE, Albain KS, Stringer-Reasor E, Clark AS, Boughey JC, Ellis ED, Yee D, DeMichele A, Isaacs C, Perlmutter J, Rugo HS, Schwab R, Hylton NM, Symmans W, Melisko ME, van't Veer LJ, Wilson A, Singhrao R, Asare SM, Sanil A, Berry DA, Esserman LJ. Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer. San Antonio Breast Cancer Symposium.
Liu MC, Robinson PA, Yau C, Wallace AM, Chien A, Stringer-Reasor E, Nanda R, Yee D, Albain KS, Boughey JC, Han HS, Elias AD, Kalinsky K, Clark AS, Kemmer K, Isaacs C, Lang JE, Lu J, Sanft T, DeMichele A, Hylton NM, Melisko ME, Perlmutter J, Rugo HS, Schwab R, Symmans W, van't Veer LJ, Haugen PK, Wilson A, Singhrao R, Asare S, Sanil A, Berry DA, Esserman LJ. Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer. San Antonio Breast Cancer Symposium.
Garber H, Rauch G, Adrada B, Candelaria R, Mittendorf E, Thompson A, Litton J, Damodaran S, Lim B, Arun B, Ueno N, Valero V, Ibrahim N, Murthy R, Tripathy D, Piwnica-Worms H, Symmans F, Huo L, Moulder S. Residual cancer burden in patients with early stage triple negative breast cancer who progress on anthracycline-based neoadjuvant chemotherapy in an ongoing clinical trial (ARTEMIS). San Antonio Breast Cancer Symposium.
Echeverria GV, Ge Z, Seth S, Jeter-Jones SL, Zhang X, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Lau R, Shao J, Sun Y, Bristow C, Carugo A, Ma X, Harris A, Wu Y, Moulder S, Symmans WF, Marszalek JR, Heffernan TP, Chang JT, Piwnica-Worms H. Resistance to neoadjuvant chemotherapy in triple negative breast cancer mediated by a reversible drug-tolerant state. San Antonio Breast Cancer Symposium.
Litton J, Symmans F, Citron M, Gogineni K, Saltzman M, Telli ML, Usha L, Chakrabarti J, Tudor IC, Quek RGW, Czibere A. A phase 2, nonrandomized, open-label, single-arm, multi-center study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early triple-negative breast cancer. San Antonio Breast Cancer Symposium.

Book Chapters

Abramovitz, M, Williams, CB, De, P, Dey, N, Willis, S, Young, B, Andreopoulou, E, Symmans, WF, Sicklick, JK, Schilsky, R, Lazar, V, Bresson, C, Mendelsohn, J, Kurzrock, R, Leyland-Jones, B. Precision Medicine Clinical Trials. In: Predictive Biomarkers in Oncology, 593-603, 2018.
Abramovitz, M, Williams, CB, De, P, Dey, N, Willis, S, Young, B, Andreopoulou, E, Symmans, WF, Sicklick, JK, Kurzrock, R, Leyland-Jones, B. Personalized Cancer Treatment and Patient Stratification Using Massive Parallel Sequencing (MPS) and Other OMICs Data. In: Predictive Biomarkers in Oncology. Springer, 131-147, 2018.
Symmans, WF. Pathology After Neoadjuvant Treatments. In: Breast Cancer: Innovations in Research and Management. Springer, 141-147, 2017.
Brown, AS, Symmans, WF. Pathology. In: Breast Surgical Techniques and Interdisciplinary Management. Springer, 633-643, 2011.
Symmans WF. Pathology Post-Neoadjuvant Therapy. In: Kuerer's Breast Surgical Oncology. 1st. McGraw Hill, 2010.
Liedtke, C, Pusztai, L, Symmans, WF. Molecular Pathology and Transcriptional Profiling in Early Drug Development. In: Molecular Pathology and Drug Discovery and Development. Jon Wiley & Sons, Inc, 47-84, 2009.
Meric-Bernstam F, Symmans WF. Prognostic and Predictive Profiling in Breast Cancer. In: Advanced Therapy in Surgical Oncology. 1st. BC Decker Inc, 533-542, 2008.
Pusztai L, Symmans WF. Histopathologic and Molecular Markers of Prognosis and Response to Therapy. In: Breast Cancer (2nd Edition). 2nd. Springer, 323-343, 2008.
Symmans WF, Pusztai L. Selection of Patients for Endocrine Therapies. In: Endocrine Therapies in Breast Cancer. Oxford University Press, 1-12, 2007.
Ross, JS, Linette, GP, Stec, J, Clark, E, Ayers, M, Symmans, WF, Hortobagyi, GN, Pusztai, L. Breast Cancer. In: Molecular Pathology in Clinical Practice. 1st. Springer, 269-278, 2006.
Symmans, WF, Inghirami, G. Molecular Pathology Assays for Breast Cancer. In: Breast Cancer (2nd Edition). 2nd. Churchill Livingstone, 145-168, 2005.
Symmans WF, Ross JS, Hortobagyi GN. Histopathology of Breast Cancer. In: Molecular Oncology Of Breast Cancer. 1st. Jones & Bartlett Learning, 106-116, 2004.
Symmans WF, Ross JS, Hortobagyi GN. Cytology: Clinical Sample Procurement and On-Slide Technologies. In: Molecular Oncology Of Breast Cancer. 1st. Jones & Bartlett Learning, 96-105, 2004.
Pusztai L, Symmans W, Buchholz TA, Stec J, Ayers M, Clark E, Meric F, Stivers D, Hess K. Application of DNA Microarray Technology to Clinical Biopsies of Breast Cancer. In: Computational and Statistical Approaches to Genomics. 1st. Springer, 257-275, 2002.
Symmans WF, Inghirami G. Molecular Pathologic Assays for Breast Cancer. In: Breast Cancer. Saunders Co, 1999.

Letters to the Editor

Speers, C, Barlow, W, Symmans, WF. Reply to Y. Wang et al and Q. Sui et al. Journal of Clinical Oncology 41: 3763-3764, 2023.
Yau, C, Osdoit, M, Esserman, L, Symmans, WF. Survivorship after neoadjuvant chemotherapy – Authors' reply. Lancet Oncol 23: e96, 2022.
Mukhtar, RA, Symmans, WF, Esserman, L. Association of Residual Cancer Burden after Neoadjuvant Therapy and Event-Free Survival in Breast Cancer - Reply. JAMA Oncology 8, 2022.
Mayer, IA, Zhao, F, Arteaga, CL, Symmans, WF, Park, BH, Burnette, BL, Tevaarwerk, AJ, Garcia, S, Smith, KL, Makower, D, Block, M, Morley, KA, Jani, CR, Mescher, C, Dewani, SJ, Tawfik, B, Flaum, LE, Mayer, E, Sikov, W, Rodler, E, Wagner, LI, DeMichele, A, Sparano, JA, Wolff, AC, Miller, KD. Reply to T. Shimoi et al and Y. Shimanuki et al. J Clin Oncol 39: 3522-3523, 2021.
Yee, D, Haddad, T, Albain, KS, Barker, A, Benz, C, Boughey, JC, Buxton, M, Chien, AJ, DeMichele, A, Dilts, D, Elias, A, Haluska, P, Hogarth, M, Hu, A, Hytlon, N, Kaplan, HG, Kelloff, GJ, Khan, Q, Lang, J, Leyland-Jones, B, Liu, MC, Nanda, R, Northfelt, D, Olopade, OI, Park, JW, Parker, B, Parkinson, DR, Pearson-White, S, Perlmutter, J, Pusztai, L, Symmans, WF, Rugo, H, Tripathy, D, Wallace, A, Wholley, D, Van't Veer, L, Berry, D, Esserman, L. Adaptive trials in the neoadjuvant setting. Journal of Clinical Oncology 30: 4584-4586, 2012.
Dixon, JM, Wilson, V, Verrill, M, Symmans, WF. HER2 testing in patients with breast cancer. BMJ (Online) 344, 2012.
Albarracin, C, Edgerton, ME, Gilcrease, M, Huo, L, Krishnamurthy, S, Middleton, LP, Resetkova, E, Sahin, AA, Sneige, N, Symmans, WF, Wu, Y. Is it too soon to start reporting HER2 genetic heterogeneity?. Arch Pathol 134: 162-163, 2010.
Symmans, WF. In Reply. Journal of Clinical Oncology 26: 3095, 2008.
Waisman, J, Symmans, WF, Ljung, BM, Youngson, BJ, Rosen, PP. Epithelial Displacement. American Journal of Surgical Pathology 19: 1092, 1995.
Symmans, WF, Marboe, CC. Cardiac allograft pathology-A comment on the problem of chronic rejection. Cardiovasc J 4: 223, 1995.

Web Publications

Symmans WF. Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer.
Symmans WF. Residual Cancer Burden Calculator.

Patents

Compositions, kits, and methods for identification, assessment, prevention and therapy of breast cancer (USA serial # 10/285,393 joint inventor). Patent Number: US Patent No: 7,504,222 (MDA03-128).
Targeted Measure of Transcriptional Activity Related to Hormone Receptors. Patent Number: United States Patent No. 11,459,617.
Method of measuring residual cancer and predicting patient survival. (USA serial # 60/792,245 joint inventor). Patent Number: US Patent No. 7,711,494 (MDA06-119).